1958 — The determination of the formation of the carpophores and sclerotia in culture of Psilocybe mexicana Heim, a Mexican, hallucinogenic agaric, and the demonstration of the presence of psilocybin and psilocin.
1958 — Psilocybin, an active psychotropic material from the Mexican hallucinogenic fungus.
1958 — [Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim].
1958 — [The pharmacology of psilocybin, an ac' principle from Psilocybe mexicana Heim].
1958 — [Elucidation of the structure and the synthesis of psilocybin].
1959 — [The place of psilocybin among other psychotropic substances].
1959 — Comparison of the reactions induced by psilocybin and LSD-25 in man.
1959 — [Studies on psilocybin, a hallucinogenic drug from the Mexican mushroom Psilocybe mexicana].
1959 — [Effect of psilocybin on the behavior of normal mice & waltzing mice; comparison with lysergic acid monoethylamide & diethylamide].
1959 — Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen
1959 — Abwandlungsprodukte von Psilocybin und Psilocin. 2. Mitteilung über synthetische Indolverbindungen
1959 — [Identification of psilocin].
1959 — Psilocybin - eine neue psychotrope Substanz
1959 — [The action of psilocybin on the rabbit brain].
1959 — [Therapeutic effect of psilocybin on convulsive neurosis].
1959 — [Teonanacatl and psilocybin].
1960 — Studies on psilocybin and related compounds. I. Communication. Structure/activity relationship of oxyindole-derivatives with regard to their effect on the knee jerk of spinal cats.
1960 — Production of Cross-Tolerance to Psychosis-Producing Doses of Lysergic Acid Diethylamide and Psilocybin
1960 — Psilocybin (experiments and subjective criticism).
1960 — Zur Identifizierung von Psilocin, einem psychotropen Inhaltstoff mexikanischer Rauschpilze der Gattungen Psilocybe und Stropharia
1960 — [Psilocybin, a new hallucinogen].
1960 — Some observations on psilocybin, a new hallucinogen, in volunteer subjects.
1960 — Some observations on psilocybin, a new hallucinogen, in volunteer subjects
1960 — The relationship between the metabolic fate and pharmacological actions of serotonin, bufotenine and psilocybin.
1960 — Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects.
1960 — Controlled sensory input: a note on the technic of drug evaluation with a preliminary report on a comparative study of sernyl, psilocybin, and LSD-25.
1960 — Comparative effects of the administration of taraxein, d-LSD, mescaline, and psilocybin to human volunteers
1961 — [Action of psilocybin on the excitability of the nerve centers].
1961 — [Clinical experiences with psilocybin Sandoz (CY39 Sandoz)].
1961 — [Clinical experiences with psilocybin (CY39 Sandoz)].
1961 — [Psychopsychic correlations under the effect of psycholytics (LSD, psilocybin and similar drugs)].
1961 — Cross tolerance between LSD and psilocybin.
1961 — Dephosphorylation of psilocybin to psilocin by alkaline phosphatase.
1961 — [Expressive phenomenology of model psychoses (psilocybin). Comparison with self-description and psychic deficiency of performance].
1961 — The effects of psilocybin and lycergic acid on the extinction of avoidance behavior in rats.
1961 — Psilocybin in psychiatry, and beyond.
1961 — Clinical, biochemical and psychologic effects of psilocybin.
1961 — The inhibitory effect of psilocybin and related compounds on human cholinesterases
1961 — [Serotonin metabolism in experimental psilocybin psychosis].
1961 — The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates.
1961 — [The effects of psilocybin in a case of hysteria].
1962 — [Initial results of the action of psilocybin in a group of psychiatric patients].
1962 — The fate of psilocin in the rat.
1962 — Comparison of psilocin with psilocybin, mescaline and LSD-25.
1962 — [On the treatment of therapy-resistant neuroses with model psychoses (psilocybin)].
1962 — Occurrence of psilocybin and psilocin in certain Gonocybe and Psilocybe species.
1962 — CLINICAL OBSERVATIONS OF SIMULTANEOUS HALLUCINOGEN ADMINISTRATION IN IDENTICAL TWINS
1962 — Changes in spider webs brought about by mescaline, psilocybin and an increase in body weight.
1962 — Occurrence of psilocin in Psilocybe baeocystis.
1962 — The effect of psilocybin upon the systemic, pulmonary, and coronary circulation of the intact dog.
1962 — Serotonin-like and antiserotonin properties of psilocybin and psilocin.
1962 — Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures.
1962 — Effects of LSD-25, psiolocybin, and psilocin on temporal lobe EEG patterns and learned behavior in the cat.
1962 — The Hallucinogenic Mushrooms of Mexico and Psilocybin: a Bibliography
1962 — Dephosphorylation of psilocybin in the intact mouse.
1962 — [Pharmacopsychiatric observations with psilocybin].
1963 — [OUR CLINICAL EXPERIENCE WITH A NEW PHARMACOLOGICAL PREPARATION PSILOCYBIN].
1963 — [AUTO-OBSERVATION OF2 EXPERIMENTAL INTOXICATIONS WITH PSILOCYBIN].
1963 — [CLINICAL EXPERIENCES WITH PSILOCYBIN].
1963 — [Auto-experimentation with LSD-25 and psilocybin].
1963 — [The psychomimetic effects of LSD and psilocybin in the clinical exploration of the personality].
1963 — Inter-relations of the effects of psilocybin on subjective sensation, photopic critical frequency of fusion, and circulating non-esterified fatty acids.
1963 — [Psilocybin: prospects of its use in clinical psychiatry].
1963 — AN ELECTROGRAPHIC STUDY OF PSILOCIN AND4-METHYL-α-METHYL TRYPTAMINE (MP-809)
1963 — An electrographic study of psilocin and 4-methyl-alpha-methyl tryptamine (MP-809).
1963 — Some biochemical studies on psilocybin and psilogin.
1963 — [EFFECT OF PSILOCYBIN ON THE CLINICAL AND ELECTROENCEPHALOGRAPHIC PICTURE IN ORGANIC CNS LESIONS].
1963 — [COMPARISON OF PSYCHOPHARMACA LSD-25, BOL-148 AND PSILOCYBIN IN CLINICAL PRACTICE].
1963 — Mescaline, LSD, psilocybin, and personality change.
1963 — THE IN VITRO INHIBITORY EFFECT OF PSILOCYBIN AND RELATED COMPOUNDS OF HUMAN CHOLINESTERASES.
1963 — EFFECT OF MESCALINE, LYSERGIC ACID DIETHYLAMIDE AND PSILOCYBIN ON COLOR PERCEPTION.
1963 — ANALOGUES OF PSILOCIN AND LYSERGIC ACID DIETHYLAMIDE I. CHLORO, NITRO, AND AMINO DERIVATIVES OF3-SUBSTITUTED INDOLES
1963 — [PSYCHOMIMETIC SUBSTANCES. (CONTRIBUTION TO THE CLINICAL PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN)].
1963 — SIMULTANEOUS STUDIES OF BLOOD SUGAR, BEHAVIOURAL CHANGES AND EEG ON THE WAKE RABBIT AFTER ADMINISTRATION OF PSILOCYBIN.
1963 — LYSERGIC ACID DIETHYLAMIDE (LSD-25). 34. COMPARISON WITH EFFECT OF PSILOCYBIN ON THE SIAMESE FIGHTING FISH.
1963 — REACTIONS TO PSILOCYBIN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT.
1964 — THERAPEUTIC APPLICATION OF THE CHANGE IN CONSCIOUSNESS PRODUCED BY PSYCHOLYTICA (LSD, PSILOCYBIN, ETC.). THE PSYCHEDELIC EXPERIENCE IN THE TREATEMENT OF NEUROSIS.
1964 — [ACTION OF CHLORPROMAZINE AND PSILOCYBIN ON THE TELENCEPHALIC AROUSAL REACTION OF A DIPNOAN].
1964 — The production of psilocybin in submerged culture by Psilocybe cubensis.
1964 — A Working Paper: Memo on the Religious Implications of the Consciousness-Changing Drugs (LSD, Mescalin, Psilocybin)
1964 — "MODEL PSYCHOSIS" PRODUCED BY INHALATION OF GASOLINE FUMES.
1964 — [CLINICAL AND PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN].
1964 — CLINICAL SYNDROMES AND BIOCHEMICAL ALTERATIONS FOLLOWING MESCALINE, LYSERGIC ACID DIETHYLAMIDE, PSILOCYBIN AND A COMBINATION OF THE THREE PSYCHOTOMIMETIC DRUGS.
1964 — [USE OF PSILOCYBIN AS A DIAGNOSTIC TEST IN NEUROLOGY].
1964 — [A PSYCHOPATHOLOGICAL STUDY OF THE PSILOCYBIN PSYCHOSIS; COMPARISON WITH THE LSD-25 PSYCHOSIS].
1964 — PATTERNS OF HALLUCINOGENIC DRUG ABUSE.
1965 — [THE EXPERIENCE OF ORAL REGRESSION DUE TO THE EFFECT OF HALLUCINOGENS (LSD-25 AND PSILOCYBIN)].
1965 — Drugs and phantasy: the effects of LSD, psilocybin, and sernyl on college students
1965 — A new behavior change program using psilocybin.
1965 — CONSISTENCY OF PSILOCYBIN INDUCED CHANGES IN THE MINNESOTA MULTIPHASIC PERSONALITY INVENTORY.
1965 — The effects of psilocybin on a test of after-image perception.
1965 — Pathologic laughter as manifestation of the psychotomimetic action of psilocybin.
1965 — Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects.
1965 — The effects of psychotomimetic drugs on primary suggestibility.
1965 — Production of Psilocybin in Psilocybe baeocystis Saprophytic Culture
1965 — Similarity of schizophrenia and the psilocybin syndrome as determined by objective methods.
1966 — Effect of Psilocybin, LSD, and mescaline on small, involuntary eye movements.
1966 — Time contraction and psychomotor performance produced by "Psilocybin".
1966 — Inhibition of isolation-induced attack behavior of mice by drugs.
1966 — Psilocybin reactivity and time contraction as measured by psychomotor performance.
1966 — Biosynthesis of psilocybin in submerged culture of Psilocybe cubensis. 1. Incorporation of labelled tryptophan and tryptamine.
1966 — Psilocin: effects on behaviour and brain serotonin in mice.
1966 — Botanical and Chemical Characterisation of a Forensic Mushroom Specimen of the Genus Psilocybe
1966 — A possible correlation between drug-induced hallucinations in man and a behavioural response in mice.
1966 — Investigations On Psilocybin And Its Analogs In Certain Fungi.
1967 — Baeocystin, a mono-methyl analog of psilocybin from Psilocybe baeocystis saprophytic culture.
1967 — [Alteration of music perception in experimental psychosis (psilocybin)].
1967 — Effects of chlorpromazine and psilocin on pregnancy of c57bl/10 mice and their offspring at birth. Abstr.
1967 — Psilocybin: reaction with a fraction of rat brain.
1967 — Effects of mescaline and psilocybin on dominance behavior of the rat.
1967 — Dynamics of Psychedelic Drug Abuse
1967 — Formation of blue oxidation product from psilocybin.
1967 — [Psilocybine induced changes in extraoptical perception].
1967 — [The association of proprioceptive sensations and neurologic symptoms after psilocybine].
1967 — [Psilocybine in brain injured subjects and its different effects in relation to the localization of the lesion].
1967 — 2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug.
1967 — 34)Psilocybin投与による情動の変化と血中17-CHCSの動態(精神生理)(第8回日本精神身体医学会総会)
1968 — Biosynthesis of psilocybin. II. Incorporation of labelled tryptamine derivatives.
1968 — 催幻覚薬に関する薬理学的研究(第3報):第1篇 Psilocybinの文献的考察ことに中枢作用について
1968 — A biosynthetic sequence from tryptophan to psilocybin.
1968 — Structure-activity relationships among 5-methoxy-n:n-dimethyltryptamine, 4-hydroxy-n:n-dimethyltryptamine (psilocin) and other substituted tryptamines.
1968 — [Pharmacological studies of hallucinogens. Report 3. II. Pharmacological studies of influence of psilocybin on the central nervous system].
1968 — [Pharmacological studies of hallucinogens. Report 3. I. Bibliographical considerations of psilocybin, with special reference to its actions on the central nervous system].
1968 — Psilocybin-induced changes in psychologic function, electroencephalogram, and light-evoked potentials in human subjects.
1968 — PSILOCYBIN-INDUCED CHANGES IN PSYCHOLOGIC FUNCTION, ELECTROENCEPHALOGRAM, AND LIGHT-EVOKED POTENTIALS IN HUMAN SUBJECTS
1968 — Quantitative measurement of time contraction induced by psilocybin.
1968 — The effects of psilocybin, dextro-amphetamine and placebo on performance of the trail making test.
1968 — Tolerance and cross-tolerance among psychotomimetic drugs.
1968 — Interrelationship of phosphate nutrition, nitrogen metabolism, and accumulation of key secondary metabolites in saprophytic cultures of Psilocybe cubensis, Psilocybe cyanescens, and Panaeolus campanulatus.
1968 — Baeocystin and norbaeocystin: new analogs of psilocybin from Psilocybe baeocystis.
1968 — Behavioural Effects of some Morphine Antagonists and Hallucinogens in the Rat
1968 — Psilocybin-induced Autonomic, Perceptual, and Behavioral Change
1969 — Autoradiographic studies on the distribution of psychoactive drugs in the rat brain. 3. 14C-psilocin.
1969 — Action de la psilocybine sur le comportement d'un cercopithecinae papio-papio
1969 — Effects of excitatory and tranquilizing drugs on visual perception. Spatial distortion thresholds.
1969 — A study of the role of noradrenaline in behavioral changes produced in the rat by psychotomimetic drugs.
1969 — Effects of psychodysleptic drug psilocybin on visual perception. Changes in brightness preference.
1969 — The relationship of carbon and nitrogen nutrition of Psilocybe baeocystis to the production of psilocybin and its analogs.
1969 — Alteration of a learned response of the squirrel monkey by hallucinogens
1969 — Measurement of handwriting area to pressure ratios during psilocybin-induced hallucinations.
1969 — [Electrophysiological effects of psilocybin in a cercopithecinae, Papio papio].
1969 — Additional evidence supporting the occurrence of psilocybin in Panaeolus foenisecii.
1969 — Occurrence of psilocybin in the sporophores of Psilocybe semilanceata
1969 — Hypnotic Induction of the Interference of Psilocybin with Optically Induced Spatial Distortion
1969 — The action of tryptamine on the dog spinal cord and its relationship to the agonistic actions of LSD-like psychotogens.
1970 — On similar linguistic structures in creative performance and psilocybin-induced experience.
1970 — [Chromosome defects in patients treated with Psilocybine].
1970 — Personality trait dependent performance under psilocybin.
1970 — Personality trait dependent performance under psilocybin. II.
1970 — The occurrence of the psychotomimetic agent psilocybin in an Australian agaric, Psilocybe subaeruginosa
1970 — Psilocybin-Induced Transformations of Visual Space
1970 — ChemInform Abstract: AUFTRETEN DES PSYCHOTOMIMETISCHEN AGENS PSILOCYBIN IN DEM AUSTRALISCHEN BLAETTERPILZ PSILOCYBE SUBAERUGINOSA
1970 — Psilocybin-induced contraction of nearby visual space.
1970 — PsilocybinおよびLSDの精神身体症状におよぼす影響-1-LSDに就て
1970 — Effects of psilocybin, dimethyltryptamine and various lysergic acid derivatives on photically-induced epilepsy in the baboon (Papio papio).
1970 — Microcrystalloptic tests for lysergic acid diethylamide and other hallucinogens
1970 — ChemInform Abstract: INDOLE 22. MITT. INDOLSYNTH., ANWENDUNG AUF PSILOCIN
1971 — EEG changes after psilocybin in organic brain lesions.
1971 — Different reaction of focal and diffuse epileptic EEG activity to psilocybin.
1971 — ChemInform Abstract: CHLORIERTE 2-HYDROXY- UND2-METHOXY-PHENOXYAETHYLAMINE, ANALOGA VON PSILOCYBIN
1971 — An electroencephalographic analysis of personality-dependent performance under psilocybin.
1971 — Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons.
1971 — Effects of psilocybin, dimethyltryptamine, mescaline and various lysergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio).
1971 — Lysergic acid diethylamide (LSD) as a discriminative cue: drugs with similar stimulus properties.
1971 — A rapid screening procedure for some "street drugs" by thin-layer chromatography.
1971 — Synthesis of the sulphur analogue of psilocin and some related compounds
1972 — The effect of bufotenine, melatonin, psilocybin, and related compounds on the 5-hydroxytryptamine excitatory receptors of Helix aspersa neurons
1972 — Psychedelic Drugs in Correctional Treatment
1972 — 精神分裂病者の病像とPsilocybin,LSD-25反応に関する精神病理学的研究
1973 — [Studies on hallucinogens. 3. Synthesis of psilocin (author's transl)].
1973 — Molecular structures of hallucinogenic substances: lysergic acid diethylamide, psilocybin, and 2,4,5-trimethoxyamphetamine.
1973 — Vasoconstriction produced by hallucinogens on isolated human and sheep umbilical vasculature.
1973 — ChemInform Abstract: SYNTH. DES SCHWEFELANALOGEN VON PSILOCIN UND EINIGEN VERWANDTEN VERBINDUNGEN
1973 — Hallucinogenic drug-induced behavior under sensory attenuation. Prediction of response to psilocybin.
1973 — Psychophysics of psilocybin and 9 -tetrahydrocannabinol.
1973 — The effects of LSD, psilocybin, harmaline and amphetamine on the body temperature of para-chlorophenylalanine pretreated rats.
1973 — Theoretical studies on the conformations of psilocin and mescaline.
1973 — Induction and extinction of psilocybin induced transformations of visual space.
1973 — Theoretical studies on the conformations of psilocin and mescaline.
1973 — Quantitative measurement of mixtures of hallucinogens by fluorometry and phosphorimetry.
1973 — ChemInform Abstract: BENZO(B)THIOPHENE DERIVATIVES PART19, THE SULFUR ISOSTERES OF PSILOCIN AND RELATED ISOMERS
1973 — Benzo[b]thiophene derivatives. XXI. On the proof of structure of the sulfur isostere of psilocin
1973 — An analysis of some discriminative properties of d-amphetamine.
1973 — The effects of 5-hydroxytryptamine and some related compounds on the cat superior cervical ganglion in situ.
1974 — Psilocybin: a pharmacological profile.
1974 — [Studies on hallucinogens. V. Synthesis of psilocybin].
1974 — Crystal structures of the Teonanácatl hallucinogens. Part II. Psilocin, C12 H15 N2 O
1974 — Crystal structures of the Teonanácatl hallucinogens. Part I. Psilocybin C12 H17 N2 O4 P
1974 — Distribution patterns of 14-C-psilocin in the brains of various animals.
1974 — The effects of psilocybin on EEG and behaviour in monkeys.
1974 — A comparison of psychotomimetic drug effects on rat brain norepinephrine metabolism.
1974 — The effect of LSD, psilocybin, harmaline and amphetamine on the body temperature of para-chlorophenylalanine pretreated rabbits.
1974 — Underlying mechanism of psilocybin induced psychosis
1974 — ChemInform Abstract: BENZO(B)THIOPHENE DERIVATIVES PART21, ON THE PROOF OF STRUCTURE OF THE SULFUR ISOSTERE OF PSILOCIN
1974 — ChemInform Abstract: CRYSTAL STRUCTURES OF THE TEONANACATL HALLUCINOGENS PART2, PSILOCIN C12H15N2O
1974 — ChemInform Abstract: CRYSTAL STRUCTURES OF THE TEONANACATL HALLUCINOGENS PART1, PSILOCYBIN C12H17N2O4O
1974 — 幻覚剤に関する研究-5-Psilocybinの合成(ノ-ト)
1974 — ChemInform Abstract: NEUER ZUGANG ZU PSILOCIN-DERIVATEN
1974 — Hypersensitivity to lysergic acid diethylamide (LSD-25) and psilocybin in essential headache.
1975 — Comparison of the discriminative stimulus properties of delta9-THC and psilocybin in rats.
1975 — Adaptive changes in behavior after repeated administration of various psychoactive drugs.
1975 — Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors.
1975 — The Psilocybin Mushroom Pandemic
1975 — Color changes induced by certain indole alkaloids in the fiddler crab, Uca.
1975 — The Effect of Psycholitics-Hallucinogens on Tonus and Concentrations of Vegetative Organs
1975 — Therapeutic usefulness of hallucinogenic drugs as a function of their chemical structure.
1975 — Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
1975 — Hallucinogenic Mushrooms Including Chemical Hallucinogens: Bufotenin and Psilocybin; a Select Bibliography.
1976 — Detection of psilocybin in species of Psilocybe, Panaeolus and Psathyrella.
1976 — The psilocybin-induced "state of drunkenness" in normal volunteers and schizophrenics.
1976 — Polymorphe Modifikationen und Solvate von Psilocin und Psilocybin
1976 — Drug-induced conditioned suppression: specificity due to drug employed as UCS.
1976 — Extraordinary experiences during cross-modal perception.
1976 — A Comparison of the Phenomenology of Hallucinogens and Schizophrenia From Some Autobiographical Accounts*
1976 — Electroencephalographic and behavioral effects of 4-phosphoryloxy N, N-dimethyltryptamine (psilocybin) on the New Zealand albino rabbit
1977 — Baeocystin in psilocybe, conocybe and panaeolus.
1977 — The effects of psilocybin on primary process content in language.
1977 — Baeocystin in Psilocybe semilanceata.
1977 — Psilocin analogs. 1. Synthesis of 3-[2-(dialkylamino)ethyl] -and 3-[2-(cycloalkylamino)ethyl] indol-4-ols
1977 — Psilocybin: biphasic dose-response effects on the acoustic startle reflex in the rat.
1977 — GLC-Mass Spectral Analysis of Psilocin and Psilocybin
1977 — ChemInform Abstract: PSILOCIN ANALOGS. 1. SYNTHESIS OF3-(2-(DIALKYLAMINO)ETHYL)- AND3-(2-(CYCLOALKYLAMINO)ETHYL)INDOL-4-OLS
1977 — Comparative effects of hallucinogenic drugs on rotational behavior in rats with unilateral 6-hydroxydopamine lesions.
1977 — Behavioral effects of LSD in the cat: proposal of an animal behavior model for studying the actions of hallucinogenic drugs.
1978 — Effects of mescaline and psilocin on acquisition, consolidation, and performance of light-dark discrimination in two inbred strains of mice
1978 — The occurrence of psilocybin in Gymnopilus species.
1978 — Defining the histamine H2-receptor in brain: the interaction with LSD.
1978 — The identification of LSD-like hallucinogens using the chronic spinal dog.
1978 — Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test.
1978 — Stimulation of rat prolactin secretion by indolealkylamine hallucinogens.
1978 — Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications.
1978 — Psychoactivity of normacromerine in animals.
1978 — High-affinity 3H-serotonin binding to caudate: inhibition by hallucinogens and serotoninergic drugs.
1978 — The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle.
1979 — Psilocin, Bufotenine and Serotonin: Historical and Biosynthetic Observations
1979 — Severe aggression in rats induced by mescaline but not other hallucinogens.
1979 — Application of Mass Spectrometry/Mass Spectrometry (MS/MS) to the Identification of Natural Products in Psilocybe Cyanescens
1979 — Persistent psychiatric symptoms after eating psilocybin mushrooms.
1979 — The inhibition of food intake in the dog by LSD, mescaline, psilocin, -amphetamine and phenylisopropylamine derivatives
1979 — A characteristic effect of hallucinogens on investigatory responding in rats.
1979 — The danger of hallucinogenic mushrooms.
1980 — Application of a radioimmunoassay screening test for detection and management of phencyclidine intoxication.
1980 — Profiles of psychedelic drugs. Psilocybin.
1980 — EEG effects of hallucinogens and cannabinoids using sleep-waking behavior as baseline.
1980 — Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus.
1980 — Psilocybin intoxication.
1980 — Analysis of psilocybin and psilocin in mushroom extracts by reversed-phase high performance liquid chromatography.
1980 — LDS-25 as a discriminative stimulus for response selection by pigeons.
1980 — Analysis of Psilocybin and Psilocin in Mushroom Extracts by Reversed-Phase High Performance Liquid Chromatography
1980 — Mushrooms and madness. Hallucinogenic mushrooms and some psychopharmacological implications.
1981 — Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-(N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols
1981 — On travels in the universe of the soul: reports on self-experiments with delysid (LSD) and psilocybin (CY).
1981 — Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy
1981 — Interaction of D-LSD with blood platelets of rabbits: shape change and specific binding.
1981 — Quantitative analysis of psilocybin and psilocin and psilocybe baecystis (singer and smith) by high-performance liquid chromatography and by thin-layer chromatography
1981 — Isolation of Psilocybin From Psilocybe argentipes and Its Determination in Specimens of Some Mushrooms
1981 — Determination of psilocybin in Psilocybe semilanceata using high-performance liquid chromatography on a silica column
1981 — Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats.
1981 — Occurrence of Psilocybin/Psilocin in Pluteus Salicinus (Pluteaceae)
1981 — The content of Psilocybin in Norwegian Psilocybe semilanceata.
1981 — Occurrence of Psilocybin/Psilocin in Pluteus salicinus (Pluteaceae)
1981 — ChemInform Abstract: COMPARISON OF SOLUTION CONFORMATIONAL PREFERENCES FOR THE HALLUCINOGENS BUFOTENIN AND PSILOCIN USING 360-MHZ PROTON NMR SPECTROSCOPY
1981 — ChemInform Abstract: PSILOCIN ANALOGS. PART2. SYNTHESIS OF3-(2-(DIALKYLAMINO)ETHYL)-, 3-(2-(N-METHYL-N-ALKYLAMINO)ETHYL)-, AND3-(2-(CYCLOALKYLAMINO)ETHYL)INDOL-4-OLS
1981 — Sequelae of a 'magic mushroom banquet'.
1981 — Clinical toxicology of "magic mushroom" ingestion.
1981 — Chloroquine psychosis: a chemical psychosis?
1982 — Neurophysiological effects of hallucinogens on serotonergic neuronal systems.
1982 — Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'.
1982 — Physostigmine reversal of psilocybin intoxication.
1982 — Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer
1982 — Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, U.S.A.
1982 — Psilocin analogs. III. Synthesis of 5-methoxy- and 5-hydroxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles
1982 — Analysis of indole alkaloids in Norwegian Psilocybe semilanceata using high-performance liquid chromatography and mass spectrometry
1982 — The problem of psilocybin mushroom abuse.
1983 — Review of Enquiries made to the NPIS Concerning Psilocybe Mushroom Ingestion, 1978-1981
1983 — Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.).
1983 — The quantitation of psilocybin in hallucinogenic mushrooms using high performance liquid chromatography.
1983 — Phenomenally phunny phungi--psilocybin toxicity.
1984 — Differential effects of hallucinogenic drugs on the activity of serotonin-containing neurons in the nucleus centralis superior and nucleus raphe pallidus in freely moving cats.
1984 — Ethnobotany of psilocybin mushrooms, especially Psilocybe cubensis.
1984 — The genus psilocybe
1984 — Psilocybin in Finnish Psilocybe semilanceata.
1984 — Long-lasting behavioral effects of bromocriptine in cats.
1984 — Detection of Psilocybin and Psilocin in Norwegian Species ofPluteusandConocybe
1984 — Occurrence of Psilocybin and Baeocystin in the genus Inocybe (Fr.) Fr
1985 — An aqueous-organic extraction method for the isolation and identification of psilocin from hallucinogenic mushrooms.
1985 — New trends in drug use among youth in California.
1985 — An Aqueous-Organic Extraction Method for the Isolation and Identification of Psilocin from Hallucinogenic Mushrooms
1985 — A technique for the rapid isolation and identification of psilocin from psilocin/psilocybin-containing mushrooms.
1985 — A Technique for the Rapid Isolation and Identification of Psilocin from Psilocin/Psilocybin-Containing Mushrooms
1985 — Occurrence of psilocybin in various higher fungi from several European countries.
1986 — Poisoning by hallucinogenic mushroom hikageshibiretake (Psilocybe argentipes K. Yokoyama) indigenous to Japan.
1986 — Quantitative Bestimmung der Indolderivate von Psilocybe semilanceata (Fr.) Kumm.
1986 — Psilocybin in Mycelkulturen von Inocybe aeruginascens
1986 — Synthesis of psilocin labelled with 14C and 3H
1986 — Studies of the relationship between molecular structure and hallucinogenic activity.
1986 — Relationship of CNS tryptaminergic processes and the action of LSD-like hallucinogens.
1986 — Psilocybin in Fruchtkörpern vonInocybe aeruginascens
1986 — Determination of tryptamine derivatives in hallucinogenic mushrooms using high-performance liquid chromatography with photodiode array detection
1987 — [Diagnosis and therapy of mushroom poisoning (1)].
1987 — Occurrence of Psilocybin and Baeocystin in Fruit Bodies of Pluteus salicinus.
1987 — The Occurrence of Psilocybin and Psilocin in Finnish Fungi
1987 — Relief of obsessive-compulsive symptoms by LSD and psilocin
1987 — Variation of the Amount of Alkaloids in Fruit Bodies of Inocybe aeruginascens.
1987 — Absence of psilocybin in species of fungi previously reported to contain psilocybin and related tryptamine derivatives
1988 — [Poisoning by the hallucinogenic mushroom hikageshibiretake (Psilocybe argentipes)--with special reference to subjective experiences during psilocybin poisoning].
1988 — Synthesis of Baeocystin, a natural Psilocybin Analogue
1988 — Hallucinogenic mushrooms.
1988 — The Occurrence of Tryptamine Derivatives in Psilocybe semilanceata
1988 — Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
1988 — Occurrence of psilocybin, psilocin and baeocystin in Gymnopilus purpuratus
1989 — Clinical features and management of intoxication due to hallucinogenic drugs.
1989 — Biotransformation of tryptamine derivatives in mycelial cultures of Psilocybe.
1989 — Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon.
1989 — Analysis and Cultivation of Fruit Bodies and Mycelia of Psilocybe bohemica
1989 — Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline.
1989 — Biotransformation of Tryptamine in Fruiting Mycelia of Psilocybe cubensis.
1990 — Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection
1990 — Possible uses of psilocybin and muscarin alkaloids in the chemotaxonomy of Inocybe (Fr.)Fr.
1990 — [Hallucinogenic psilocybine containing mushrooms. Toxins contained in Danish wild mushrooms].
1990 — 'Magic mushroom' poisoning in a dog.
1990 — Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
1990 — A Novel Extraction Procedure for Psilocybin and Psilocin Determination in Mushroom Samples
1990 — 'Magic mushroom' poisoning in a colt.
1991 — Psilocin, psilocybin, serotonin and urea in Panaeolus cyanescens from various origin
1992 — Psychoactive mushroom use in Koh Samui and Koh Pha-Ngan, Thailand.
1992 — Adolescent drug use in Wales.
1992 — [Consumption of psilocybin-containing hallucinogenic mushrooms by young people].
1992 — Human hallucinogen interactions with drugs affecting serotonergic neurotransmission.
1993 — [Neuroleptics and serotonin].
1993 — Wasson's alternative candidates for soma.
1993 — Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically.
1993 — Skinner, Maslow, and Psilocybin
1993 — Species identification and chemical analysis of psychoactive fungi in the Hawaiian islands.
1993 — Clinical symptomatology and management of mushroom poisoning.
1994 — Extraction and analysis of indole derivatives from fungal biomass.
1994 — [Psychedelic experiences at the onset of productive episodes of endogenous psychoses].
1994 — Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus.
1994 — Bufotenine - A Hallucinogen in Ancient Snuff Powders of South America and a Drug of Abuse on the Streets of New York City.
1994 — Occurrence of psilocybin and psilocin in Psilocybe pseudobullacea (Petch) Pegler from the Venezuelan Andes
1994 — Ethnomycology, biochemistry, and cultivation of Psilocybe samuiensis Guzmán, Bandala and Allen, a new psychoactive fungus from Koh Samui, Thailand.
1995 — [A caution for psilocybine in wild mushrooms. A young addict acquired acute delirium].
1996 — A review of the usefulness of the standard EEG in psychiatry.
1996 — Listening for the logos: a study of reports of audible voices at high doses of psilocybin
1996 — Serotonin, psilocybin, and body dysmorphic disorder: a case report.
1996 — Increased activation of indirect semantic associations under psilocybin.
1996 — Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
1997 — Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.
1997 — Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man
1997 — Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis.
1997 — A Five-Step Synthesis of Psilocin from Indole-3-carbaldehyde
1998 — [The forensic chemical study of psilocybine-containing fungi].
1998 — Dr. Leary's Concord Prison Experiment: a 34-year follow-up study.
1998 — Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction.
1998 — Strategies for the capillary electrophoretic separation of indole alkaloids in Psilocybe semilanceata.
1998 — Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions.
1998 — Analysis of psilocin in Polish hallucinogenic mushrooms
1998 — Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction
1998 — 11C-radiolabeling of hallucinogenic psilocin, a potential radioligand for studying the role of serotonin receptors in psychotic symptom formation
1998 — Methodological issues of human experimental research with hallucinogens.
1998 — Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.
1998 — 529 The hallucinogen psilocybin increases prepulse inhibition of the startle reflex in healthy humans
1998 — Recent findings from the Ontario Student Drug Use Survey.
1998 — Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans.
1998 — Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
1998 — Capillary electrophoresis of psilocybin in hallucinogenic mushrooms
1999 — A New Synthesis of Psilocin
1999 — [The morphofunctional changes in the internal organs in the modelling of poisonings by psilocybine-containing mushrooms].
1999 — Analysis of psilocybin and psilocin in Psilocybe subcubensis GUZMÁN by ion mobility spectrometry and gas chromatography-mass spectrometry
1999 — H-D Exchange of Psilocin and Its Analogs
1999 — South African fungi 9: Psilocybe natalensis - a blueing hallucinogenic species from South Africa
1999 — Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.
1999 — 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.
1999 — Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin
1999 — Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.
1999 — ChemInform Abstract: Chemistry of Indoles. Part 88. A Five-Step Synthesis of Psilocin from Indole-3-carbaldehyde.
1999 — [Biological addictive drugs--is there a change in drug taking behavior of young drug addicts?].
1999 — ChemInform Abstract: A New Synthesis of Psilocin
1999 — ChemInform Abstract: Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin.
1999 — On-line coupling of automated solid-phase extraction with high-performance liquid chromatography and electrochemical detection. Quantitation of oxidizable drugs of abuse and their metabolites in plasma and urine.
1999 — Analysis of psilocybin and psilocin in psilocybe subcubensis Guzman by ion mobility spectrometry and gas chromatography-mass spectrometry
1999 — Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
1999 — Chromatographic screening techniques in systematic toxicological analysis.
1999 — Panaeolus bisporus - an adventitious fungus in central Europe, rich in psilocin
2000 — Bufotenine: toward an understanding of possible psychoactive mechanisms.
2000 — [Microscopic study of powders of hallucinogenic mushrooms--Psilocybe sp].
2000 — TRAGIC FLYING ATTEMPT UNDER THE INFLUENCE OF "MAGIC MUSHROOMS"
2000 — Neurotropic Effect of Extracts from the Hallucinogenic Mushroom Psilocybe cubensis (Earle) Sing. (Agaricomycetideae). In Vitro Studies
2000 — Multifocal cerebral demyelination after magic mushroom abuse.
2000 — 177. NMDA and 5-HT2A receptor dysfunction in working memory deficits in schizophrenia
2000 — [Development of synthetic methods for 4-substituted indoles and their applications for the syntheses of natural products].
2000 — Detecting psychoactive drugs in the developmental stages of mushrooms.
2000 — Nonmedical drug use among adolescent students: highlights from the 1999 Ontario Student Drug Use Survey.
2000 — Detection of psilocin in body fluids
2000 — Hallucinogenic mushrooms on the German market - simple instructions for examination and identification.
2000 — Hallucinogenic drugs attenuate the subjective response to alcohol in humans.
2000 — [Intoxications by hallucinogenic mushrooms].
2000 — Liquid chromatography-mass spectrometry as a routine method in forensic sciences: a proof of maturity.
2000 — Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
2000 — The effects of psychoactive drugs and neuroleptics on language in normal subjects and schizophrenic patients: a review.
2000 — Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine).
2001 — Drug addiction. Part I. Psychoactive substances in the past and presence.
2001 — The effect of Psilocybe cubensis extract on hippocampal neurons in vitro.
2001 — Towards a molecular approach for the identification of fungal taxa that contain psilocybin
2001 — The detection of psilocin in human urine.
2001 — The Detection of Psilocin in Human Urine
2001 — Patterns of recreational drug use at dance events in Edinburgh, Scotland.
2001 — A systems model of altered consciousness: integrating natural and drug-induced psychoses.
2001 — Brain mechanisms of hallucinogens and entactogens.
2002 — Synthetic Studies of Psilocin Analogs Having Either a Formyl Group or Bromine Atom at the 5- or 7-Position.
2002 — Jekyll and Hyde revisited: paradoxes in the appreciation of drug experiences and their effects on creativity.
2002 — Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.
2002 — Entheogens and Existential Intelligence: The Use of Plant Teachers as Cognitive Tools
2002 — Identifying the presence of ‘magic mushrooms’ by DNA profiling
2002 — Possible mechanisms of panic attack and schizophrenia via APUD system.
2002 — Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
2002 — What geometric visual hallucinations tell us about the visual cortex.
2002 — Drugs of abuse monitoring in blood for control of driving under the influence of drugs.
2002 — 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens.
2002 — ChemInform Abstract: The Chemistry of Indoles. Part 109. Synthetic Studies of Psilocin Analogues Having Either a Formyl Group or Bromine Atom at the 5- or 7-Position.
2002 — Ecstasy and drug consumption patterns: a Canadian rave population study.
2002 — Synthesis of a psilocin hapten and a protein-hapten conjugate
2002 — Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man
2002 — The pharmacology of psilocybin.
2002 — Psychotropic drugs in developmental mushrooms: a case study review.
2002 — Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.
2003 — [Neurological syndromes associated with the ingestion of plants and fungi with a toxic component (II). Hallucinogenic fungi and plants, mycotoxins and medicinal herbs].
2003 — Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.
2003 — A double-blind, placebo controlled study of the effect of the hallucinogenic 5-HT1A&2A agonist psilocybin on binocular rivalry rate and rhythmicity
2003 — Electrocardiographic examination of heart function in rats exposed to hallucinogens from Psilocybe mushrooms
2003 — The influence of psilocin and phenylethylamine on the energy metabolism in the rat heart
2003 — [Discrimination of psychoactive fungi (commonly called "magic mushrooms") based on the DNA sequence of the internal transcribed spacer region].
2003 — Preparation of the 4-Hydroxytryptamine Scaffold via Palladium-Catalyzed Cyclization: A Practical and Versatile Synthesis of Psilocin
2003 — The examination of mushroom poisonings at Akita University.
2003 — Concise Large-Scale Synthesis of Psilocin and Psilocybin, Principal Hallucinogenic Constituents of “Magic Mushroom”
2003 — [Hallucinogens, amphetamines and entactogens].
2003 — [Levels of psilocybin and psilocin in various types of mushrooms].
2003 — Psychoactive drugs and quality of life.
2003 — [Acute higher funghi mushroom poisoning and its treatment].
2003 — P.6.057 Effects of 2A receptor challenge by psilocybin on cognitive performance and neuroendocrine measures in healthy humans: A serotonin model of psychosis
2003 — Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples
2003 — Designer Hallucinogens
2003 — Morphological and chemical analysis of magic mushrooms in Japan.
2003 — The Effects of he Hallucinogenic Serotonin 1A/2A Agonist, Psilocybin, on Binocular Rivalry and Visual Contrast Detection Thresholds
2004 — Preparation of Monoclonal Antibodies Reactive to a Hallucinogenic Drug, Psilocin
2004 — Khat and mushrooms associated with psychosis.
2004 — Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys.
2004 — Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.
2004 — Forensic analysis of hallucinogenic fungi: a DNA-based approach.
2004 — Hallucinogens and dissociative agents naturally growing in the United States.
2004 — Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
2004 — The Meixner test in the detection of α-amanitin and false-positive reactions caused by psilocin and 5-substituted tryptamines
2004 — Psilocybin impairs high-level but not low-level motion perception.
2004 — Development of a psilocin immunoassay for serum and blood samples
2004 — Determination of psilocin in magic mushrooms and rat plasma by liquid chromatography with fluorimetry and electrospray ionization mass spectrometry
2004 — The noetic connection: synaesthesia, psychedelics, and language
2005 — Study on the biological characteristics and cultivation of panaeolus bisporus
2005 — Response consistency in young adolescents' drug use self-reports: a recanting rate analysis.
2005 — Substance abuse on the college campus.
2005 — Liquid chromatography-mass spectrometric and liquid chromatography-tandem mass spectrometric determination of hallucinogenic indoles psilocin and psilocybin in "magic mushroom" samples.
2005 — Liquid Chromatography-Mass Spectrometric and Liquid Chromatography-Tandem Mass Spectrometric Determination of Hallucinogenic Indoles Psilocin and Psilocybin in “Magic Mushroom” Samples
2005 — [DNA and chemical analyses of commercial fly agaric-related products].
2005 — Determination of psilocybin in hallucinogenic mushrooms by reversed-phase liquid chromatography with fluorescence detection.
2005 — Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.
2005 — Can psychedelics have a role in psychiatry once again?
2005 — Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
2005 — Determination of psilocin and psilocybin using flow injection analysis with acidic potassium permanganate and tris(2,2′-bipyridyl)ruthenium(II) chemiluminescence detection respectively
2005 — B31 3,4-METHYLENEDIOXYMETHAPMHETAMINE (MDMA) AND4-OH-DIMETHYLTRYPTAMINE (PSILOCIN) INTERACTION IN RATS: BEHAVIORAL STUDY ON PREPULSE INHIBITION OF ACOUSTIC STARTLE REACTION AND ON LOCOMOTION
2005 — Psychopathological effects of S-ketamine and dimethyltryptamine (DMT) in humans: a double-blind, cross-over human experimental study of the NMDA antagonist and the 5HT2A agonist model of psychosis
2005 — Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.
2005 — Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study.
2005 — SAR of psilocybin analogs: discovery of a selective 5-HT2C agonist.
2005 — Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
2005 — Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse.
2005 — Personality Characteristics of Adolescents with Hallucinogen, Methamphetamine, and Cannabis Dependence: A Comparative Study
2005 — SAR of Psilocybin Analogues: Discovery of a Selective 5-HT2C Agonist.
2006 — The Determination of Psilocin and Psilocybin in Hallucinogenic Mushrooms by HPLC Utilizing a Dual Reagent Acidic Potassium Permanganate and Tris(2,2′-bipyridyl)ruthenium(II) Chemiluminescence Detection System
2006 — [Chronic cluster headache: Response to psilocybin].
2006 — Psilocin multiple intake resulted and in cardiotoxic effects
2006 — Can mushrooms help save the world? Interview by Bonnie J. Horrigan.
2006 — Effects of the N343A mutation in TM6 of the human serotonin 5-HT2A Receptor
2006 — Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography
2006 — Effects of psilocybin on time perception and temporal control of behaviour in humans.
2006 — Psilocin Identified in a DUID Investigation
2006 — Values and beliefs of psychedelic drug users: a cross-cultural study.
2006 — Patterns of simultaneous polysubstance use in drug using university students.
2006 — Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens.
2006 — Response of cluster headache to psilocybin and LSD.
2006 — Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a “magic mushroom” user
2006 — Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al.
2006 — Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al.
2006 — Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al.
2006 — Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al.
2006 — PSILOCYBIN STUDIES TURN A NEW LEAF
2006 — Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
2006 — Hallucinogens
2006 — Hallucinogen research inspires “neurotheology”
2006 — Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
2006 — Phylogenetic relationship of psychoactive fungi based on rRNA gene for a large subunit and their identification using the TaqMan assay (II).
2006 — The adverse effects of hallucinogens from intramural perspective.
2006 — Detection and determination of abused hallucinogens in biological material.
2007 — [Hallucinogenic fungi (psilocybe). Part II. Identification of Psilocybe semilanceata by PCR].
2007 — [Concentration of selected microelements in blood serum of rats exposed to the action of psilocin and phenylethylamine].
2007 — 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users.
2007 — HPLC/DAD analysis of psilocin and psilocybin in psilocybe cubensis
2007 — Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
2007 — Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
2007 — Psilocybin Results Inspire Researchers
2007 — The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval.
2007 — Mad Thoughts on Mushrooms: Discourse and Power in the Study of Psychedelic Consciousness
2007 — Liquid chromatography-tandem mass spectrometry method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and metabolites, in urine.
2007 — Psilocybin-induced stimulus control in the rat.
2007 — Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action.
2007 — Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
2007 — [Automutilation after consumption of hallucinogenic mushrooms].
2007 — Involvement of 5-HT2A Receptor in the Regulation of Hippocampal-Dependent Learning and Neurogenesis
2007 — The Screening of Mushrooms Found in Trinidad to Determine the Presence of the Psychoactive Substances Psilocin and Psilocybin
2008 — Between prohibitions: patterns and meanings of magic mushroom use in the UK.
2008 — Antagonism of phencyclidine-induced stimulus control in the rat by other psychoactive drugs.
2008 — Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.
2008 — The Phenomenology and Potential Religious Import of States of Consciousness Facilitated by Psilocybin
2008 — Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder
2008 — Chemical Constituents of Gymnopilus spectabilis and Their Antioxidant Activity.
2008 — Entheogens and the Public Mystery: The Rhetoric of R. Gordon Wasson
2008 — Identification of a serotonin/glutamate receptor complex implicated in psychosis.
2008 — Effects of varied doses of psilocybin on time interval reproduction in human subjects.
2008 — Ausdrucksphänomenologie der Modellpsychosen (Psilocybin); pp. 69-84
2008 — Klinische Erfahrungen mit Psilocybin (CY39 Sandoz)
2008 — Ausdrucksphänomenologie der Modellpsychosen (Psilocybin); pp. 85-100
2008 — Psychophysische Korrelationen unter der Einwirkung von Psycholytika (LSD, Psilocybin und ähnl.)
2008 — II. The Effects of Some Hallucinogens on Aggressiveness of Mice and Rats
2008 — [Hallucinogen-induced psychological disorders].
2008 — Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.
2008 — Benefits of 'magic mushroom' therapy long lasting
2008 — Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI
2008 — Effects of the hallucinogenic 5-HT2A agonist psilocybin on object completion in humans
2008 — Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
2008 — The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists.
2008 — Serotonin research: contributions to understanding psychoses.
2008 — Unrecognized magic mushroom abuse in a 28-year-old man.
2008 — Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
2009 — Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.
2009 — Chemical interactions with pyramidal neurons in layer 5 of the cerebral cortex: control of pain and anxiety.
2009 — Agonist-trafficking and hallucinogens.
2009 — Detection of Psilocybin Mushroom Analogs in Chocolate: Incorporating Current Events into the Undergraduate Teaching Laboratory
2009 — Psilocybin: Historical and pharmacological perspective and current authorized research
2009 — Enhancement of Indole Alkaloids Produced by Psilocybe cubensis (Earle) Singer (Agaricomycetideae) in Controlled Harvesting Light Conditions
2009 — [Acute encephalopathy caused by cyanogenic fungi in 2004, and magic mushroom regulation in Japan].
2009 — GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies.
2009 — A multi-component LC-MS/MS method for detection of ten plant-derived psychoactive substances in urine.
2009 — [Mushroom poisoning--the dark side of mycetism].
2009 — Apical regional wall motion abnormalities reminiscent to Tako-Tsubo cardiomyopathy following consumption of psychoactive fungi.
2009 — [Simple and rapid screening for psychotropic natural products using Direct Analysis in Real Time (DART)-TOFMS].
2009 — Analysis of mushroom exposures in Texas requiring hospitalization, 2005-2006.
2009 — Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials.
2009 — Effects of Psilocybe argentipes on marble-burying behavior in mice.
2009 — Availability of websites offering to sell psilocybin spores and psilocybin.
2009 — Unifying electron transfer mechanism for psilocybin and psilocin
2009 — Palladium-catalyzed synthesis of tryptamines and tryptamine homologues: synthesis of psilocin
2009 — [Student's use of illicit drugs: a survey in a preventive health service].
2009 — Detection of Psilocybin Mushroom Analogs in Chocolate
2009 — Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan
2009 — Current Research on the Human Experience of Spirituality Following the Ingestion of ‘Magic’ Psilocybin Mushrooms: An Annotated Bibliography for Social Workers and Other Health Care Professionals
2009 — Aspects of secondary metabolism in basidiomycetes: I. biological and biochemical studies on Psilocybe cubensis II. a survey of phenol-o-methyltransferase in species of Lentinus and Lentinellus
2009 — Other Times I Can Barely See: The Effects of Hallucinogens on Vision and Attention
2010 — Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography.
2010 — Comparative study of ATR and transflection IR spectroscopic techniques for the analysis of hallucinogenic mushrooms.
2010 — Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases
2010 — ChemInform Abstract: Palladium-Catalyzed Synthesis of Tryptamines and Tryptamine Homologues: Synthesis of Psilocin.
2010 — Using psilocybin to investigate the relationship between attention, working memory and the serotonin 5-HT1A and 5-HT2A receptors
2010 — Psilocybin slows binocular rivalry switching through serotonin modulation
2010 — The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series
2010 — Psilocybin Mushrooms of the World: an identification guide. Paul Stamets.
2010 — Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin.
2010 — The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
2010 — Acute toxicity of Psilocybe cubensis (Ear.) Sing., Strophariaceae, aqueous extract in mice
2010 — Determining the subjective effects of TFMPP in human males.
2010 — Psychometric evaluation of the altered states of consciousness rating scale (OAV).
2010 — The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
2010 — Turn on, tune in, but don't drop out: The impact of neo-liberalism on magic mushroom users' (in)ability to imagine collectivist social worlds.
2010 — Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
2011 — Heaven and hell--a phenomenological study of recreational use of 4-HO-MET in Sweden.
2011 — Voice of the psychonauts: coping, life purpose, and spirituality in psychedelic drug users.
2011 — Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
2011 — Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.
2011 — Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.
2011 — Biophotons, hallucinogens, and fluorescence
2011 — Alternative headache treatments: nutraceuticals, behavioral and physical treatments.
2011 — The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.
2011 — Harm potential of magic mushroom use: a review.
2011 — Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.
2011 — P.1.e.017 The functional brain correlates of the psychedelic state: an arterial spin labelling study with psilocybin
2011 — Determining the pharmacokinetics of psilocin in rat plasma using ultra-performance liquid chromatography coupled with a photodiode array detector after orally administering an extract of Gymnopilus spectabilis
2011 — Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms
2011 — Iconography in Bradshaw rock art: breaking the circularity.
2011 — Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.
2011 — Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
2011 — Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
2011 — Salvia divinorum use and phenomenology: results from an online survey.
2011 — Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
2011 — The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.
2011 — Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
2011 — Study Suggests Hallucinogen May Be Personality Changer
2012 — Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
2012 — Prediction of psilocybin response in healthy volunteers.
2012 — Psychedelic synaesthesia: Evidence for a serotonergic role in synaesthesia
2012 — Flavone Glycoside Antagonizes Psilocybin-Induced Toxicity by Reducing Oxidative Stress in Rats Model
2012 — GAMBARAN KARAKTERISTIK SOSIODEMOGRAFIK, TINGKAT PENGETAHUAN DAN POLA PENGGUNAAN JAMUR Psilocybin PADA MAHASISWA S1 UNIVERSITAS PADJAJARAN PERIODE AJAR2010-2011
2012 — Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.
2012 — Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.
2012 — Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.
2012 — Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
2012 — Effects of the hallucinogenic drugs mescaline, phencyclidine and psilocybin on zebrafish behavior and physiology
2012 — Neuroimaging: a scanner, colourfully.
2012 — Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
2012 — Anticholinergic toxicity after the ingestion of serotonergic 'magic mushrooms'
2012 — A Comparative Review of the Neuro-Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness: The Uniqueness of Some Hallucinogens
2012 — Spirituality and Hallucinogen Use: Results from a Pilot Study among College Students
2012 — Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.
2012 — Moral transhumanism: the next step.
2012 — High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.
2012 — Opening Doors of Perception: Psychedelic Drugs and End-of-Life Care
2012 — A fatal case of 'magic mushroom' ingestion in a heart transplant recipient.
2012 — A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability
2012 — Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.
2012 — Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
2012 — Effects of psilocybin on the human brain functional network
2013 — [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
2013 — Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia.
2013 — Experienced drug users assess the relative harms and benefits of drugs: a web-based survey.
2013 — Psychedelics and mental health: a population study.
2013 — Methoxetamine (MXE)--a phenomenological study of experiences induced by a "legal high" from the internet.
2013 — Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi.
2013 — [Suicide under the influence of "magic mushrooms"].
2013 — Peak experiences of psilocybin users and non-users.
2013 — Over 30 million psychedelic users in the United States.
2013 — The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
2013 — Substance use initiation: the role of simultaneous polysubstance use.
2013 — Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations
2013 — DETEKSI PSILOCIN URIN PADA MENCIT SWISS WEBSTER TERHADAP PEMBERIAN JAMUR PSILOCYBE CUBENSIS DOSIS BERTINGKAT.
2013 — The Use of Synthetic Cathinones and Tryptamines in a Psychiatric Population
2013 — Animal models of serotonergic psychedelics.
2013 — Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.
2013 — Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice.
2013 — Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
2013 — Magic truffles or Philosopher's stones: a legal way to sell psilocybin?
2013 — Activity and Enzyme Kinetics of Human UDP-Glucuronosyltransferases: Studies of Psilocin Glucuronidation and the Effects of Albumin on the Enzyme Kinetic Mechanism
2013 — Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS
2013 — A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
2013 — Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
2013 — Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol
2013 — Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning.
2013 — Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
2013 — PSYCHEDELIC DRUGS, MAGICAL THINKING AND PSYCHOSIS
2013 — A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.
2013 — Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.
2013 — Broadband cortical desynchronization underlies the human psychedelic state.
2013 — Exposure to Potent Hallucinogens in an Adolescent
2013 — Serotonergic hallucinogens as translational models relevant to schizophrenia.
2013 — Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.
2013 — Altered states: psychedelics and anesthetics.
2013 — Literature review: Considerations for Psychedelic Research
2013 — EPA-1211 - Role of 5-HT2a and mglu2 as a gpcr heterocomplex in antipsychotic action
2013 — EPA-0137 - EEG power spectra and connectivity changes in animal serotonergic and glutamatergic models of psychosis - implications for treatment
2014 — Psilocybin and Obsessive Compulsive Disorder.
2014 — The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers.
2014 — The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.
2014 — A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
2014 — Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
2014 — The Heffter Research Institute: past and hopeful future.
2014 — Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision.
2014 — Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
2014 — Magic Mushroom Growing Kits: A new method for infringement of the narcotic laws.
2014 — PSILOCYBIN RESEARCH AT JOHNS HOPKINS: A 2014 REPORT
2014 — My Experience as a Guide in the Johns Hopkins Psilocybin Research Project
2014 — Stanislav Grof's Contributions to FDA Drug Development Research with Psychedelics
2014 — Psychedelic Research Resurrected: The Contributions of Stanislav Grof
2014 — Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are Overrated
2014 — P.4.022 The impact of serotonin system modulation on behavior and quantitative EEG in an animal model of psychosis induced by psilocin
2014 — Psilocybin--summary of knowledge and new perspectives.
2014 — TINJAUAN PELAKSANAAN KETENTUAN PIDANA UNDANGUNDANG NOMOR 35 TAHUN 2009 TERHADAP PENYALAHGUNAAN MAGIC MUSHROOM
2014 — Synthesis, hydrolysis and stability of psilocin glucuronide
2014 — Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists.
2014 — The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat
2014 — Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
2014 — Psychedelics, Glutamate, and Neuroimaging Studies
2014 — Examining the psychological mechanisms of psilocybin-assisted smoking cessation treatment: A pilot study
2014 — Characterization of challenging experiences (i.e., bad trips) after ingesting psilocybin
2014 — Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs.
2014 — 14C-Psilocin tissue distribution in pregnant rats after intravenous administration
2014 — Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.
2014 — ENTHEOGENS, MYSTICISM, AND NEUROSCIENCE
2014 — P.1.g.005 Serotonergic modulation of emotion processing by the mixed 5-HT1A/2A receptor agonist psilocybin reduces amygdala activation to negative stimuli - a pharmacological fMRI study
2014 — Hallucinogens induce a specific barcode of phosphorylation on the serotonin2A receptor that underlies a weaker receptor desensitization and internalization
2014 — Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
2014 — Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of hallucinogenic drugs in hair of psychedelic plants and mushrooms consumers.
2014 — Enhanced repertoire of brain dynamical states during the psychedelic experience.
2014 — Pholiotina cyanopus, a rare fungus producingpsychoactive tryptamines
2014 — Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.
2014 — Homological scaffolds of brain functional networks.
2014 — The challenging experience questionnaire: Characterization of acute adverse reactions to psilocybin
2014 — Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenology
2014 — Turn on and tune in to evidence-based psychedelic research
2015 — Effect of Psilocin on Extracellular Dopamine and Serotonin Levels in the Mesoaccumbens and Mesocortical Pathway in Awake Rats
2015 — Taxonomic Identification of Hallucinogenic Mushrooms Seized on the Illegal Market Using a DNA-Based Approach and LC/MS-MS Determination of Psilocybin and Psilocin
2015 — Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey.
2015 — Restructuring consciousness -the psychedelic state in light of integrated information theory.
2015 — The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network.
2015 — Recreational use, analysis and toxicity of tryptamines.
2015 — Can psychedelic compounds play a part in drug dependence therapy?
2015 — Hallucinogenic drugs in pre-Columbian Mesoamerican cultures.
2015 — PENGARUH PEMBERIAN EKSTRAK JAMUR PSILOCYBE CUBENSIS DOSIS BERTINGKAT TERHADAP RASA INGIN TAHU MENCIT SWISS WEBSTER YANG DIUKUR DENGAN MANUAL HOLE BOARD
2015 — Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.
2015 — Drug models of schizophrenia.
2015 — Analysis of Psilocin, Bufotenine and LSD in Hair
2015 — [Ilicit drugs frequently used by drug addicts].
2015 — Psychedelics not linked to mental health problems or suicidal behavior: a population study.
2015 — Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
2015 — Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
2015 — Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
2015 — The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making
2015 — 5HT2a Receptors - a New Target for Depression?
2015 — Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice
2015 — Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.
2015 — Legal highs: staying on top of the flood of novel psychoactive substances.
2015 — Psilocybin-containing mushrooms, upper palaeolithic rock art and the neuropsychological model
2015 — Phylogenetic and chemical studies in the potential psychotropic species complex of Psilocybe atrobrunnea with taxonomic and nomenclatural notes.
2015 — Light microscopy can reveal the consumption of a mixture of psychotropic plant and fungal material in suspicious death.
2015 — Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.
2015 — The hallucinogenic world of tryptamines: an updated review.
2015 — Psilocybin, psychological distress, and suicidality.
2015 — P.1.i.005 The 5-HT2A/1A agonist psilocybin reduces social pain and enhances empathy in healthy volunteers
2015 — [Psilocybin - public available psychodysleptic].
2015 — A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State.
2015 — Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
2015 — Lysergic Acid Diethylamide and Psilocybin Revisited.
2015 — Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
2015 — The Psyche in Psychedelic
2015 — Comparative phenomenology of psilocybin experiences in research and non-research settings
2015 — Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
2015 — Validation of the revised mystical experiences questionnaire in experimental sessions with psilocybin
2015 — Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts
2015 — Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain
2015 — Motivationen und Morphologie des Freizeitgebrauchs von Psychedelika (LSD, Psilocybin-Pilze): eine qualitative Interviewstudie
2016 — HPLC Analysis of Hallucinogenic Mushroom Alkaloids (Psilocin and Psilocybin) Applying Hydrophilic Interaction Chromatography (HILIC)
2016 — The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
2016 — Commentary: Effects of psilocybin on time perception and temporal control of behavior in humans.
2016 — Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.
2016 — The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.
2016 — The epistemic innocence of psychedelic states.
2016 — Psilocybin, LSD, Mescaline and drug-induced synesthesia
2016 — MEMO ON THE RELIGIOUS IMPLICATIONS OF THE CONSCIOUSNESS-CHANGING DRUGS (LSD, Mescalin, Psilocybin)
2016 — MAGIC MUSHROOM AND ITS EFFECTIVENESS
2016 — Classic hallucinogens in the treatment of addictions.
2016 — The use of illicit drugs as self-medication in the treatment of cluster headache: Results from an Italian online survey.
2016 — Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache.
2016 — Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior
2016 — The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)
2016 — [Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning].
2016 — Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
2016 — Psychedelics.
2016 — Observations concerning the synthesis of tryptamine homologues and branched tryptamine derivatives via the borrowing hydrogen process: synthesis of psilocin, bufotenin, and serotonin
2016 — Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
2016 — Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.
2016 — On the Origin of the Genus Psilocybe and Its Potential Ritual Use in Ancient Africa and Europe1
2016 — Sixty seconds on... psilocybin.
2016 — A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects
2016 — PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG
2016 — PM502. Effect of psilocybin on EEG brain connectivity in healthy volunteers - preliminary report
2016 — PM502. Effect of psilocybin on EEG brain connectivity in healthy volunteers - preliminary report
2016 — PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG
2016 — DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in “grow-kits” seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin
2016 — Sex differences and serotonergic mechanisms in the behavioural effects of psilocin
2016 — Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.
2016 — MAGIC MUSHROOMS: from sacred entheogen to Class A drug
2016 — ChemInform Abstract: Observations Concerning the Synthesis of Tryptamine Homologues and Branched Tryptamine Derivatives via the Borrowing Hydrogen Process: Synthesis of Psilocin, Bufotenin, and Serotonin.
2016 — Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.
2016 — Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor.
2016 — Hallucinogen Use Disorders.
2016 — Altered states: psilocybin for treatment-resistant depression.
2016 — Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
2016 — Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
2016 — Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case
2016 — Question-based Drug Development for psilocybin - Authors' reply.
2016 — Question-based Drug Development for psilocybin.
2016 — Psilocybin: panacea or placebo?
2016 — Psychedelic Psychotherapy: Insights From 25 Years of Research
2016 — Psilocybin as an alternative medicine for patients suffering from depression
2016 — Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models.
2016 — Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination task
2016 — Psilocybin-induced psychosis in humans and in rats − translational quantitative EEG study
2016 — Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
2016 — Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
2016 — Return of the psychedelics: Psilocybin for treatment resistant depression.
2016 — Psilocybin: promising results in double-blind trials require confirmation by real-world evidence.
2016 — Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip.
2016 — The role of psychedelics in palliative care reconsidered: A case for psilocybin.
2016 — Psilocybin for depression and anxiety associated with life-threatening illnesses.
2016 — Psilocybin and palliative end-of-life care.
2016 — Psilocybin in end of life care: Implications for further research.
2016 — Psilocybin: Psychotherapy or drug?
2016 — Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
2016 — Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
2016 — Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.
2016 — Psychedelics in the treatment of unipolar mood disorders: a systematic review.
2016 — The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
2016 — Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging.
2016 — Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
2016 — Lysergsyradietylamid (LSD) och psilocybin vid depression och ångestsjukdom: En litteraturstudie om effekter och biverkningar av LSD- och psilocybin-assisterad psykoterapi
2017 — Clinical potential of psilocybin as a treatment for mental health conditions.
2017 — Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
2017 — The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.
2017 — LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.
2017 — Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
2017 — Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.
2017 — Self unbound: ego dissolution in psychedelic experience.
2017 — Could Hallucinogens Induce Permanent Pupillary Changes in (Ab)users? A Case Report from New Zealand.
2017 — Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
2017 — Role of psilocybin in the treatment of depression.
2017 — Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse.
2017 — Statistical comparison of mass spectra for identification of amphetamine-type stimulants.
2017 — It's time to take psilocybin seriously as a possible treatment for substance use disorders.
2017 — Long-term follow-up of psilocybin-facilitated smoking cessation.
2017 — Neuronal dynamics of the anterior cingulate cortex during working memory and serotonergic manipulation
2017 — Simultaneous determination of γ-hydroxybutyric acid, ibotenic acid and psilocybin in saliva samples by capillary electrophoresis coupled with a contactless conductivity detector
2017 — Narrative therapy-assisted psilocybin use for treatment of depression
2017 — Maddening Therapies: How Hallucinogens Morphed into Novel Treatments
2017 — Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats
2017 — A New Spectrophotometric Method for the Determination of Psilocin and Psilocybin
2017 — Psilocybin and Mescaline - Molecule of the Month October 1999 [Archived version]
2017 — Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
2017 — Psilocybin in long-term meditators: Effects on default mode network functional connectivity and retrospective ratings of qualitative experience
2017 — Comparison of anomalous experiences after ingesting psilocybin mushrooms in research and non-research settings
2017 — Designer Drugs 2.0.
2017 — Psychedelics as Medicines: An Emerging New Paradigm.
2017 — Psilocybin for treating substance use disorders?
2017 — The fibrinolytic system: A new target for treatment of depression with psychedelics.
2017 — No clinically relevant effects in children after accidental ingestion of Panaeolina foenisecii (lawn mower's mushroom).
2017 — Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.
2017 — Anti-inflammatory effects of serotonin 5-HT2A receptor activation in ovalbumin-induced allergic asthma models
2017 — The Development and Regulation of Psychedelic Medicines
2017 — Should addiction researchers be interested in psychedelic science?
2017 — Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
2017 — Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis
2017 — Alterations of consciousness and mystical-type experiences after acute LSD in humans.
2017 — The Effects of LSD and Psilocin on Anxiety-Related Behaviours in Zebrafish
2017 — Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress
2017 — Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia.
2017 — Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression
2017 — Developing Guidelines and Competencies for the Training of Psychedelic Therapists
2017 — New psychoactive substances of natural origin: A brief review.
2017 — [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
2017 — Potential Therapeutic Effects of Psilocybin.
2017 — An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.
2017 — Navigating Psychedelic Medicines through (Inter)national Regulation
2017 — Psilocybin and Mescaline - Molecule of the Month October 1999 [Archived version]
2017 — Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice.
2017 — Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness.
2017 — [New patterns of substance use and abuse among French adolescents, a knowledge synthesis].
2017 — Enzymatische Synthese von Psilocybin
2017 — Horizontal gene cluster transfer increased hallucinogenic mushroom diversity
2017 — NATURALIZING PSYCHEDELIC SPIRITUALITY
2017 — ‘Magic mushroom’ enzyme mystery solved
2017 — Effect of Psilocybin on Empathy and Moral Decision-Making.
2017 — Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches.
2017 — Google Trends Analyses and Case Report: A Persistently Dilated Pupil in Psychedelics’ User
2017 — Enzymatic Synthesis of Psilocybin.
2017 — Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.
2017 — LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark.
2017 — Psilocybin: Good Trip or Bad Trip.
2017 — The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
2017 — Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
2017 — Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
2017 — Neuroticism is associated with challenging experiences with psilocybin mushrooms.
2017 — Psychedelic Drugs in Biomedicine.
2017 — Psychedelic Medicine for Mental Illness and Substance Use Disorders: Overcoming Social and Legal Obstacles
2017 — Can Psilocybin Treat Severe Depression
2017 — Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.
2017 — „Terapia szokowa”, czyli agoniści receptor 5-HT2A w leczeniu depresji i lęku
2017 — Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression
2017 — If you give a mouse a mushroom: Behavioral effects of hallucinogens in mice
2017 — Mikrodosering av lysergsyradietylamid och psilocybin och dess effekter på psykisk hälsa
2018 — Rapid-Acting Antidepressants.
2018 — Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.
2018 — More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression.
2018 — Dimensions of consciousness and the psychedelic state.
2018 — Psychedelics, Meditation, and Self-Consciousness.
2018 — Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.
2018 — Psilocybin and Mental Health-Don't Lose Control.
2018 — Hallucinogen persisting perception disorder: A literature review and three case reports.
2018 — Mushroom poisoning epidemiology in the United States.
2018 — Biological Effects and Biodistribution of Bufotenine on Mice.
2018 — Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy.
2018 — Unifying Theories of Psychedelic Drug Effects.
2018 — "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.
2018 — The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.
2018 — Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.
2018 — Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition.
2018 — d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
2018 — Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain.
2018 — Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
2018 — Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens.
2018 — The relationships of classic psychedelic use with criminal behavior in the United States adult population.
2018 — Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
2018 — Hallucinogens and Serotonin 5-HT Receptor-Mediated Signaling Pathways.
2018 — The Effects of Hallucinogens on Gene Expression.
2018 — Therapeutic Applications of Classic Hallucinogens.
2018 — Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
2018 — Effect of Hallucinogens on Unconditioned Behavior.
2018 — Phenomenology, Structure, and Dynamic of Psychedelic States.
2018 — Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.
2018 — Integration and segregation in whole-brain networks: implications for altered states of consciousness
2018 — Psychedelics, the Spiritual and Consciousness-an Evolving Confluence in the Cultural Stream
2018 — Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Psychological Distress
2018 — Are psychedelics effective in treating anxiety associated with a lifethreatening disease
2018 — Unlearning to See: Linking the Perceptual and Clinical Effects of Psychedelic Drugs.
2018 — The theory and practice of psilocybin assisted psychotherapy: an intervention design checklist
2018 — The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports
2018 — ANALISIS SENYAWA HALUSINOGEN DALAM MINUMAN MAGIC MUSHROOM (Psilocybin baeocystis) YANG BEREDAR DI KAWASAN KUTA-BALI
2018 — Taking Psychedelics Seriously (TH316)
2018 — Can psychedelic drug help with depression?
2018 — The hidden therapist: evidence for a central role of music in psychedelic therapy.
2018 — Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
2018 — Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
2018 — Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
2018 — Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
2018 — The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.
2018 — Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
2018 — Visual hallucinations and lifetime use of hallucinogen perception persisting disorder associated recreational drugs: results from a large online survey
2018 — Alteration of Depressive-like Behaviors by Psilocybe cubensis Alkaloid Extract in Mice: the Role of Glutamate Pathway
2018 — Horizontal gene cluster transfer increased hallucinogenic mushroom diversity.
2018 — Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF).
2018 — Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.
2018 — Taking Psychedelics Seriously.
2018 — Psychedelic Drugs as Therapeutics: No Illusions About the Challenges.
2018 — T263. Psilocybin Improves Cognitive Control and Downregulates Parietal Cortex in Treatment-Seeking Smokers
2018 — Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?
2018 — Analysis of new psychoactive substances in oral fluids by means of microextraction by packed sorbent followed by ultra-high-performance liquid chromatography-tandem mass spectrometry.
2018 — Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.
2018 — Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.
2018 — Out of the box: A psychedelic model to study the creative mind.
2018 — [Trends in Abuse of Biogenic Drugs in Parts of Germany 2007-2013].
2018 — High dose psilocybin is associated with positive subjective effects in healthy volunteers.
2018 — Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
2018 — Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi.
2018 — Psychedelic use and intimate partner violence: The role of emotion regulation.
2018 — Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
2018 — Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase-Enhanced Reactions.
2018 — Psychopharmacology of Psilocybin in Cancer Patients
2018 — Psychoactive plant- and mushroom-associated alkaloids from two behavior modifying cicada pathogens
2018 — Convergent evolution of psilocybin biosynthesis by psychedelic mushrooms
2018 — Altered trajectories in the dynamical repertoire of functional network states under psilocybin
2018 — Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
2018 — Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
2018 — Psychedelics and music: neuroscience and therapeutic implications.
2018 — Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
2018 — Psychedelics as anti-inflammatory agents.
2018 — The Utility of Psilocybin in Managing Anxiety and Depression in Cancer Patients
2018 — Entheogene Pilze: Welches Potential bietet die psychoaktive Substanz Psilocybin für die moderne Psychotherapie in Forschung und Praxis? / Sophie-Charlotte Alice Adler
2018 — Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats
2018 — Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
2018 — Detection and Identification of Psilocybe cubensis DNA Using a Real-Time Polymerase Chain Reaction High Resolution Melt Assay.
2018 — Serotonin, psychedelics and psychiatry
2018 — 1.13 Microdosing of Hallucinogens Among College Students: Frequency, Correlates, and Consequences
2018 — Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
2018 — The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training
2018 — DARK Classics in Chemical Neuroscience: Ibogaine.
2018 — Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
2018 — DARK Classics in Chemical Neuroscience: Psilocybin.
2018 — Psychedelics and Personality.
2018 — Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).
2018 — Iterative l-Tryptophan Methylation in Psilocybe Evolved by Subdomain Duplication.
2018 — The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
2018 — Mushroom Poisoning Cases in Dogs and Cats: Diagnosis and Treatment of Hepatotoxic, Neurotoxic, Gastroenterotoxic, Nephrotoxic, and Muscarinic Mushrooms.
2018 — Effects of psilocybin therapy on personality structure.
2018 — The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
2018 — Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
2018 — Psychiatry & the psychedelic drugs. Past, present & future.
2018 — TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT receptor pharmacological tool, or none of the above?
2018 — Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers
2018 — Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers
2018 — Psychedelic drugs in the treatment of anxiety, depression and addiction.
2018 — Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016.
2018 — Monoamine Biosynthesis via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom.
2018 — Second and third year medical students' self-reported alcohol and substance use, smoking habits and academic performance at a South African medical school.
2018 — Use of MDMA & Psilocybin in the Treatment of PTSD
2018 — The Psychedelic Altered State of Consciousness: An Assessment of the Current Status of Psychedelic Research
2018 — THE POTENTIAL THERAPEUTIC VALUE OF PSILOCYBIN: In Relation to Depression
2019 — Psilocybin occupancy of brain serotonin 2A receptors correlates with psilocin levels and subjective experience: a [11C]Cimbi-36 PET study in humans
2019 — Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
2019 — Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
2019 — The ethics of psychedelic research in disorders of consciousness.
2019 — Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers.
2019 — Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20 Century.
2019 — Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.
2019 — Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
2019 — Psychedelics as a treatment for disorders of consciousness.
2019 — The Past and Future of Psychedelic Science: An Introduction to This Issue.
2019 — Psychedelic-Assisted Group Therapy: A Systematic Review.
2019 — Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
2019 — Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being.
2019 — [Neurotrophic mechanisms of psychedelic therapy].
2019 — Psychedelic drugs-a new era in psychiatry?.
2019 — Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study.
2019 — Psychedelic fungus (Psilocybe sp.) authentication in a case of illegal drug traffic: sporological, molecular analysis and identification of the psychoactive substance.
2019 — Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.
2019 — Rapid-acting antidepressants.
2019 — Microcrystal Tests for the Identification of Illicit Drugs: Phencyclidine, Pseudoephedrine, and Psilocin
2019 — 2018: A watershed year for psychedelic science
2019 — Effects of psilocybin on functional connectivity measured with fNIRS: Insights from a single-subject pilot study
2019 — Psilocybin induces aberrant prediction error processing for tactile mismatch responses
2019 — These fungi drug cicadas with psilocybin or amphetamine to make them mate nonstop
2019 — Serotonergic Psychoactive Compounds as a Treatment for Addiction, Anxiety, and Depression: Their Efficacy and Legality
2019 — Psilocybin-Assisted Therapy: A Double-Blind Randomized Controlled Trial
2019 — Serotonergic Psychedelics LSD & Psilocybin Increase the Fractal Dimension of Cortical Brain Activity in Spatial and Temporal Domains
2019 — Production Options for Psilocybin: Making of the Magic.
2019 — The effects of psilocybin microdosing on perception: a double-blind controlled study
2019 — Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances.
2019 — Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
2019 — Qualitative analysis of synthetic opioids, synthetic hallucinogens and LSD in urine using LC-MS/MS
2019 — One Ultimate Journey? AKA the Huxley’s Method: Perspectives of (Ab)Users of Hallucinogens and Entheogens on Having Planned Pre-Mortem Psychedelic Trip
2019 — Psychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens
2019 — Is Psychedelic Medicine on the Horizon?
2019 — Acute renal injury cause by confirmed mushroom ingestion.
2019 — Modeling Retention Behavior on Analysis of Hallucinogenic Mushrooms Using Hydrophilic Interaction Liquid Chromatography.
2019 — A Study of Psilocybin for Major Depressive Disorder (MDD)
2019 — Relationship Of Magic Mushroom Literation As A Drug With Abuse It's Use As A Hallucination
2019 — Psychedelic medicine: The biology underlying the persisting psychedelic effects.
2019 — Increased use of illicit drugs in a Dutch cluster headache population.
2019 — Psychedelics Improve the Mental Health of Rats
2019 — Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
2019 — Attitudes Toward Medical Psychedelics
2019 — New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
2019 — T137. Psilocybin-Assisted Group Therapy for Demoralization in Long-Term AIDS Survivors
2019 — Psychedelic Medicine: Careful Studies, Regulations Are the Answer
2019 — Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study.
2019 — Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
2019 — Denver votes to decriminalise psilocybin mushrooms.
2019 — Generation of monoclonal antibodies for on-site analysis of psilocin and psilocybin in hallucinogenic mushrooms
2019 — Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug
2019 — Correction: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
2019 — Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
2019 — Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.
2019 — Introduction: Evidence for entheogen use in prehistory and world religions
2019 — Entheogens in Christian art: Wasson, Allegro, and the Psychedelic Gospels
2019 — Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.
2019 — Faces of HPPD: Hallucinogen Persisting Perception Disorder Patient Survey Results and a Descriptive Analysis of Patient Demographics, Medical Background, Drug Use History, Symptoms, and Treatments
2019 — The Potential of Psilocybin Administration in Terminal Cancer Patients
2019 — REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.
2019 — Motives and Side-Effects of Microdosing With Psychedelics Among Users.
2019 — Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature.
2019 — What Psilocybin Taught Me About Dying.
2019 — A SYSTEMATIC REVIEW OF PSILOCYBIN IN THE TREATMENT OF DEPRESSION AND ANXIETY
2019 — Psychedelic microdosing benefits and challenges: an empirical codebook.
2019 — Decreased Directed Functional Connectivity in the Psychedelic State
2019 — Disruptive Psychopharmacology.
2019 — Psychedelic-assisted therapies: The past, and the need to move forward responsibly.
2019 — Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.
2019 — Narrative identity, rationality, and microdosing classic psychedelics.
2019 — Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.
2019 — A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.
2019 — Non-drug altered states as psychedelic experiences
2019 — Beyond Cannabis: Psychedelic Decriminalization and Social Justice
2019 — Accounting for Microdosing Classic Psychedelics
2019 — The fumarate salts of the N-isopropyl-N-methyl derivatives of DMT and psilocin
2019 — Hallucinogens and Their Therapeutic Use: A Literature Review.
2019 — Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.
2019 — Cessation and reduction in alcohol consumption and misuse after psychedelic use.
2019 — Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice
2019 — Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users
2019 — Psilocybin for depression: Considerations for clinical trial design
2019 — Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin
2019 — Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.
2019 — Modified E. coli pump out psilocybin
2019 — Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
2019 — Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
2019 — Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
2019 — Johns Hopkins Opens Research Center on Psychedelics
2019 — Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.
2019 — Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients
2019 — The Varieties of Psychedelic Epistemology
2019 — Classical psychedelics for the treatment of depression and anxiety: A systematic review.
2019 — Replication and extension of a model predicting response to psilocybin.
2019 — Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame
2019 — Psilocybin-assisted Psychotherapy for Opioid Use Disorder
2019 — Injury-Triggered Blueing Reactions of Psilocybe “Magic” Mushrooms
2019 — Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin.
2019 — Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube.
2019 — In vivo production of psilocybin in E. coli.
2019 — P.839 Modelling the acute temporal dynamics of psilocybin psychoactive effects; relation to brain serotonin 2a receptor levels
2019 — P.609 Therapeutic mechanisms of psychedelic drugs: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
2019 — P.188 Long-term effects of psilocybin on cerebral serotonin 2A receptor levels and personality
2019 — P.228 The polypharmacological profile of psilocybin and potential behavioural effects of very low doses
2019 — Mapping Psilocybin-Assisted Therapies: A Scoping Review
2019 — The use of the psychological flexibility model to support psychedelic assisted therapy
2019 — Structure Based Drug Design towards Exploring Potential Anti-Psychotic and Anti-Depressant Activity of Possible Stiff Base of Psilocybin
2019 — Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
2019 — Development of an improved psilocybin synthesis
2019 — Psilocybin's effects on the brain and implications for depression treatment
2019 — The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder
2019 — Psilocybin and LSD in the Treatment of Depression and Anxiety
2019 — Analysis of Newspaper Coverage of Psilocybin from January 1, 1989 to December 31, 2019
2020 — Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.
2020 — Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder.
2020 — Self-Reported Illicit Drug Use Among Norwegian University and College Students. Associations With Age, Gender, and Geography.
2020 — Commentary: Psychedelic Psychiatry's Brave New World.
2020 — Hallucinogenic mushroom misuse reported to Texas poison centers.
2020 — Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
2020 — The therapeutic potential of microdosing psychedelics in depression.
2020 — Psychedelics as a Treatment for Alzheimer's Disease Dementia.
2020 — Psychedelic Research and the Need for Transparency: Polishing Alice's Looking Glass.
2020 — Editorial: Hallucinogens and Entactogens: Establishing a New Class of Drugs?
2020 — Psychedelic treatment of functional neurological disorder: a systematic review.
2020 — Psychedelic Microdosing: A Subreddit Analysis.
2020 — Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review.
2020 — Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance.
2020 — Self-reported negative outcomes of psilocybin users: A quantitative textual analysis.
2020 — Management of Treatment-Resistant Depression: Challenges and Strategies.
2020 — [Microdosing with psychedelics: what do we know?].
2020 — [Psychedelics for existential distress in terminally ill patients].
2020 — [Psychedelics in the treatment of PTSD].
2020 — A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.
2020 — Neuropharmacological modulation of the aberrant bodily self through psychedelics.
2020 — Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
2020 — Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
2020 — Microdosing psychedelics: Motivations, subjective effects and harm reduction.
2020 — The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging.
2020 — Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts
2020 — Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017
2020 — Medicinal use of psilocybin: Reducing restrictions on research and treatment.
2020 — Psilocybin may help cancer patients with depression and anxiety for years
2020 — Drugs and the Music Industry: How the Neurological and Visual Effects of LSD and Psilocybin Impact Creativity and Songwriting Abilities
2020 — Predicting the Efficacy of Psilocybin in Treating Mental Health and Addiction
2020 — Is Psilocybin an Effective Treatment to Reduce Depression and Anxiety in Cancer Patients with a Diagnosis of an Anxiety Disorder, Mood Disorder, And/Or Stress Disorder?
2020 — The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action.
2020 — Psilocybin Therapy for Depression: A Scoping Review Protocol
2020 — Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments
2020 — Repeat Dosing of Psilocybin in Migraine Headache
2020 — An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin
2020 — Simultaneous Production of Psilocybin and a Cocktail of β-Carboline Monoamine Oxidase Inhibitors in "Magic" Mushrooms.
2020 — Matthew Oram, The Trials of Psychedelic Therapy: LSD Psychotherapy in America
2020 — Comparative Acute Effects of LSD, Psilocybin and Mescaline
2020 — [Addictions].
2020 — Psychedelic therapy: Fresh promise for mental health
2020 — P.324 Acute effects of psilocybin on glutamate concentration levels, functional connectivity and subjective state
2020 — Richard Alpert (Ram Dass): Harvard psychologist who experimented with psychedelic drugs and became one of America’s most prominent and respected spiritual leaders
2020 — Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.
2020 — The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
2020 — Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
2020 — Effects of psilocin on the striatal monoamine contents in mice and rats
2020 — Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings.
2020 — Emotions and brain function are altered up to one month after a single high dose of psilocybin.
2020 — Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.
2020 — Prophylactic Effects of Psilocybin on Chronic Cluster Headache
2020 — Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin.
2020 — The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
2020 — Psilocybin-assisted therapy for depression: How do we advance the field?
2020 — Psychedelic Birth: Bodies, Boundaries and the Perception of Pain in the 1970s
2020 — Natural Psychoplastogens As Antidepressant Agents.
2020 — Trip: Psychedelics, Alienation, and Change
2020 — Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
2020 — Can Psychedelics Radically Change SUD Treatment?
2020 — Long-Term Analysis of Psilocybin in Cancer Patients With Distress
2020 — Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis
2020 — One Dose of Psilocybin in Late Adolescence Mitigates Deleterious Effects of Developmental Stress on Cognition and Behavioral Despair in Adult Female Rats
2020 — A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
2020 — Psychedelic Psychiatry's Brave New World.
2020 — Psilocybin Therapeutic Research: The Present and Future Paradigm.
2020 — Global Drug Survey
2020 — Global Drug Survey
2020 — Psychedelics for Psychiatric Disorders: More Research Needed
2020 — A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
2020 — Pharmacokinetics of Psilocybin in Normal Adult Volunteers
2020 — Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
2020 — Klassiske psykedeliske stoffer - inkl. psilocybin og LSD
2020 — Dynamic coupling of whole-brain neuronal and neurotransmitter systems.
2020 — Psychedelics and Psychedelic-Assisted Psychotherapy.
2020 — Tripping on nothing: placebo psychedelics and contextual factors.
2020 — Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
2020 — Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.
2020 — Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex
2020 — S-Adenosyl-l-Methionine Salvage Impacts Psilocybin Formation in "Magic" Mushrooms.
2020 — Binding Interactions of Psilocin and Serotonin in the 5-HT2A Receptor
2020 — Psychedelics, Safety and Clinical Trial Design
2020 — Nothing Ventured, Nothing Gained: Regulations Cripple Potentially Life-Saving Research of Illicit Substances.
2020 — Scoping Review Protocol: Mapping Psilocybin Therapy Research
2020 — Scoping Review Protocol: Mapping Psilocybin Animal Research
2020 — Ethics and ego dissolution: the case of psilocybin.
2020 — Journal Digest: Home Environment; Postpartum Mental Illness; Placebo in Psychedelic Study; Single Gene Mutation; Topiramate
2020 — Hallucinogens/psychedelics resurrected as new tools in psychiatric therapy
2020 — Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.
2020 — Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MS.
2020 — Long-term effects of psychedelic drugs: A systematic review.
2020 — Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
2020 — A potential role for psilocybin in the treatment of obsessive-compulsive disorder
2020 — How does it feel to be on psilocybin? Dose-response relationships of subjective experiences in humans
2020 — A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
2020 — Molecular docking and binding interaction between psychedelic drugs and human serum albumin
2020 — Reviewing the Potential of Psychedelics for the Treatment of PTSD.
2020 — Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.
2020 — Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives.
2020 — Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin.
2020 — Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin
2020 — Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.
2020 — Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications.
2020 — 4 Psychedelics: therapeutic mechanisms
2020 — What Psilocybin Taught Me, One Year Later.
2020 — Management of overdoses of salvia, kratom, and psilocybin mushrooms: a literature review.
2020 — Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
2020 — Confirmatory factor analysis of Mystical Experience in Freediving as a recreative way to higher efficiency in sport performance and planet saving and money making
2020 — Confirmatory factor analysis of Mystical Experience in Freediving as a recreative way to higher efficiency in sport performance and planet saving and money making
2020 — Psilocybin as an Effective Treatment for Patients with Life-Threatening Cancer and Psychological Distress: A Critically Appraised Topic
2020 — The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)
2020 — The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)
2020 — Oregon's Pioneering Effort to Enact State Law to Allow Access to Psilocybin
2020 — Delayed Anxiolytic-Like Effects of Psilocybin in Male Mice Are Supported by Acute Glucocorticoid Release
2020 — Case Report: Resolution of Rheumatoid Arthritis in a Patient Consuming Psilocybin Mushrooms
2020 — Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Magic Mushroom.
2020 — The Psilocin (4-hydroxy-N,N-dimethyltryptamine) and Bufotenine (5-hydroxy-N,N-dimethyltryptamine) Case: Ensuring the Correct Isomer has Been Identified
2020 — Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.
2020 — Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use.
2020 — Psilocybin occasioned mystical-type experiences.
2020 — Compassionate use of psychedelics.
2020 — Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.
2020 — Psilocybin Can Diminish Depression.
2020 — Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials.
2020 — Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders.
2020 — Psilocybin rescues sociability deficits in an animal model of autism
2020 — Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report
2020 — Cannabis as entheogen: survey and interview data on the spiritual use of cannabis.
2020 — Drugs in therapy. LSD, MDMA, marijuana, psilocybin, designer drugs and its potential in modern medicine.
2020 — Wait for the Science Before Widespread Use of Psilocybin
2020 — Immunochemical monitoring of psilocybin and psilocin to identify hallucinogenic mushrooms
2020 — Psilocybin-assisted group therapy: A new hope for demoralization.
2020 — Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.
2020 — Modulatory effects of ayahuasca on personality structure in a traditional framework.
2020 — Synthesis and characterization of high-purity N,N-dimethyltryptamine hemifumarate for human clinical trials.
2020 — Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis.
2020 — Psilocybin: from ancient magic to modern medicine.
2020 — The Role of Psychedelics and Counseling in Mental Health Treatment
2020 — Turn On, Tune In, Drop In: Psychedelics, Creativity and Entrepreneurship
2020 — The use of psychedelics in the treatment of disorders of consciousness. An interview with Olivia Gosseries by Charlotte Martial.
2020 — Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients
2020 — Polypharmacology or "Pharmacological Promiscuity" In Psychedelic Research: What Are We Missing?
2020 — Systematic Error for Extraction of Controlled Substances from Plant/Fungal Materials.
2020 — A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
2020 — P.227 Psilocybin induces resting-state functional connectivity changes, which correlate with plasma psilocin levels and psychedelic experience
2020 — Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.
2020 — P.804A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain
2020 — Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self
2020 — Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy
2020 — Snapshot of narcotic drugs and psychoactive substances in Kuwait: a qualitative analysis of illicit drugs and their associated mortality in Kuwait from 2015 to 2018
2020 — MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens
2020 — UHPLC-MS/MS method for simultaneously detecting 16 tryptamines and their metabolites in human hair and applications to real forensics cases.
2020 — A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
2020 — Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
2020 — Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.
2020 — Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review.
2020 — The emerging role of psilocybin and MDMA in the treatment of mental illness.
2020 — P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap.
2020 — Historic psychedelic drug trials and the treatment of anxiety disorders.
2020 — Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
2020 — Describing the Unspeakable: Psychedelic Communication Technologies and the Development of a Posthuman Language
2020 — DARK Classics in Chemical Neuroscience: NBOMes.
2020 — The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
2020 — Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes.
2020 — Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy
2020 — Trip Reports: Exploring the Experience of Psychedelic Intoxication
2020 — Patents on Psychedelics: The Next Legal Battlefront of Drug Development
2020 — Waiting for a Miracle: Medical Psilocybin and Mdma under 'Right to Try'
2020 — We Need a Cole Memorandum for Magic Mushrooms
2020 — The Effect of Psilocybin on Personality
2021 — Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
2021 — Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder.
2021 — Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [C]MDL100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation.
2021 — Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 Receptor.
2021 — Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes.
2021 — Erratum: A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development.
2021 — Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.
2021 — H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?
2021 — A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development.
2021 — Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead.
2021 — Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study".
2021 — Psychedelics and Other Psychoplastogens for Treating Mental Illness.
2021 — Psychedelics, Sociality, and Human Evolution.
2021 — The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies.
2021 — Neuropsychological Functioning in Users of Serotonergic Psychedelics - A Systematic Review and Meta-Analysis.
2021 — Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics.
2021 — Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems.
2021 — Trends in the Top-Cited Articles on Classic Psychedelics.
2021 — Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin
2021 — Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin
2021 — Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Well-Being.
2021 — Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy.
2021 — Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers.
2021 — Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
2021 — Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
2021 — Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample.
2021 — Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.
2021 — A "Trip" to the Intensive Care Unit: An Intravenous Injection of Psilocybin.
2021 — Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial.
2021 — Psilocybin: From Serendipity to Credibility?
2021 — A draft reference assembly of the genome.
2021 — Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT).
2021 — Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms.
2021 — Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
2021 — The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.
2021 — Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property.
2021 — The Evolved Psychology of Psychedelic Set and Setting: Inferences Regarding the Roles of Shamanism and Entheogenic Ecopsychology.
2021 — What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review.
2021 — Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.
2021 — A Trip Through Employment Law: Protecting Therapeutic Psilocybin Users in the Workplace.
2021 — People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences.
2021 — Psychedelic Medicines in Major Depression: Progress and Future Challenges.
2021 — 5-HT and 5-HT receptors as potential targets for the treatment of nicotine use and dependence.
2021 — How ecstasy and psilocybin are shaking up psychiatry.
2021 — Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.
2021 — Effects of a single dose of psilocybin on behaviour, brain 5-HT receptor occupancy and gene expression in the pig.
2021 — Taking Different Roads: l-Tryptophan as the Origin of Psilocybe Natural Products.
2021 — Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.
2021 — Making "bad trips" good: How users of psychedelics narratively transform challenging trips into valuable experiences.
2021 — Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.
2021 — Chemical Composition of Traditional and Analog Ayahuasca.
2021 — Psychedelics and Psychedelic-Assisted Psychotherapy.
2021 — Preclinical Behavioral Assessment of Chronic, Intermittent Low-Dose Psilocybin in Rodent Models of Depression and Anxiety
2021 — Unmet need in depression: Psilocybin, a breakthrough treatment option
2021 — "It kind of polishes all your flaws away": long-term experiences with psilocybin mushrooms and the influence of set and setting
2021 — Exploring moral bio-enhancement through psilocybin facilitated prosocial effects
2021 — Referee report. For: A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. [version 1; peer review: 1 not approved]
2021 — Referee report. For: Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans [version 1; peer review: 1 approved with reservations, 1 not approved]
2021 — Referee report. For: Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans [version 1; peer review: 1 not approved]
2021 — Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells.
2021 — POTENCIAL USO DA PSILOCIBINA NO TRATAMENTO DA DEPRESSÃO: UMA REVISÃO / POTENTIAL USE OF PSILOCYBIN IN THE DEPRESSION TREATMENT: A REVIEW
2021 — Draft Genome Sequence of the Termite-Associated "Cuckoo Fungus," () sp. TMB Strain TB5.
2021 — Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
2021 — Narratives of the mystical among users of psychedelics
2021 — Psilocybin, Spirituality, and Palliative Care: Research and Implications
2021 — A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT Receptor Density in the Pig Brain.
2021 — [Treatment with psilocybin: applications for patients with psychiatric disorders].
2021 — Behandeling met psilocybine
2021 — Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals
2021 — Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma
2021 — Psilacetin derivatives: fumarate salts of the methyl-ethyl, methyl-allyl and diallyl variants of the psilocin prodrug
2021 — Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
2021 — Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
2021 — Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis.
2021 — Psilocybin Treatment for Mental Health Gets Legal Framework
2021 — Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
2021 — Use of psilocybin (“mushrooms”) among US adults: 2015-2018
2021 — Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience
2021 — Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice
2021 — Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
2021 — How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence
2021 — Psychedelic Strategies; Alternative Phenomenologies, Translations, and Representations of the Human Body in Relation to Interior Space
2021 — Chemistry and Toxicology of Major Bioactive Substances in Mushrooms.
2021 — Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2
2021 — Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports
2021 — P.214 (Sub)acute effects of psilocybin on creative cognition: a double-blind, placebo-controlled experimental study
2021 — The acute effects of classic psychedelics on memory in humans.
2021 — Session on Psychedelics Sure to Be Enlightening
2021 — Stroke and Adverse Effects on The Immune and Cardiovascular Systems: The Danger of the Rise and Use of Psychedelic Drugs for Depression and PTSD
2021 — Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice.
2021 — The DMT and Psilocin Treatment Changes CD11b+ Activated Microglia Immunological Phenotype
2021 — Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials
2021 — Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials
2021 — Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans
2021 — A Rare Presentation of Anticholinergic Toxicity in a Young Patient Due to Over-The-Counter Cold Medicines.
2021 — Complete mitochondrial genome sequence of.
2021 — Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)
2021 — Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)
2021 — The Return of Psychedelics: Still Time to Prevent Tragedy
2021 — Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
2021 — Associations between lifetime classic psychedelic use and markers of physical health.
2021 — Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.
2021 — Dose-response relationships of psilocybin-induced subjective experiences in humans.
2021 — Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
2021 — Use and abuse of dissociative and psychedelic drugs in adolescence.
2021 — Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
2021 — Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
2021 — A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.
2021 — [Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].
2021 — Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin.
2021 — Effects of psilocybin-assisted therapy on treatment-resistant depression
2021 — Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?
2021 — Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)
2021 — Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)
2021 — ‘Is There Magic in These Mushrooms?’ Discussing Current Psychiatric Treatment Options, and the Potential of Psilocybin Mushrooms in the Future of Such Treatments
2021 — Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies
2021 — Spontaneous and deliberate creative cognition during and after psilocybin exposure.
2021 — Ethical Concerns about Psilocybin Intellectual Property.
2021 — Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.
2021 — Investigation of the Structure-Activity Relationships of Psilocybin Analogues.
2021 — Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience.
2021 — Discriminative Stimulus Effects of Substituted Tryptamines in Rats.
2021 — On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.
2021 — A draft sequence reference of the Psilocybe cubensis genome
2021 — Back to the Future - The Therapeutic Potential of Psychedelic Drugs
2021 — Trial of Psilocybin versus Escitalopram for Depression.
2021 — Have Norwegians tried psilocybin, and do they accept it as a medicine?
2021 — Four individuals' experiences during and following a psilocybin truffle retreat in the Netherlands
2021 — O papel da Psilocibina no tratamento de depressão resistente / The role of Psilocybin in the treatment of resistant depression
2021 — Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
2021 — Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity.
2021 — Psychedelic-Assisted Psychotherapy Practices and Human Caring Science: Toward a Care-Informed Model of Treatment
2021 — Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
2021 — Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects
2021 — Effectiveness of Psilocybin on Depression: A Qualitative Study
2021 — Effects of Psilocybin on Suicidal Ideation in Patients With Life-Threatening Cancer
2021 — Altered Prediction-Error Processing May Underlie Psilocybin-Induced Changes in Self-Processing
2021 — Characterization of Altered Waking States of Consciousness in Healthy Humans
2021 — Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment
2021 — Addressing the Implicit Impacts of Sexual Trauma: An Exploration of Somatic Experiencing as an Adjunct to Psilocybin-Assisted Therapy
2021 — Effects of the putative antidepressant psilocin on the lipid-raft proteome and lipid-raft signaling
2021 — Psilocybin and MDMA for the treatment of trauma-related psychopathology.
2021 — Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review.
2021 — Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder.
2021 — Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression-Quo Vadis?
2021 — Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
2021 — Non-Traditional Psychotherapy Techniques: An Assessment of the Value of MDMA, Psilocybin and LSD.
2021 — A utilização terapêutica da psilocibina como coadjuvante no tratamento do transtorno depressivo maior: uma revisão narrativa de literatura / The therapeutic use of psilocybin as an adjunct in the treatment of major depressive disorder: a narrative literature review
2021 — Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year.
2021 — New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review
2021 — New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review
2021 — The Therapeutic Potential of Psilocybin.
2021 — LSD and psilocybin flatten the brain’s energy landscape: insights from receptor-informed network control theory
2021 — The need for publicly funded research on therapeutic use of psychedelic drugs
2021 — Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network
2021 — Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network
2021 — Decreased brain modularity after psilocybin therapy for depression.
2021 — Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Wellbeing
2021 — Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Wellbeing
2021 — Psychedelic science in post-COVID-19 psychiatry.
2021 — Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders
2021 — Psilocybin: the magic medicine for depression?
2021 — Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses
2021 — Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses
2021 — Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis
2021 — Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
2021 — Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
2021 — Psilocybin: the magic medicine for depression?
2021 — Silencing indigenous pasts: critical Indigenous theory and the history of psychedelics
2021 — Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice
2021 — Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
2021 — Psychedelic Assisted Therapy for Major Depressive Disorder: A Review
2021 — Psychedelic Assisted Therapy for Major Depressive Disorder: A Review
2021 — Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?
2021 — Sensitive quantitative analysis of psilocin and psilocybin in hair samples from suspected users and their distribution in seized hallucinogenic mushrooms
2021 — Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
2021 — The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.
2021 — Cannabis-induced oceanic boundlessness.
2021 — Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
2021 — Psilocybin Therapy May Work as Well as Common Antidepressant
2021 — A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.
2021 — The Influence of Psychedelic Drugs on the 'Sense of Self'
2021 — Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives.
2021 — Psilocybin for Depression: The ACE Model Manual
2021 — Psilocybin for Depression: The ACE Model Manual
2021 — Naturalistic Entheogenics: Précis of Philosophy of Psychedelics
2021 — Naturalistic Entheogenics: Précis of Philosophy of Psychedelics
2021 — A dynamic and multilocus metabolic regulation strategy using quorum-sensing-controlled bacterial small RNA.
2021 — Both partners practicing orgasmic meditation report having a mystical-type experience: results using the Mystical Experience Questionnaire
2021 — Psychedelic Therapy Hits Another Milestone, But Caution Urged
2021 — Safer Tripping: Serotonergic Psychedelics and Drug Checking. Submission and Detection Rates, Potential Harms, and Challenges for Drug Analysis
2021 — Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia-Relevance for Mental Diseases.
2021 — A Case Series Describing the Tale of ‘The Magic Mushroom’; An Increasing Trend of Psychedelic Misuse Among Substance Abusers in Terengganu
2021 — The Potential Role of Serotonergic Hallucinogens in Depression Treatment.
2021 — Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without.
2021 — Pharmacologic Similarities and Differences Among Hallucinogens.
2021 — [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
2021 — Mit Psilocybin gegen Depression
2021 — Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells.
2021 — Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review.
2021 — What can we learn from the history of research on psychedelic drugs in the addictions?
2021 — Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?
2021 — Effects of psilocybin-assisted therapy on treatment-resistant depression
2021 — Psychedelics: A new era of treatment?
2021 — Treating addiction with psychedelics - are we waking up?
2021 — Psychedelics and psychiatric disorders: A emerging role
2021 — Therapeutic interventions for PTSD - current evidence on the the role of psychedelics
2021 — The cranial windows of perception.
2021 — Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.
2021 — Structure Elucidation and Spectroscopic Analysis of Chromophores Produced by Oxidative Psilocin Dimerization
2021 — Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review
2021 — Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.
2021 — Beckley raises funds for psychedelic drugs
2021 — Psilocybin for Depression.
2021 — Treatment-Resistant Depression: Approaches to Treatment.
2021 — Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.
2021 — Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience
2021 — Further development of a liquid chromatography-high-resolution mass spectrometry/mass spectrometry-based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions.
2021 — Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach.
2021 — Blinding and expectancy confounds in psychedelic randomized controlled trials.
2021 — Sociological investigations of human enhancement drugs: The case of microdosing psychedelics.
2021 — Rethinking enhancement substance use: A critical discourse studies approach.
2021 — Spiritual experiences in psychedelic-assisted psychotherapy: Case reports of communion with the divine, the departed, and saints in research using psilocybin for the treatment of alcohol dependence.
2021 — Treating Major Depression Disorder with Psychedelics: A Potential Therapeutic Application for Psilocybin?
2021 — New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy
2021 — Is MDD the right target for early-stage psychedelic-assisted therapy trials?
2021 — The therapeutical role of psychedelic drugs in treatment of mental disorders
2021 — Derivatization-assisted enzyme-linked immunosorbent assay for identifying hallucinogenic mushrooms with enhanced sensitivity.
2021 — A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing
2021 — New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
2021 — Testing human hair after magic mushrooms abuse by LC-MS/MS: Pitfalls and limitations
2021 — A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear.
2021 — Psilocybin: Next to treat depression, OCD and nicotine addiction
2021 — Rediscovering Psilocybin as an Antidepressive Treatment Strategy.
2021 — Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study
2021 — Magic mushroom: all is not as it seems.
2021 — 6.2 OVERVIEW OF PSYCHEDELIC COMPOUNDS AND THEIR USE IN TREATMENT
2021 — Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis.
2021 — Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.
2021 — 6.3 CURRENT RESEARCH ON PSILOCYBIN TREATMENT ON END-OF-LIFE ANXIETY AND MDMA TREATMENT OF SOCIAL ANXIETY IN AUTISM SPECTRUM DISORDER
2021 — Many Drugs of Abuse May Be Acutely Transformed to Dopamine, Norepinephrine and Epinephrine In Vivo.
2021 — Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity
2021 — Delix to synthesize psychedelic drugs
2021 — Psychedelics and Mindfulness: A Systematic Review and Meta-Analysis
2021 — Psychedelics and Mindfulness: A Systematic Review and Meta-Analysis
2021 — Case Report: Magic Mushroom (Psilocybe Cubensis) Intoxication
2021 — Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders
2021 — The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
2021 — Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction
2021 — Analysis of Five Mushroom Toxins in Blood by UPLC-HRMS.
2021 — A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents.
2021 — Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics.
2021 — An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report.
2021 — Psilocybin steps closer to credibility
2021 — Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
2021 — Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.
2021 — Psychedelics and their therapeutic effects
2021 — Daily briefing: Largest trial shows psilocybin is effective to treat depression.
2021 — Policy in focus: Is psilocybin the next cannabis?
2021 — Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
2021 — Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism.
2021 — Researchers hope psilocybin could improve quit rates for smokers
2021 — Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study.
2021 — Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test
2021 — Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test
2021 — Mestizo Visionary Art of the Americas in the Late Twentieth Century: Hallucinogens, Politics, Aesthetics and Mass Consumer Culture in the United States, Mexico, and Colombia
2021 — Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors.
2021 — Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies
2021 — Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity
2021 — Psychedelic Epistemology: William James and the “Noetic Quality” of Mystical Experience
2021 — Psychedelic Drugs for Mental Disorders and Human Potential: Placebo or Panacea
2021 — P.0620 Psilocybin as a treatment of addictions: a review of the literature
2021 — Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter.
2021 — Marijuana, Hallucinogen Use Reach Historic Levels Among Young Adults
2021 — Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial.
2021 — Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
2021 — Use of hallucinogens in Slovakia: Does it differ from global trends?
2021 — Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.
2021 — Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.
2021 — Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
2021 — P.0858 Psilocin induces perceptual alterations in rats: visual discrimination study
2021 — P.0553 Effect of chronic microdosing of psilocin on cell proliferation and behavior in rats
2021 — P.0729 Highlights of psychedelic history and current research on psilocybin application for treatment of depression - a comprehensive literature review
2021 — P.0885 The effect of psilocybin therapy for depression on low-frequency brain activity in response to music
2021 — P.0623 The clinical relevance of the pharmacokinetics of psilocybin
2021 — P.0298 Evaluation of the acute mechanism of action of psilocybin in mice
2021 — P.0828 Psilocybin enhances emotional response to music in healthy individuals
2021 — P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - study design, rationale and current status
2021 — P.0353 Study protocol: psilocybin as a treatment for anorexia nervosa: a pilot study
2021 — P.0593 Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals
2021 — Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity
2021 — Announcement of two special issues: behavioural pharmacology of synaptopathies and psychedelic drugs
2021 — A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects
2021 — A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects
2021 — Effects of Psilocybin in Major Depressive Disorder
2021 — Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health
2021 — Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects
2021 — A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.
2021 — Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies.
2021 — Predictors of Psychedelic Experience: A Thematic Analysis
2021 — Predictors of Psychedelic Experience: A Thematic Analysis
2021 — LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study
2021 — Conformational Analysis of Psilocybin: A Computational Approach
2021 — Critique of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Therapy Clinical Memorandum, Dated May 2020
2022 — Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
2022 — The association between naturalistic use of psychedelics and co-occurring substance use disorders.
2022 — Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice.
2022 — Editorial: Old and new psychoactive substances: Pharmacology and potential applications.
2022 — "A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.
2022 — The economics of psychedelic-assisted therapies: A research agenda.
2022 — Lower-dose psycholytic therapy - A neglected approach.
2022 — Therapeutic use of psilocybin: Practical considerations for dosing and administration.
2022 — Classic psychedelics, health behavior, and physical health.
2022 — Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives.
2022 — [Treatment-resistant depression. From classification to new therapies.].
2022 — Are Magic Mushrooms Really Magic?: Psilocybin in the Treatment of Depression.
2022 — A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
2022 — Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression.
2022 — Five new species of from China: Morphological characteristics, phylogenetic analyses, and toxin detection.
2022 — Electrical spiking of psilocybin fungi.
2022 — A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy.
2022 — Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals.
2022 — 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.
2022 — Effects of classic psychedelic drugs on turbulent signatures in brain dynamics.
2022 — Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms.
2022 — Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.
2022 —  (Inocybaceae), a new poisonous species from Eurasia, based on morphological, ecological, molecular and biochemical evidence.
2022 — Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
2022 — Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review.
2022 — Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives.
2022 — Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.
2022 — Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees.
2022 — Self-administration of Psilocybin in the Setting of Treatment-resistant Depression.
2022 — Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.
2022 — Produces Amino Acids to Stimulate Protein Synthesis in Ruminal Tissue Explants the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta-Serine/Threonine Kinase-Mammalian Target of Rapamycin Complex 1 Pathway.
2022 — The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.
2022 — Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.
2022 — Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.
2022 — Will psilocybin lose its magic in the clinical setting?
2022 — Psilocybin-Assisted Compassion Focused Therapy for Depression.
2022 — Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019.
2022 — Corrigendum: Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes.
2022 — Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI).
2022 — Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.
2022 — Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.
2022 — Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.
2022 — Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.
2022 — Psychedelic Identity Shift: A Critical Approach to Set And Setting.
2022 — Multi-locus identification of by high-resolution melting (HRM).
2022 — [A Novel System for Discovering High-affinity Antibody Mutants That Enables Immunoassays with Higher Sensitivities -Development and Application of Clonal Array Profiling (CAP)].
2022 — Psilocybin for Trauma-Related Disorders.
2022 — Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
2022 — Psychedelics and Anti-inflammatory Activity in Animal Models.
2022 — Psychedelics in the Treatment of Headache and Chronic Pain Disorders.
2022 — Psilocybin Conspectus: Status, Production Methods, and Considerations.
2022 — Human behavioral pharmacology of psychedelics.
2022 — Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
2022 — The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
2022 — Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
2022 — MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
2022 — Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples.
2022 — The Potential of Psychedelics for End of Life and Palliative Care.
2022 — Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
2022 — Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.
2022 — Psychedelic medicines for mood disorders: current evidence and clinical considerations.
2022 — Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
2022 — Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
2022 — Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
2022 — Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
2022 — Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
2022 — Dosing Psychedelics and MDMA.
2022 — Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.
2022 — United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
2022 — Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.
2022 — Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
2022 — Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions.
2022 — Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
2022 — Psychedelics and health behaviour change.
2022 — Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
2022 — Psychedelic philanthropy: The nonprofit sector and Timothy Leary's 1960s psychedelic movement.
2022 — Unravelling a New Conformer of Psilocin Through Computational Methods
2022 — Rats hallucinate in a similar manner to humans after psilocin
2022 — Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness
2022 — Should Adolescents be Included in Emerging Psychedelic Research?
2022 — An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma
2022 — Standards Without Labs: Drug Development in the Psychedelic Underground
2022 — Selling the Priceless Mushroom: A History of Psilocybin Mushroom Trade in the Sierra Mazateca (Oaxaca)
2022 — Pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of oral psilocybin administration in healthy subjects
2022 — The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial
2022 — Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer
2022 — Psychedelic Agents as Potential Therapeutics for Obsessive Compulsive Disorder
2022 — The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trial
2022 — Investigating cue-reactivity as biomarker for treatment success in psilocybin-assisted therapy for alcohol use disorder
2022 — Comparison of subjective, autonomic, and endocrine effects of LSD and psilocybin in healthy subjects
2022 — Investigation of neuronal basis underlying antidepressant effect of serotonergic psychedelics
2022 — Exploratory review of psilocybin usage and awareness amongst college students and potential consumer goods tradeoffs resulting from increased usage
2022 — SPECIAL ISSUE: Do Biofeedback, Neurofeedback, and Neuromeditation Have a Role in Psychedelic-Assisted Therapies?
2022 — Investigation of the neural network responsible for antidepressant effect of serotonergic psychedelics
2022 — Acute change in functional brain entropy following psilocybin administration in healthy volunteers
2022 — The role of psilocybin in memory consolidation in the animal model
2022 — The effect of psilocybin and sleep manipulation on neuroplasticity and sleep architecture in rats
2022 — Neurochemical and behavioural characterisation of the psychedelic 5HT2AR agonist psilocybin in mice
2022 — Effects of psilocybin in relative and global cerebral blood flow and behavioural correlates
2022 — Differential effects of repeated treatment with DOI and psilocybin on the head-twitch response (HTR), locomotor activity and anxiety-like behaviour
2022 — Neurochemical properties of psilocybin in comparison to ketamine in vivo
2022 — Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulatory effects in healthy humans
2022 — Classic psychedelics in the treatment of depression: mechanisms of action and the role of therapy
2022 — Pennsylvania bill seeks clinical research on psychedelics
2022 — [Psilocybin compared with escitalopram for depression].
2022 — Psilocybine vergeleken met escitalopram bij depressie
2022 — Psychedelics hold promise for primary care research
2022 — Structure-based discovery of nonhallucinogenic psychedelic analogs.
2022 — Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.
2022 — Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine.
2022 — Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
2022 — Crystallographic hallucinations.
2022 — Analysis of recreational psychedelic substance use experiences classified by substance.
2022 — Hallucinogen Use and Misuse in Older Adults.
2022 — Genomic Analysis of Reveals Its Nutritional Strategy and Application Potential in Bioremediation.
2022 — Hallucinogen chemistry guides antidepressant drug discovery
2022 — Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?
2022 — Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis.
2022 — A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
2022 — Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD).
2022 — Increased low-frequency brain responses to music after psilocybin therapy for depression
2022 — Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
2022 — Natural language signatures of psilocybin microdosing
2022 — Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
2022 — Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.
2022 — The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.
2022 — Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.
2022 — [Are psychedelics fast acting antidepressant agents?].
2022 — Beating pain with psychedelics: Matter over mind?
2022 — [Rapid-acting antidepressants-neurobiological mechanisms of action].
2022 — Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees
2022 — Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity
2022 — Rediscovering psychedelics
2022 — Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro
2022 — 184. Hallucinogens on TikTok
2022 — Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.
2022 — Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
2022 — The mushroom, the frog, and the rainbow of desire: A participatory-psychedelic spiritual emergence.
2022 — Counselors’ attitudes toward psychedelics and their use in therapy
2022 — Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin
2022 — Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?
2022 — Neuroimaging Documentation of Psychedelic Drugs Effect on the Brain: DMT, LSD, Psilocybin, and Ibogaine as Examples: A Mini Review
2022 — Increased global integration in the brain after psilocybin therapy for depression.
2022 — Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development.
2022 — Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
2022 — Verbal behavior related to drug reinforcement in polysubstance cannabis users: Comparison across drugs.
2022 — Psilocybe mexicana R. Heim - Mexikanischer Kahlkopf
2022 — Psylocybin and Psilocin as new tools to fight depression: an overview of the Pharmacodynamic and pharmacokinetic mechanisms
2022 — Evaluation of a quantitative analytical method for psilocin and psilocybin using HPLC-DAD
2022 — Production and extraction of psilocybin and psilocin from Psilocybe spp. mushrooms
2022 — Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
2022 — Charismatic, Synchronous and Psychedelic Religious Experiences: A Personal Account
2022 — Combining FTIR-ATR and OPLS-DA methods for magic mushrooms discrimination
2022 — Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
2022 — Models of psychedelic drug action: modulation of cortical-subcortical circuits.
2022 — Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.
2022 — P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy
2022 — P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression
2022 — Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
2022 — Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
2022 — Sex-Specific Effects of Psychedelic Drug Exposure on Central Amygdala Reactivity and Behavioral Responding
2022 — Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression
2022 — Socio-psychedelic imaginaries: envisioning and building legal psychedelic worlds in the United States
2022 — Unraveling the Mysteries of Mental Illness With Psilocybin.
2022 — Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon.
2022 — The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
2022 — Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
2022 — Receptor binding profiles and behavioral effects of psilocybin analogs
2022 — The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
2022 — A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
2022 — A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
2022 — Grounded in Biology: Why the Context-Dependency of Psychedelic Drug Effects Means Opportunities, Not Problems for Anthropology and Pharmacology
2022 — Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
2022 — The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis
2022 — Psilocybin-induced takotsubo cardiomyopathy.
2022 — Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence.
2022 — Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression
2022 — New Paradigms of Old Psychedelics in Schizophrenia.
2022 — An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus
2022 — Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits
2022 — Unique Effects of Sedatives, Dissociatives, Psychedelics, Stimulants, and Cannabinoids on Episodic Memory: A Review and Reanalysis of Acute Drug Effects on Recollection, Familiarity, and Metamemory
2022 — Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland.
2022 — The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder.
2022 — SP56 Psychedelic drugs and pain
2022 — 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review.
2022 — Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.
2022 — Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?
2022 — How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
2022 — Development of an -based norbaeocystin production platform and evaluation of behavioral effects in rats.
2022 — The promises and perils of psychedelic pharmacology for psychiatry.
2022 — Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.
2022 — Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
2022 — Effects of the 5-HT receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents.
2022 — The therapeutic potential of psilocybin: a systematic review.
2022 — The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review.
2022 — Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.
2022 — Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.
2022 — Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
2022 — Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.
2022 — Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice.
2022 — Serotonin toxicity of serotonergic psychedelics.
2022 — Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
2022 — Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study.
2022 — Association of Psilocybin Use in Adolescents with Major Depressive Episode
2022 — Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin
2022 — Optimization through a Box-Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi ().
2022 — Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
2022 — Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies.
2022 — Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior.
2022 — Applying Lessons From Cannabis to the Psychedelic Highway
2022 — Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience.
2022 — The Neuroimaging Documentation of Psychedelic Drugs’ Effect on the Brain: dmt, lsd, Psilocybin, and Ibogaine as Examples: A Mini Review
2022 — Associations between classic psychedelics and nicotine dependence in a nationally representative sample.
2022 — Classic and non-classic psychedelics for substance use disorder: A review of their historic, past and current research
2022 — MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of Depression
2022 — Neuroimaging in psychedelic drug development: Past, present, and future
2022 — Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
2022 — Neuroimaging in psychedelic drug development: Past, present, and future
2022 — Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults
2022 — Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
2022 — A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
2022 — Classic Psychedelics and Human-Animal Relations.
2022 — Neural mechanisms underlying psilocybin's therapeutic potential - the need for preclinical in vivo electrophysiology.
2022 — The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.
2022 — Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS.
2022 — Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.
2022 — A systematic literature review of clinical trials and therapeutic applications of ibogaine.
2022 — Psychedelic-inspired approaches for treating neurodegenerative disorders.
2022 — Molecular insights into psychedelic drug action.
2022 — From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.
2022 — Psilocybin: A brief overview for psychiatric mental health nurse practitioners.
2022 — A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
2022 — Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.
2022 — Psychedelic use in India, its pattern and personal significance - findings from an online survey
2022 — Electrical spiking of psilocybin fungi
2022 — Synapses, predictions, and prediction errors: a neocortical computational study of MDD using the temporal memory algorithm of HTM
2022 — Brain dynamics predictive of response to psilocybin for treatment-resistant depression
2022 — Psychedelics in the treatment of unipolar and bipolar depression.
2022 — Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines
2022 — Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis
2022 — From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)
2022 — From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)
2022 — Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity
2022 — Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape
2022 — A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS.
2022 — Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder
2022 — 9 Signs You Need Help With Magic Mushrooms uk
2022 — Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines.
2022 — Genetic Survey of Psilocybe Natural Products.
2022 — Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: Translational implications
2022 — Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
2022 — Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents.
2022 — Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
2022 — Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples
2022 — Mushrooms' Legal Trip: As psilocybin research ramps up, the drug's status under the law is shifting.
2022 — Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
2022 — From Mushrooms to Myolysis: A Case of Rhabdo in Psilocybin-Induced Mood and Psychotic Disorder.
2022 — Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies.
2022 — Don't be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review.
2022 — Phosphate moiety in FDA-approved pharmaceutical salts and prodrugs.
2022 — Postpartum depression: A role for psychedelics?
2022 — The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field.
2022 — Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.
2022 — Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex.
2022 — Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.
2022 — Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
2022 — Med Check: Psilocybin for OCD, Nuplazid Vote, and More
2022 — Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.
2022 — Psilocybin administration
2022 — Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The “Velada”
2022 — Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study
2022 — Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice.
2022 — Psilocybin and the Meaning Response: Exploring the Healing Process in a Retreat Setting in Jamaica
2022 — Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine
2022 — Review of potential psychedelic treatments for PTSD.
2022 — Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.
2022 — Molecular insights into the regulation of constitutive activity by RNA editing of 5HT serotonin receptors.
2022 — A-118 Psychedelic Interventions for Neuropsychological Conditions
2022 — Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Mushroom via Amino Acid Metabolism Pathways.
2022 — Delix Therapeutics: psychedelics without the trip
2022 — Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test?
2022 — Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative
2022 — Psychedelics as potent anti-inflammatory therapeutics
2022 — ‘Shrooms for the Blues: Psilocybin to alleviate difficult-to-treat depression
2022 — Psychedelic Psychiatry
2022 — The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.
2022 — Psychedelics for Alzheimer's Disease Palliative Care.
2022 — Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder.
2022 — Use of psychedelics in the Czech Republic: results of recent population surveys.
2022 — [The use of psilocybin for treatment-resistant depression].
2022 — Psychedelics as preventive treatment in headache and chronic pain disorders.
2022 — Natural language signatures of psilocybin microdosing.
2022 — Magic mushroom extracts in lipid membranes.
2022 — The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research.
2022 — P03-18 Simultaneous detection and quantification of psilocybin and psilocin by gas chromatography coupled to mass spectrometry (GC-MS)
2022 — Association of Psilocybin Use in Adolescents with Major Depressive Episode
2022 — Interplay of hydrogen bonding in deciding the conformers of psilocin: Computational insights
2022 — A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms
2022 — Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop
2022 — Psychopathological descriptive model of hallucinogenic/psychedelic drugs effect in the treatment of depression and addictions
2022 — Therapeutic potential of serotoninergic psychedelic substances in the treatment of Obsessive Compulsive Disorder
2022 — Psychedelics in the Treatment of Substance Use Disorders
2022 — Psychedelics for Psychiatric Disorders: Promise, Not Panacea
2022 — From neuroplasticity to psychoplasticity: Psilocybin may reverse personality disorders and political fanaticism
2022 — P03-21 Magic mushrooms and psilocybin: pharmacokinetics, pharmacodynamics, and clinical applications
2022 — Psychedelics’ binding depends on receptor mutations
2022 — Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.
2022 — Skepticism about Recent Evidence That Psilocybin "Liberates" Depressed Minds.
2022 — Psilocybin therapy reduces heavy drinking.
2022 — Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder
2022 — Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
2022 — Effective connectivity of emotion and cognition under psilocybin
2022 — Neural mechanisms of psychedelic visual imagery
2022 — Long-term transformative effects and integration challenges of psychedelic experiences
2022 — Psilocybin as a healer
2022 — Psychedelic drugs for psychiatric disorders.
2022 — Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives - A Computational Study
2022 — Brain dynamics predictive of response to psilocybin for treatment-resistant depression
2022 — Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)
2022 — Differences across sexes on head-twitch behavior and 5-HT receptor signaling in C57BL/6J mice.
2022 — The psychedelic escape from depression
2022 — The psychedelic remedy for chronic pain
2022 — Taking the tripping out of psychedelic medicine
2022 — Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
2022 — Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing
2022 — Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing
2022 — THE RENAISSANCE OF PSYCHEDELICS IN PSYCHIATRY: EVIDENCE, ETHICS, AND POTENTIAL IN MENTAL HEALTH TREATMENT FOR ADOLESCENTS
2022 — The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?
2022 — Potential Therapeutic Effects of Psilocybin: A Systematic Review.
2022 — Microdosing with classical psychedelics: Research trajectories and practical considerations.
2022 — Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
2022 — Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?
2022 — Animal Behavior in Psychedelic Research.
2022 — The Emerging Field of Psychedelic Psychotherapy.
2022 — A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.
2022 — Why Otolaryngologists Should Be Interested in Psychedelic Medicine.
2022 — Expectancy in placebo-controlled trials of psychedelics: if so, so what?
2022 — Serotonin 5-HT, 5-HT and 5-HT receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response.
2022 — Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.
2022 — Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
2022 — Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
2022 — Prevalence and associations of classic psychedelic-related seizures in a population-based sample.
2022 — New investigational agents for the treatment of major depressive disorder.
2022 — Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data.
2022 — Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.
2022 — Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
2022 — Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
2022 — Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin.
2022 — If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.
2022 — Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.
2022 — 19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations
2022 — Chinese Cordyceps: Bioactive Components, Antitumor Effects and Underlying Mechanism-A Review.
2022 — Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape.
2022 — Group Format Psilocybin-Assisted Therapy: Commentary on the HOPE trial (HOPE: a pilot study of psilocybin-enhanced group psychotherapy in patients with cancer)
2022 — Psilocybin for Treatment of Alcohol Use Disorder.
2022 — Conformational Landscape and Properties of Psilocybin: A Computational Approach
2022 — Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355
2022 — Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355
2022 — Psilocybin: a revolution in psychedelic medicines in the US?
2022 — Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
2022 — Fungal Hallucinogens: Chemistry, Synthesis, Behavior, Toxicity and Detection Methods in Forensic Perspective
2022 — An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
2022 — Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial).
2022 — Psilocybin treatment for AUD: Promise in new study
2022 — Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity.
2022 — Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial
2022 — The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
2022 — Serotonergic antidepressant use is associated with weaker psilocybin effects
2022 — Serotonergic antidepressant use is associated with weaker psilocybin effects
2022 — Psychedelics for Use and Wellbeing Cultural Context and Recent Developments: A Jamaican Perspective
2022 — What Are Magic Mushrooms? Why They Are Popular In British Columbia
2022 — Kan psilocybin forbedre vores moral?
2022 — A Rare Case of Magic Mushroom (Psilocybin) Related AKI and Hypertensive Emergency
2022 — Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis.
2022 — Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial.
2022 — Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer.
2022 — Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
2022 — Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.
2022 — The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.
2022 — Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis.
2022 — Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.
2022 — Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers
2022 — The psychedelic renaissance: can psilocybin possibly combat depression?
2022 — Psilocybin reduces symptoms in treatment resistant depression, trial results show.
2022 — Psilocybin in Treatment-Resistant Depression.
2022 — Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
2022 — 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
2022 — Experts assess role of therapists in psychedelic-assisted therapy
2022 — A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
2022 — Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice.
2022 — Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids.
2022 — Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.
2022 — Psychedelic compounds directly excite 5-HT2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT2A Gq -mediated activation mechanism
2022 — Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine
2022 — Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine
2022 — Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications.
2022 — NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.
2022 — Mode of action of psilocybin
2022 — Fast and sustained effect of 2 administrations of psilocybin on depression
2022 — Antidepressant properties of psilocybin might be related to changes in sleep
2022 — Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report.
2022 — A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.
2022 — Psychedelic-Assisted Therapy for People with Eating Disorders.
2022 — Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects
2022 — Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields.
2022 — Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.
2022 — Set and setting in microdosing: an oft-overlooked principle.
2022 — Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019.
2022 — The psychedelic renaissance: the next trip for psychiatry?
2022 — Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens
2022 — Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice.
2022 — Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum
2022 — Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster
2022 — Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis.
2022 — High time? Psychedelics on cannabis-like fast track to legalization
2022 — Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
2022 — DNA Authentication and Chemical Analysis of Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites.
2022 — Depression Improves Following Single Dose of Psilocybin
2022 — A Review of Synthetic Access to Therapeutic Compounds Extracted from.
2022 — The Potential of Psilocybe Genus Fungi to Treat Depression and Some Addictions
2022 — Psilocybin for Depression: From Credibility to Feasibility, What's Missing?
2022 — From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia
2022 — Ego Birth: Measure 109, The NMHA, and Forward Movement in the Nascent Psilocybin Industry
2023 — Psychedelics, epilepsy, and seizures: a review.
2023 — Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.
2023 — Group psychedelic therapy: empirical estimates of cost-savings and improved access.
2023 — Exploring spp. mycelium and fruiting body chemistry for potential therapeutic compounds.
2023 — Biological studies of clavine alkaloids targeting CNS receptors.
2023 — Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample.
2023 — Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD.
2023 — A Proposal to Study the Safety and Efficacy of in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder.
2023 — "How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
2023 — Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.
2023 — Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges.
2023 — Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.
2023 — Bedside to bench: the outlook for psychedelic research.
2023 — Manic episode following psilocybin use in a man with bipolar II disorder: a case report.
2023 — Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the "high-risk" addiction patient.
2023 — Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.
2023 — Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder.
2023 — Psychedelics for treatment resistant depression: are they game changers?
2023 — Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.
2023 — History of the administration of psychedelics in France.
2023 — An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.
2023 — Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.
2023 — Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.
2023 — The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness.
2023 — Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests.
2023 — Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics.
2023 — Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers.
2023 — Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study.
2023 — Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.
2023 — Assessing potential of psilocybin for depressive disorders.
2023 — Adapting psychedelic medicine for headache and chronic pain disorders.
2023 — Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.
2023 — Serotonin 5-HT receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents.
2023 — What is the progress of experimental drug development for fibromyalgia?
2023 — Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study.
2023 — Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective.
2023 — Case report: Psychedelic-induced seizures captured by intracranial electrocorticography.
2023 — Medical student attitudes and perceptions of psychedelic-assisted therapies.
2023 — Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
2023 — Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.
2023 — A case-study evaluation of the "Copenhagen Music Program" for psilocybin-assisted therapy.
2023 — The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.
2023 — Acute psilocybin increased cortical activities in rats.
2023 — Henri Michaux's program for the psychedelic humanities.
2023 — Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.
2023 — Empirically validated theoretical analysis of visual-spatial perception under change of nervous system arousal.
2023 — Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.
2023 — Mini-review: The neurobiology of treating substance use disorders with classical psychedelics.
2023 — Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique.
2023 — Use of Selective Alternative Therapies for Treatment of OCD.
2023 — Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives.
2023 — The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.
2023 — Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis.
2023 — Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users.
2023 — Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences.
2023 — Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders.
2023 — Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.
2023 — Editorial: What is up with psychedelics anyway?
2023 — The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.
2023 — Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBG.
2023 — Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report.
2023 — Therapeutic effect of psilocybin in addiction: A systematic review.
2023 — Classic psychedelics do not affect T cell and monocyte immune responses.
2023 — When art therapy went chemical: Alfred Bader, pharmacology, and art brut, c.1950-1970s.
2023 — Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment.
2023 — Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
2023 — UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES.
2023 — Biological embedding of early trauma: the role of higher prefrontal synaptic strength.
2023 — Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response.
2023 — The Resurgence of Hallucinogen Drugs in Clinical Research.
2023 — Next generation antidepressants with novel mechanisms for treatment resistant depression.
2023 — Functional MRI markers for treatment-resistant depression: Insights and challenges.
2023 — Psilocybin in Palliative Care: An Update.
2023 — Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
2023 — Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective.
2023 — Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
2023 — Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.
2023 — Psychedelic Drug Legislative Reform and Legalization in the US.
2023 — Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome.
2023 — Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression.
2023 — Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.
2023 — Body mass index (BMI) does not predict responses to psilocybin.
2023 — Psilocin - The “real deal” or an extraction byproduct
2023 — Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
2023 — Mescaline: The forgotten psychedelic.
2023 — The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
2023 — Towards an understanding of psychedelic-induced neuroplasticity.
2023 — The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
2023 — Sustained effects of single doses of classical psychedelics in humans.
2023 — How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?
2023 — The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.
2023 — Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
2023 — The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics.
2023 — Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
2023 — Electrophysiological study of visual and auditory processing in psilocin-induced hallucinations: exploring evoked potentials and 5-HT2A receptor involvement
2023 — Predictors of Psychedelic Experience: A Thematic Analysis.
2023 — Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use
2023 — A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
2023 — Psilocybin as a treatment for anorexia nervosa: 6-week and 3-month follow-up results
2023 — The right to privacy in the decriminalisation of psilocybin mushrooms in South Africa
2023 — Psychedelic Drug Therapy for Mental Disorders?
2023 — Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change
2023 — Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
2023 — Therapeutic mechanism of psilocybin in the treatment of depression and other psychiatric disorders.
2023 — Company on brink takes psilocybin to trial for fragile X syndrome
2023 — Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data
2023 — Italian psychedelic therapies of the past century: An historical overview
2023 — Visualizing drug actions on dendrites: psilocybin and other classic psychedelics
2023 — Investigating changes in EEG entropy rate in response to psilocybin - a comparison of lempel ziv and state-space entropy rate measures
2023 — A multi-metric evaluation of psilocybin effects on functional brain entropy in healthy volunteers
2023 — Change in whole blood BDNF after escitalopram or psilocybin intervention in patients with depression and healthy controls
2023 — Withdrawal of antidepressants does not impact the efficacy of COMP360 psilocybin therapy: results from a phase IIb randomised controlled trial
2023 — Behavioral effects of a 14-day repeated treatment with psilocybin at a low non-psychedelic dose: a preliminary study in C57BL/6J mice
2023 — Effect of co-administration of low doses of psilocybin and mGluR2/3 antagonist LY341495 in chronic restraint stress model of depression
2023 — The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a long-term observational follow-up study
2023 — Psilocybin rescues depressive phenotype and modulates serotonin-2A and glucocorticoid receptor mRNA expression in brain cortex of a stress animal model
2023 — Acute neurovascular effects of psilocybin administration in healthy humans: Implications for cerebral blood flow measurements using arterial spin labelling
2023 — In Search of: A Federal Safe Harbor for State Legalization of Psilocybin
2023 — Psilocin esters - An investigation of synthetic feasibility, chemical, and metabolic stability
2023 — Psilocybin in the treatment of generalized anxiety disorder (GAD), alcoholism and smoking: a literature review
2023 — Cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in South Africa
2023 — Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst
2023 — Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst
2023 — The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review
2023 — Healing at death’s door: one patient’s mystical experience with psilocybin
2023 — Acute psilocybin enhances cognitive flexibility in rats.
2023 — Conformational Landscape and Hydrogen Bonding Pattern of Psilocin: Computational Insights
2023 — The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
2023 — Indigenous-Amazonian Traditional Medicine's Usage of the Tobacco Plant: A Transdisciplinary Ethnopsychological Mixed-Methods Case Study.
2023 — On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.
2023 — Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands
2023 — Recruitment discrimination of lifetime classic psychedelic users is unjustified: Evidence from employees' motivation-based workplace absenteeism
2023 — Is psilocybin an effective antidepressant and what is its Mechanism of action?
2023 — Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder
2023 — Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder
2023 — Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial
2023 — Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.
2023 — SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression
2023 — Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
2023 — Psilocybin therapy for depression. A good trip?
2023 — Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.
2023 — Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.
2023 — 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.
2023 — Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.
2023 — Matrix-assisted laser-desorption/ionization-mass spectrometric imaging of psilocybin and its analogues in psychedelic mushrooms using a cesium chloride-coated target plate.
2023 — Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
2023 — Novel antidepressant drugs: Beyond monoamine targets.
2023 — More on psilocybin
2023 — Wirkt Psilocybin nachhaltig antidepressiv?
2023 — Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.
2023 — The therapeutic potential of psychedelics: the European regulatory perspective
2023 — Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.
2023 — The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy
2023 — Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.
2023 — Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.
2023 — Considerations in assessing the abuse potential of psychedelics during drug development.
2023 — Psychedelics for the Neuropsychiatric Symptoms of Alzheimer's disease
2023 — Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition
2023 — Psychedelics Legislation Gains Momentum
2023 — Psychedelic Renaissance: Clinical Health Justice, Patient Safety, and Equity Need to Be Put First
2023 — UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.
2023 — Psilocybin for Treatment-Resistant Depression.
2023 — Effect of psilocybin on decision-making and motivation in the healthy rat.
2023 — The Effects of Serotonergic Psychedelics on Neural Activity: A Meta-Analysis of Task-Based Functional Neuroimaging Studies
2023 — Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice.
2023 — A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.
2023 — [Psychedelic Therapy with Psilocybin and Psychotherapy - Where do we Stand?].
2023 — Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
2023 — Intoxication of dogs and cats with common stimulating, hallucinogenic and dissociative recreational drugs.
2023 — Utility of preclinical models in the study of psilocybin - A comprehensive review.
2023 — Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling
2023 — Interaction of psychedelic tryptamine derivatives with a lipid bilayer.
2023 — Genome sequencing progenies of magic mushrooms (Psilocybe subaeruginosa) identifies tetrapolar mating and gene duplications in the psilocybin pathway.
2023 — Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.
2023 — Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.
2023 — Update on treatments for anxiety-related disorders.
2023 — [Attitudes of Mental Health Experts Towards Psilocybin].
2023 — A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.
2023 — A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.
2023 — Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review.
2023 — Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training?
2023 — How psychedelics spark neuronal growth
2023 — Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles.
2023 — Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?
2023 — Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study
2023 — Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study
2023 — Understanding psychedelic 'mystical experience'-A case example
2023 — Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study
2023 — Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study
2023 — Understanding psychedelic 'mystical experience'-A case example
2023 — Patternizing Psilocybin in Logic Space
2023 — Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
2023 — The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice.
2023 — Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
2023 — Canalization and plasticity in psychopathology.
2023 — The varieties of psychedelic law.
2023 — Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD
2023 — Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD
2023 — Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study
2023 — The Unique Neural Signature of Your Trip: Functional Connectome Fingerprints of Subjective Psilocybin Experience
2023 — Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism.
2023 — Default Mode Network Modulation by Psychedelics: A Systematic Review.
2023 — Experts to Discuss the Ethics of Psychedelics
2023 — View, meditation, action: A Tibetan framework to inform psychedelic-assisted therapy
2023 — Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness
2023 — Psychotherapy with Psilocybin for Depression: Systematic Review.
2023 — Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice.
2023 — Classic psychedelic use and current meditation practice.
2023 — Systematic Review of Interventions for Demoralization in Patients With Cancer.
2023 — Liminal spaces, seasonal faces: Challenging drug market assumptions via an exploration of naturally occurring magic mushroom markets in rural Kent.
2023 — Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
2023 — Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.
2023 — Psychedelics: Science sabotaged by Social Media.
2023 — Are psychedelics the answer to chronic pain: A review of current literature.
2023 — Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.
2023 — Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.
2023 — The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics.
2023 — Microdosing psilocybin for chronic pain: a case series.
2023 — To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.
2023 — Psilocybin zeigt Wirkung bei Depression.
2023 — Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
2023 — The Theoretical Description for Psilocin Electrochemical Determination over Cobalt Oxyhydroxide
2023 — 509. Meta-Analysis of Functional Neuroimaging Studies of the Effects of Serotonergic Psychedelics on Neural Activity
2023 — Psychedelic Medicine: From Brain Science to Clinical Trials
2023 — 96. An Open Label Study of Synthetic Psilocybin in Bipolar Type II Depression
2023 — 347. Changes in Resting State Functional Connectivity After Psilocybin for Body Dysmorphic Disorder
2023 — 118. Does Psilocybin Change Synaptic Vesicular Density in the Brains of Patients With Mild Cognitive Impairment?
2023 — Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy--dimethyltryptamine in Mice.
2023 — Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
2023 — High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin
2023 — A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
2023 — The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
2023 — Psychedelic Sensationalism: An Analysis of the Schedule Classification of Psilocybin
2023 — A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history
2023 — Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
2023 — Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
2023 — Psilocybin-based mushrooms and usage
2023 — Psilocybin-Based Breakthroughs in Natural Medicine
2023 — Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis.
2023 — [Drugs in the Developmental Stage (Psychotropics)].
2023 — Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
2023 — [Contribution of serotonin 5-HT receptor to antidepressant effect of serotonergic psychedelics].
2023 — Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.
2023 — Trends in drug use among nightclub and festival attendees in New York City, 2017-2022.
2023 — Unblinding and demand characteristics in the treatment of depression.
2023 — The use of classic psychedelics among adults: a Danish online survey study.
2023 — Using Psilocybin Therapy for treating end of life distress trial
2023 — Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD.
2023 — Effects of Psilocybin in Anorexia Nervosa
2023 — The Need for Psychiatric Treatment among Polish Users of Psychoactive Substances Is Increasing: This and Other Results from the Newest PolDrugs Survey.
2023 — Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience.
2023 — Exposure therapy under psilocybin for general anxiety disorder and claustrophobia
2023 — A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin
2023 — THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE
2023 — A review of psilocybin: chemistry, clinical uses and future research directions
2023 — Characterization of Novel Tryptamines’ Anxiolytic and Anti-Inflammatory Effects in Relation to their Psychoactive Effects
2023 — Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders
2023 — Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.
2023 — TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.
2023 — Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers
2023 — Neurobiological Correlates of Psilocybin Response in Depression.
2023 — Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans
2023 — Bridging the translational neuroscience gap: Development of the ‘shiftability’ paradigm and an exemplar protocol to capture psilocybin-elicited ‘shift’ in neurobiological mechanisms in autism
2023 — Long term efficacy of psilocybin in patients with cancer and major depressive disorder (MDD).
2023 — Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.
2023 — The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs.
2023 — The Perilous Policy of Oregon's Psilocybin Services.
2023 — Psychedelics promote plasticity by directly binding to BDNF receptor TrkB.
2023 — Global species diversity and distribution of the psychedelic fungal genus.
2023 — The evolution and ecology of psilocybin in nature.
2023 — Role of Psychedelics in Treatment-Resistant Depression.
2023 — Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.
2023 — In silico characterization of the psilocybin biosynthesis pathway.
2023 — National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities.
2023 — Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review
2023 — ID: 212703 Augmenting rTMS With Psilocybin-Assisted Psychotherapy (PAP) for PTSD: A Proof-of-Concept Study Design
2023 — Psilocybin (Magic Mushrooms)
2023 — Psilocybin therapy: A novel approach to treating depression
2023 — Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression
2023 — Is Microdosing a Placebo?
2023 — Is Microdosing a Placebo?
2023 — The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of Consciousness
2023 — Is Microdosing a Placebo?
2023 — The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of Consciousness
2023 — Cardioprotective Potential of the Ethanol and Water Extracts of Four Psilocybin Mushrooms on Angiotensin II-Induced Hypertrophy and Oxidative Stress on H9C2 Cardiomyocytes
2023 — Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders.
2023 — No trip needed for psychedelics to lift mood?
2023 — Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin - A retrospective case study
2023 — Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study
2023 — Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study
2023 — The treatment of abandonment anxiety with MDMA and LSD
2023 — Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin - A retrospective case study
2023 — Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study
2023 — The treatment of abandonment anxiety with MDMA and LSD
2023 — A regulatory framework review of Schedule I psychedelics in the United States
2023 — Psychedelics reopen the social reward learning critical period
2023 — Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
2023 — In vivo mapping of pharmacologically induced functional reorganization onto the human brain's neurotransmitter landscape.
2023 — Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats
2023 — Psychedelics, Meaningfulness, and the "Proper Scope" of Medicine: Continuing the Conversation.
2023 — Psilocybin decelerates cellular senescence
2023 — Psychedelic Therapy Requires Enhanced Consent Discussions
2023 — Experts Offer Tips on Talking With Patients About Psychedelics
2023 — Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
2023 — Daily briefing: Australia will be first to prescribe these psychedelics as medicines
2023 — Classical psychedelics in psychiatry - renaissance of interest and therapeutic perspectives.
2023 — Alterations to self consciousness during mindfulness meditation and Flotation REST a comparative study
2023 — Alterations to self consciousness during mindfulness meditation and Flotation REST a comparative study
2023 — FDA issues first draft guidance on psychedelic research
2023 — Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.
2023 — Psilocybin's effects on cognition and creativity: A scoping review.
2023 — Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
2023 — Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
2023 — Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.
2023 — Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories.
2023 — New Pharmacologic Approaches to the Treatment of Bipolar Depression.
2023 — The down-scheduling of MDMA and psilocybin(e): Too fast and too soon.
2023 — Corrigendum to 'Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity': Neuroimage 2022 Oct 15;260:119434.
2023 — Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?
2023 — A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.
2023 — The molecular basis of the antidepressant action of the magic mushroom extract, psilocin
2023 — The need for establishing best practices and gold standards in psychedelic medicine.
2023 — Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
2023 — Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.
2023 — Trip Where you Stand: Towards Psychedelic Liberation
2023 — Psychedelic drug psilocybin shows promise treating anorexia in early trials
2023 — Navigating the chaos of psychedelic fMRI brain-entropy via multi-metric evaluations of acute psilocybin effects
2023 — Introduction to the chemistry and pharmacology of psychedelic drugs
2023 — Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin
2023 — Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)
2023 — Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin
2023 — Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
2023 — [Psychedelic Experiences: Phenomenology, Therapeutic Potentials and Explanatory Models].
2023 — Leveraging psychedelic therapies for binge eating disorder
2023 — Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
2023 — Confronting the figure of the “mad scientist” in psychedelic history: LSD’s use as a correctional tool in the postwar period
2023 — Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review
2023 — Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings
2023 — Psilocybin Therapy for Major Depressive Disorder: A Systematic Review
2023 — Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour
2023 — A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
2023 — A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
2023 — Pharmacognostic, Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Multidisciplinary Study with an Assessment of Peculiarities of Circulation (Use) of Smoking Mixtures of Spices and Entheogens of Amanita Muscaria Mushroom
2023 — Psilocybin as an antidepressant strategy - a review of safety aspects
2023 — Systematic Review on the Mechanisms of Action of Psilocybin in the Treatment of Depression
2023 — A systematic review to assess the use of psilocybin in the treatment of headaches
2023 — The therapeutic potential of psilocybin in depression resistant to psychotropic drugs
2023 — Knocking on the Doors of Perception: the role of psilocybin in substance use disorder treatment
2023 — Psychedelics for depression: from neurobiology to treatment
2023 — A proof-of concept randomized controlled trial to show that the antidepressant effect of psilocybin does not require a psychedelic experience: study protocol
2023 — Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression
2023 — Distinctive Molecular and Metabolic Profiles of Chemically Synthesized Psilocybin and Psychedelic Mushroom Extract
2023 — Is PTSD an Evolutionary Survival Adaptation Initiated by Unrestrained Cytokine Signaling and Maintained by Epigenetic Change?
2023 — Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.
2023 — An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.
2023 — “Why would you open someone’s brain up?” Lived experience insights inform a psilocybin-assisted psychotherapy treatment manual for body image disturbance
2023 — The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study
2023 — Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz
2023 — THE CONNECTION BETWEEN THE INDIVIDUAL SUBJECTIVE WELL-BEING AND THE MYSTICAL EXPERIENCE PRODUCED BY THE USE OF PSYCHEDELICS
2023 — Psilocybin for the treatment of anorexia nervosa.
2023 — Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
2023 — "Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli".
2023 — Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.
2023 — How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
2023 — Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.
2023 — Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis.
2023 — Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.
2023 — Psilocybin und Funktionalität bei Depression
2023 — [Not Available].
2023 — A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.
2023 — Psilocybin-assisted psychotherapy for cancer-related anxiety and depression.
2023 — Psilocybin's Emerging Role in Combating Depressive Disorder
2023 — Substance use, harm reduction attitudes and behaviors among attendees of nature rave parties in Israel.
2023 — Emerging Perspectives in Addiction Psychiatry.
2023 — Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice.
2023 — Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy.
2023 — Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells.
2023 — A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics
2023 — Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy
2023 — use of psilocybin in the treatment of psychiatric disorders - review
2023 — “Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report
2023 — “Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report
2023 — Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy
2023 — Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.
2023 — Psilocybin desynchronizes brain networks.
2023 — Intravenous psilocybin administration attenuates mechanical hypersensitivity in a rat model of chronic pain
2023 — Pharmacology and Therapeutic Effects of Psilocybin
2023 — Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.
2023 — Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?
2023 — Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.
2023 — Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.
2023 — Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy.
2023 — Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
2023 — Psilocybin history, action and reaction: A narrative clinical review.
2023 — The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
2023 — The Potential of Psychedelics for the Treatment of Episodic Migraine.
2023 — Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.
2023 — Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.
2023 — Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins.
2023 — Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
2023 — Clinical specificity profile for novel rapid acting antidepressant drugs.
2023 — Psilocybin: The most effective moral bio-enhancer?
2023 — Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis.
2023 — HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.
2023 — Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
2023 — Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models
2023 — P05-02: Assessment of the CYP450 inhibitory activity of psilocybin, psilocin, LSD, 5-MeO-DMT and mescaline: An in vitro study
2023 — Neuroimaging in psychedelic drug development: past, present, and future.
2023 — Psilocybin Use in Palliative Care #464
2023 — Comparison of fragrance and flavor components in non-psilocybin and psilocybin mushrooms using vacuum-assisted headspace high-capacity solid-phase microextraction and gas chromatography-mass spectrometry
2023 — Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
2023 — Psilocybin for anorexia nervosa: If it helps, let's learn how.
2023 — Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training
2023 — A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines
2023 — Can a single dose of psilocybin improve cognitive control in functional dissociative seizures?
2023 — Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions
2023 — Psychedelics: Threshold of a Therapeutic Revolution.
2023 — The psychedelic experience and treatment-resistant depression
2023 — Dynamic Functional Hyperconnectivity after Psilocybin Intake is Primarily Associated with Oceanic Boundlessness
2023 — Self-perception and self-recognition while looking in the mirror on psilocybin
2023 — Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder
2023 — Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators
2023 — Expectancies for Subjective and Antidepressant Effects in Psilocybin Users
2023 — Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies
2023 — Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study
2023 — Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
2023 — Psychedelics as Therapeutics: Research Advances and Implications for Practice
2023 — Use of Psychedelics for Pain: A Scoping Review.
2023 — The zebrafish for preclinical psilocybin research.
2023 — Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.
2023 — Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms.
2023 — Letter to the editor on "Increased low-frequency brain responses to music after psilocybin therapy for depression".
2023 — Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
2023 — Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.
2023 — CROSS-SPECIES EVIDENCE FOR PSILOCIN-INDUCED VISUAL HALLUCINATIONS: RATS PERCEIVE QUALITATIVELY SIMILAR CHANGES AS HUMANS
2023 — Psilocybin kann offenbar Depressionen lindern.
2023 — 6.3 Psilocybin Therapy for the Treatment of Young Adults With Anorexia Nervosa: State of the Research
2023 — DOES THE PHENOMENOLOGY OF THE PSILOCYBIN EXPERIENCE PREDICT LONG-TERM EFFECTS ON MOOD AND WELL-BEING IN HEALTHY VOLUNTEERS?
2023 — PSILOCYBIN EXERTS ANTIDEPRESSANT EFFECTS IN A CHRONIC UNPREDICTABLE MILD STRESS (CUMS) ANIMAL MODEL
2023 — MODULATION OF SYNAPTIC FUNCTION AND NEURONAL NETWORK ACTIVITY BY SEROTONERGIC PSYCHEDELICS
2023 — UNRAVELLING THE ROLE OF5-HT2AR ACTIVATION IN THE LONG-LASTING BEHAVIORAL EFFECTS OF PSILOCYBIN
2023 — An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).
2023 — Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?
2023 — Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology
2023 — Psilocybin, Depression, and Synaptogenesis: Insights into the Field’s Past, Present, and Future
2023 — Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study
2023 — Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study
2023 — Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential.
2023 — Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I
2023 — Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II
2023 — Assessing Metro Vancouver Residents’ Knowledge and Opinions of Psilocybin
2023 — The Psychedelic,-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors.
2023 — Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?
2023 — Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
2023 — Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.
2023 — Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
2023 — Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
2023 — Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences
2023 — Is psilocybin effective for treatment of depression?
2023 — Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms
2023 — Extended difficulties following the use of psychedelic drugs: A mixed methods study
2023 — Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocol
2023 — A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues
2023 — A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues
2023 — Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’
2023 — A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics.
2023 — The Psychedelic Social Club: a regulatory concept for people who use psychedelics?
2023 — Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.
2023 — [Determination of amanita peptide and tryptamine toxins in wild mushrooms by high performance liquid chromatography-tandem mass spectrometry].
2023 — [Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland].
2023 — Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
2023 — Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats.
2023 — Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.
2023 — Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study.
2023 — Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.
2023 — "But the reality is it's happening": A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy.
2023 — An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations.
2023 — Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception
2023 — Peak Experiences: Lessons Learned from a Feasibility Study of Psilocybin-assisted Therapy for Demoralization in Patients Receiving Hospice Care
2023 — Anxiolytic behavior accompanied by the alteration of the intestinal bacteriome during psilocybin treatment
2023 — Cultivation, chemistry, and genome of.
2023 — A "Magic Mushroom" Multi-Product Sesquiterpene Synthase.
2023 — Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury.
2023 — LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain.
2023 — The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic Review
2023 — Investigation of the structure, stability, and relative solubility of psilocybin in water and pure organic solvents: A molecular simulation study
2023 — Beyond the 5-HT Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.
2023 — Pharmacists’ perspectives on psilocybin in Canada
2023 — Managing expectations with psychedelic microdosing
2023 — The entropic heart: Tracking the psychedelic state via heart rate dynamics
2023 — The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
2023 — Aesthetic Chills Mitigate Maladaptive Cognition In Depression
2023 — The potential use of psilocybin in psychiatry
2023 — Psychedelic Integration: Psychotherapy for non-ordinary states of consciousness
2023 — Wood-loving magic mushrooms from Australia are saprotrophic invaders in the northern hemisphere
2023 — Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials
2023 — Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach
2023 — Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach
2023 — [Feeling unwell after eating a piece of chocolate].
2023 — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).
2023 — The potential of psilocybin use to enhance well-being in healthy individuals - A scoping review
2023 — Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings.
2023 — A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.
2023 — Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.
2023 — Perceptions of psychedelic-assisted therapy among Black Americans.
2023 — Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers.
2023 — Psilocybin's Erasure of EGO.
2023 — Psilocybin therapy to reduce depression following a terminal diagnosis.
2023 — The possible place for psychedelics in pharmacotherapy of mental disorders.
2023 — Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
2023 — Mindfulness meditation and psychedelics: potential synergies and commonalities.
2023 — Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
2023 — Preclinical models of treatment-resistant depression: challenges and perspectives.
2023 — Cardiovascular safety of psychedelic medicine: current status and future directions.
2023 — Potential use of psilocybin drugs in the treatment of depression.
2023 — A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond.
2023 — Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use.
2023 — Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.
2023 — Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy?
2023 — Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021.
2023 — Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.
2023 — Flies on ’Shrooms: Studying the Psychotherapeutic Potential of Psilocybin using Drosophila
2023 — Studying classic psychedelics for the management of headache disorders: Considerations for Veterans.
2023 — A history and future of psychedelics: The case of the Canadian military.
2023 — Peer support and psychedelics.
2023 — Domestication through clandestine cultivation constrained genetic diversity in magic mushrooms relative to naturalized populations.
2023 — Statistical diversity distinguishes global states of consciousness
2023 — CHIẾT XUẤT PSILOCIN TỪ NẤM THỨC THẦN LÀM NGUYÊN LIỆU THIẾT LẬP CHUẨN
2023 — Psychotropics: A scientific, regulatory, and public view on the medicinal uses of cannabinoids and psilocybin
2023 — Development and validation of a sensitive LC-MS-MS method to quantify psilocin in authentic oral fluid samples
2023 — Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms
2023 — Psychedelics and cognitive function: A systematic review
2023 — Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats.
2023 — Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue.
2023 — Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders
2023 — Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain.
2023 — Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity.
2023 — Application of psilocybin in mental health disorders
2023 — Molecular and Medical Aspects of Psychedelics.
2023 — Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin
2023 — Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview
2023 — Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.
2023 — Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin
2023 — Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview
2023 — Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depression
2023 — Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis.
2023 — The Therapeutic Effect and Potential Application of Psilocybin
2023 — Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge
2023 — Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge
2023 — Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
2024 — Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.
2024 — Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use.
2024 — A novel method for quantitative analysis of subjective experience reports: application to psychedelic visual experiences.
2024 — Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial.
2024 — Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.
2024 — Fire Kasina advanced meditation produces experiences comparable to psychedelic and near-death experiences: A pilot study.
2024 — Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities.
2024 — Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens.
2024 — Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports.
2024 — Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use.
2024 — A narrative exploration of psilocybin's potential in mental health.
2024 — Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada.
2024 — Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia.
2024 — Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.
2024 — CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality.
2024 — Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.
2024 — Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City.
2024 — On the mushrooming reports of "quiet quitting": Employees' lifetime psilocybin use predicts their overtime hours worked.
2024 — Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences.
2024 — Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects.
2024 — The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.
2024 — Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.
2024 — [The nursing role in psychedelic-assisted psychotherapy].
2024 — Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants.
2024 — Revisiting psychiatry's relationship with spirituality.
2024 — Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report.
2024 — Psilocybin for the treatment of Alzheimer's disease.
2024 — Psilocybin's Potential Mechanisms in the Treatment of Depression: A Systematic Review.
2024 — Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data.
2024 — Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension.
2024 — Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.
2024 — Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action".
2024 — A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity.
2024 — Effect of oral tryptamines on the gut microbiome of rats-a preliminary study.
2024 — Attitudes of European psychiatrists on psychedelics: a qualitative study.
2024 — Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review.
2024 — Palliative care patients' attitudes and openness towards psilocybin-assisted psychotherapy for existential distress.
2024 — Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators.
2024 — The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov.
2024 — Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists.
2024 — Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.
2024 — Safety pharmacology of acute psilocybin administration in healthy participants.
2024 — The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.
2024 — Scoping Review: The Role of Psychedelics in the Management of Chronic Pain.
2024 — Where do the symptoms come from in depression? Topography and dynamics matter.
2024 — Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.
2024 — Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
2024 — Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.
2024 — Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.
2024 — Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials.
2024 — Keeping the promise: a critique of the current state of microdosing research.
2024 — Effects of hallucinogenic drugs on the human heart.
2024 — Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.
2024 — Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.
2024 — Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.
2024 — Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals.
2024 — Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders.
2024 — Ayahuasca for the treatment of alcohol use disorder.
2024 — Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.
2024 — Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).
2024 — [Up-to-Date on clinical and preclinical studies of psilocybin therapy].
2024 — Valuing the Acute Subjective Experience.
2024 — The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
2024 — Older adults in psychedelic-assisted therapy trials: A systematic review.
2024 — CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity.
2024 — The safety of supported psilocybin use in Oregon.
2024 — Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary.
2024 — Psilocybin Without Psychotherapy: A Cart Without a Horse?
2024 — Is Poorly Assisted Psilocybin Treatment an Increasing Risk?
2024 — Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
2024 — Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.
2024 — Is there credible evidence to assert psilocybin-assisted therapy for depression?
2024 — Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.
2024 — IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
2024 — Psychedelia: The interplay of music and psychedelics.
2024 — Drug-drug interactions involving classic psychedelics: A systematic review.
2024 — Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
2024 — Psilocybin and Other Classic Psychedelics in Depression.
2024 — The psychedelic effects of cannabis: A review of the literature.
2024 — Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.
2024 — When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.
2024 — The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
2024 — Potential Benefits of Psilocybin for Lupus Pain: A Case Report.
2024 — Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study.
2024 — Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM.
2024 — Must Psilocybin Always "Assist Psychotherapy"?
2024 — Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.
2024 — Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence.
2024 — Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series.
2024 — Educational Materials and Image Induction Increase Treatment Credibility.
2024 — Pharmacological characterization of psilocin affinity towards different 5-HT receptors and receptor regulation after psilocybin administration in pigs
2024 — Brazilian Psychedelic Science and the Frontiers of Psychiatry
2024 — Psilocybin for the treatment of posttraumatic stress disorder: A magic to treat a harmony of illusions?
2024 — Investigational COMP360 psilocybin treatment for treatment-resistant depression: assessing altered states of consciousness
2024 — Psychedelic Mushrooms: The Use of Psilocybin in the Treatment of Mental Disorders
2024 — Introduction to the Special Section on Psychedelics Research and Treatment
2024 — Exploring the molecular basis of treatment-resistant depression: Discoveries from a rat model and psilocybin therapy
2024 — Psychedelics: The New Kid on the Block
2024 — Cannabis and Psilocybin: Insurance Reimbursement, Legalization, and Rescheduling
2024 — The Therapeutic Potential of Psilocybin for Depression
2024 — Evaluation of the long-term cognitive effects of psilocybin in a chronic stress mouse model
2024 — Associations between behavioral and neuronal changes in self-referential processing following a single, moderate dose of psilocybin in depressed patients
2024 — Insights into the serotonergic mechanisms of psilocybin-induced improvements in anorexia-like behaviour in female rats
2024 — Neural effects of psilocybin-treatment in patients with treatment-resistant depression
2024 — Effects of psilocybin and sleep quality on brain water diffusivity and microstructure in healthy individuals and chronic cluster headache patients
2024 — Psilocybin vs Escitalopram for depression: 6-month follow-up
2024 — Changes in positive and negative affect in participants with treatment-resistant depression following COMP360 psilocybin treatment
2024 — Panini and Psilocybin
2024 — Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 3 approved with reservations]
2024 — Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 1 approved with reservations]
2024 — Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 1 approved, 3 approved with reservations]
2024 — Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 2 approved with reservations]
2024 — Referee report. For: A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. [version 2; peer review: 1 approved with reservations, 1 not approved]
2024 — RAPIDLY TRADING DOWN DEPRESSION'S3 PILLARS TO 5HT3-RECEPTORS THROUGH ECT OR PSILOCYBIN?
2024 — Psilocybin’s Role in Major Depressive Disorder: A Scoping Review
2024 — Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary
2024 — Perceptions of Psychedelics: University Students' Attitudes and Motives for Psilocybin Use
2024 — Differential effects of psychedelics and classical antidepressants on TrkB dimerization and neurotrophic signalling
2024 — Psilocybin as a treatment for psychiatric disorders: a review of the literature
2024 — Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
2024 — Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review
2024 — Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder
2024 — Usikker effekt av psilocybin ved anoreksi
2024 — Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin
2024 — Psilocybin Promotes Cell-Type-Specific Changes in the Orbitofrontal Cortex Revealed by Single-Nucleus RNA-seq
2024 — In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
2024 — Rapid-acting antidepressant drugs modulate affective bias in rats.
2024 — Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.
2024 — Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study
2024 — Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study
2024 — Psilocybin virker godt mot depresjon
2024 — MicroRNAs underlying the antidepressant effect of psilocybin - Establishing an nCounter pipeline for microRNA-quantification in the pig brain
2024 — How should psychotherapy proceed when adjoined with psychedelics?
2024 — Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma
2024 — Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.
2024 — Psychedelic-like Activity of Norpsilocin Analogues.
2024 — Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action
2024 — Psychedelics for mental health: a biochemical perspective
2024 — Psilocybin biphasically modulates cortical and behavioral activity in mice
2024 — Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
2024 — The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
2024 — Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects
2024 — Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice
2024 — The Effects of Psilocybin on Lipopolysaccharide-Induced Inflammation in THP-1 Human Macrophages
2024 — The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation.
2024 — Psilocybin-assisted psychotherapy for cancer patients
2024 — Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach
2024 — A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder.
2024 — The effect of casing and gypsum on the yield and psychoactive tryptamine content of Psilocybe cubensis (Earle) Singer.
2024 — Will Psilocybin-Assisted Therapy Reduce the Incidence of Medical Assistance in Dying?
2024 — Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey.
2024 — Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry
2024 — Synthetic surprise as the foundation of the psychedelic experience.
2024 — Do the therapeutic effects of psilocybin involve actions in the gut?
2024 — Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT receptor agonist TCB-2 in male DBA/2J mice.
2024 — The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.
2024 — The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
2024 — The development of psilocybin therapy for treatment-resistant depression: an update.
2024 — Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis.
2024 — Effect of psilocybin on pain
2024 — Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLD
2024 — Psilocybin gegen Depressionen
2024 — A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
2024 — Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.
2024 — Psychedelics and sexual functioning: a mixed-methods study.
2024 — Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.
2024 — Effects of DMT on mental health outcomes in healthy volunteers.
2024 — Repeat Dosing of Psilocybin in Headache Disorders
2024 — Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice.
2024 — The Effects of Psychedelics on Neuronal Physiology.
2024 — Tryptamine Derivatives of Norpsilocin Induce Psychedelic-Like Responses in Mice
2024 — Psilocybin induces dose-dependent changes in functional network organization in rat cortex.
2024 — Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.
2024 — Effect of a single psilocybin treatment on Fos protein expression in male rat brain.
2024 — NIDA: Psilocybin mushroom seizures rose significantly
2024 — Development of a digital intervention for psychedelic preparation (DIPP).
2024 — Indigenous psilocybin mushroom practices: An annotated bibliography
2024 — The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects.
2024 — Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol Addiction
2024 — The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey
2024 — Psychedelika-assistierte Psychotherapie
2024 — Psilocybin and the Development of Serotonin Toxicity.
2024 — Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review.
2024 — Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic.
2024 — American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A7-Year Follow-Up Survey.
2024 — The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.
2024 — Screening and confirmation of psilocin, mitragynine, phencyclidine, ketamine and ketamine metabolites by liquid chromatography-tandem mass spectrometry
2024 — Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.
2024 — Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT receptor the unique player?
2024 — Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.
2024 — Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS)
2024 — Post-traumatic stress symptoms, post-traumatic stress disorder, and post-traumatic growth among cancer survivors: a systematic scoping review of interventions.
2024 — Psilocybin zur Behandlung depressiver Erkrankungen
2024 — A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.
2024 — Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent.
2024 — Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
2024 — Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
2024 — New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.
2024 — Magic mushroom and zebrafish: A new recipe?
2024 — Psilocybin poisoning from Psilocybe argentipes ingestion
2024 — Pioneering Methods in Brain Optimization and Mental Health Treatment.
2024 — UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study.
2024 — Problems of Qualification of Trafficking in Plants and Plant Parts Containing Psychoactive Substances and Mushrooms Containing Psilocybin and (or) Psilocin
2024 — Psychedelic drugs and the law: What’s next?
2024 — Scanning the new frontier of mental health: psychedelic brain imaging
2024 — Five New Species of from Xizang Autonomous Region of China and Surrounding Areas.
2024 — Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond.
2024 — Ethical considerations for psychedelic-assisted therapy in military clinical settings.
2024 — A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
2024 — Psychedelic Renaissance: Evidence and Culture
2024 — Psychedelic Drugs: A Mind-expanding Hallucinogens
2024 — Psychedelics: reconnecting the brain to heal the mind
2024 — Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.
2024 — MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide
2024 — Natural Product Synthesis in the 21st Century: Beyond the Mountain Top.
2024 — Methyl transfer in psilocybin biosynthesis.
2024 — Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights.
2024 — Use of Prescribed and Non-Prescribed Treatments for Cluster Headache in a Swedish Cohort.
2024 — Pharmacology of Classical Psychedelic in Mouse Models of Chronic Pain
2024 — From Outsider to Insider: A Look at the Subculture of Microdosing
2024 — The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
2024 — The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
2024 — Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.
2024 — Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
2024 — A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.
2024 — Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder.
2024 — Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin.
2024 — Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.
2024 — Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer.
2024 — Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis.
2024 — Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom.
2024 — Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala.
2024 — Evidence versus expectancy: the development of psilocybin therapy.
2024 — Inhibition of cytochrome P450 3A4 enzyme activity by alkaloid psilocin from magic mushrooms: potential for drug interactions
2024 — Microdosing psychedelics in the treatment of ADHD and comorbid disorders
2024 — Fallbeispiele zur Therapie der rezidivierenden Depression mit Psilocybin
2024 — Current situation regarding psychedelics and magic mushroom in Korea
2024 — A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions
2024 — [Psychedelic psychiatry].
2024 — A pilot study of the effect of group-administered psilocybin on psychological flexibility and outcomes
2024 — Mushroom Therapy: Psilocybin’s Role in Treating Substance Use Disorders (P3-9.018)
2024 — Who will staff the psychedelic resurgence?
2024 — Psychedelic therapists, pharma collaborate on clinical trial
2024 — A dual-receptor model of serotonergic psychedelics
2024 — Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
2024 — Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.
2024 — Therapeutics Uses of Psychedelics in patients with psychiatric disorders A Systematic Review
2024 — The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study
2024 — Psilocybin reduces functional connectivity and the encoding of spatial information by neurons in mouse retrosplenial cortex
2024 — The selective 5-HT2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents
2024 — Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.
2024 — MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More
2024 — Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
2024 — Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.
2024 — 300 Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: An fMRI pilot study
2024 — Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
2024 — Genetic regulation of L-tryptophan metabolism in Psilocybe mexicana supports psilocybin biosynthesis.
2024 — The 'PSILAUT' protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin.
2024 — Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study
2024 — Psychedelic Mysticism and Christian Spirituality: From Science to Love
2024 — Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon.
2024 — Measuring Insight Level After Psychedelic Experience Among The Indian Population
2024 — In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin
2024 — 1. Psilocybin and 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) at Encoding Distort Episodic Familiarity and Positively Bias Emotional Metamemory
2024 — Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hy­droxy-N,N-di­methyl­tryptamine)
2024 — New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity.
2024 — Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
2024 — Psilocybin for depression.
2024 — Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice.
2024 — Psychedelics and the 'inner healer': Myth or mechanism?
2024 — Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.
2024 — Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
2024 — Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
2024 — Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade.
2024 — Expectancy Effects in Psychedelic Trials.
2024 — The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis.
2024 — Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy.
2024 — National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017-2022.
2024 — Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
2024 — A Brief Historical Overview of Psychedelic Research.
2024 — Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.
2024 — Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
2024 — From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream Medicine
2024 — Brain Connectivity Pattern Changes Associated With Psychedelic-Assisted Psychotherapy
2024 — Efficacy of Psilocybin in the Treatment of Substance and Alcohol Use Disorders
2024 — EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
2024 — Effects of Classical Psychedelics on Implicit and Explicit Emotional Empathy and Cognitive Empathy: A Meta-analysis of MET task
2024 — Psilocybin facilitates fear extinction: importance of dose, context, and serotonin receptors
2024 — Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial
2024 — The Psilocybin Connection: Psychedelics, the Transformation of Consciousness, and Evolution on the Planet
2024 — An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients
2024 — Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT Receptor Agonists.
2024 — Calls to Poison Centers Involving Psilocybin Rising in Youth
2024 — Psychedelics Use and the Risk of Reduced Formal Mental Health Care
2024 — Psilocybin-induced anxiolytic effects supported by transient elevation of corticosterone
2024 — The Classical Psychedelic Psilocybin Mitigates Oxycodone Withdrawal
2024 — Rapid, biochemical tagging of cellular activity history in vivo.
2024 — Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.
2024 — Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial.
2024 — Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.
2024 — Psilocybin as a new way for depression treatment
2024 — Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens
2024 — Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor.
2024 — Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats
2024 — Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
2024 — Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
2024 — Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
2024 — On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
2024 — Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology
2024 — Medical Uses and Adverse Effects of Psilocybin.
2024 — Therapeutic Psilocybin's Adverse Effects Mostly Resolved Within 2 Days.
2024 — Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT.
2024 — Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.
2024 — Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history.
2024 — WED-123 Female mice with cirrhosis are more prone to acute and chronic effects of psilocybin exposure without tolerance compared to male mice
2024 — THU-285 Lownonpsychedelic dosed of psilocybin for the therapy of MASLD
2024 — Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats.
2024 — Impact of Psilocybin on Peripheral Cytokine Production.
2024 — A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?
2024 — Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report.
2024 — Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
2024 — In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
2024 — The Intersection of Mental Health and Sexual and Gender Minority Identities for Older Adults Living with Human Immunodeficiency Virus: A Narrative Review.
2024 — Mechanisms of therapeutic change after psychedelic treatment in OCD.
2024 — Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.
2024 — Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety.
2024 — Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
2024 — Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
2024 — Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
2024 — Psilocybin in Bipolar II Study Provides Preliminary Data on Safety.
2024 — Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney's lesions.
2024 — [Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application].
2024 — Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.
2024 — Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hydroxy-N,N-dimethyltryptamine)
2024 — Therapeutic Implications of Psilocybin in the Wake of Decriminalization
2024 — Minorities’ Diminished Psychedelic Returns: Gender, Perceived Stigma, and Distress
2024 — Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA
2024 — 5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood-a retrospective case study
2024 — Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA
2024 — 5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood-a retrospective case study
2024 — Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
2024 — Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies
2024 — A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder
2024 — Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies
2024 — Therapeutic Potential of Fungally Derived Psilocybin Extract in Morphine-Dependent Mice: A Research Protocol
2024 — Psychedelics’ Use as Medicine Hits Significant Roadblock
2024 — Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology.
2024 — Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience
2024 — Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
2024 — Increased 5-HT2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics
2024 — Licit use of illicit drugs for treating depression: the pill and the process.
2024 — Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study
2024 — Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
2024 — RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-,-diisopropyltryptamine.
2024 — Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials
2024 — The influence of psilocybin on subconscious and conscious emotional learning.
2024 — At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse.
2024 — Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders
2024 — Ketamine-Induced Unresponsiveness Shows a Harmonic Shift from Global to Localised Functional Organisation
2024 — Historical Perspectives and Pharmacodynamic Actions of the Magic Mushroom (Psilocybin) for Future Global Healthcare
2024 — Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming.
2024 — IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
2024 — Treating Anxiety and Depression With Psilocybin Therapy.
2024 — Your brain on shrooms - how psilocybin resets neural networks.
2024 — Innovative and Emerging Treatments for Anorexia Nervosa.
2024 — Potential Differences in Psychedelic Actions Based on Biological Sex.
2024 — Bridging Psilocybin-Induced Changes in the Brain's Dynamic Functional Connectome With an Individual's Subjective Experience.
2024 — Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans
2024 — The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review.
2024 — Psilocybin decreases neural responsiveness and increases functional connectivity while preserving pure-tone frequency selectivity in mouse auditory cortex.
2024 — Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis.
2024 — Psychedelic therapy in depression and substance use disorders.
2024 — What is needed for the roll-out of psychedelic treatments?
2024 — A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.
2024 — Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.
2024 — Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.
2024 — Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study.
2024 — Developing Core Consensus Measures for Assessment of Psilocybin Services
2024 — Associations Between Harm Reduction Strategy Use and Acute Psychedelic Effects in Spanish Speakers who Used LSD or Psilocybin
2024 — Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications
2024 — Lifetime Depression and Psilocybin Mushroom Use in U.S. Adults, 2008-2019
2024 — Physiological Effects of Psilocybin, Psilacetin, and DOI in Rats
2024 — Acute Psychedelic Effects and Clinical Outcomes are Associated With Therapeutic Alliance Among Participants Receiving Psilocybin Therapy
2024 — High Blood Pressure Among Psilocybin and Cannabis Consumers During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study
2024 — SPONTANEOUS CHANGES IN CIGARETTE SMOKING FOLLOWING PSILOCYBIN-ASSISTED TREATMENT FOR ALCOHOL USE DISORDER
2024 — Prevalence of Psilocybin and Cannabis Concurrent Use During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study
2024 — Regional Differences of Self-Reported Past-12-month Marijuana, Psilocybin, and Cocaine Use: Results From NDEWS Rapid Street Reporting 2021-2022
2024 — Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.
2024 — Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence
2024 — The Black Book of Psychotropic Dosing and Monitoring.
2024 — [Psilocybin fungi microdose treatment in major depressive disorder: a case report].
2024 — Quantitative Natural Language Processing Markers of Psychoactive Drug Effects: A Pre-Registered Systematic Review
2024 — The trajectory of psychedelic, spiritual, and psychotic experiences: implications for cognitive scientific perspectives on religion
2024 — Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions
2024 — Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study
2024 — Assessment of psychedelic--induced states: Norwegian translation and adaptation of the revised Mystical Experience Questionnaire (MEQ-30)
2024 — Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
2024 — Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A.
2024 — Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports
2024 — Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis.
2024 — Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα
2024 — Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol
2024 — PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin
2024 — Psilocybin for the Treatment of Major Depressive Disorder
2024 — Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users
2024 — Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users
2024 — From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions
2024 — Expanding Mindscapes: A Global History of Psychedelics. By ErikaDyck, ChrisElcock (Eds.), Cambridge, MA: The MIT Press. 2023. ISBN: 9780262546935
2024 — How psilocybin affects the brain.
2024 — Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients
2024 — Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method
2024 — CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS.
2024 — Psilocybin desynchronizes the human brain.
2024 — Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness.
2024 — The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
2024 — Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study.
2024 — The cyclical revival of psychedelics in psychiatric treatment.
2024 — Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.
2024 — Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.
2024 — Psychedelic-assisted psychotherapy: where is the psychotherapy research?
2024 — Is it now time to prepare psychiatry for a psychedelic future?
2024 — Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.
2024 — Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions.
2024 — The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.
2024 — Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study
2024 — Insights into the efficacy of psilocybin in treating depression and other disorders
2024 — Psilocybin-assisted therapy and HIV-related shame.
2024 — Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression
2024 — Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms
2024 — Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium
2024 — An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
2024 — Resurrecting Ancestral Familial Health: A Role for Psilocybin?
2024 — Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression
2024 — Acute Effects of Psilocybin and Salvinorin-A on Functional Connectivity
2024 — Prevalence and Correlates of Psychedelic Use in Poland: A Study on a Representative Sample of Polish Adults
2024 — A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)
2024 — Psychedelic use and psychological flexibility: The role of meaningful intention and decentering
2024 — Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.
2024 — A virtual clinical trial of psychedelics to treat patients with disorders of consciousness
2024 — Tripping on Utopia: Margaret Mead, the Cold War, and the troubled birth of psychedelic science By BenjaminBreen. New York: Grand Central Publishing, 2024. 384 pp.
2024 — Psilocybin in the Treatment of Mental Disorders
2024 — Psilocybin, moralization and psychotherapy: a scoping review and a case report
2024 — Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
2024 — ­­­­Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study
2024 — Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse: A Cautionary Tale.
2024 — The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting
2024 — Improving Access to Psilocybin-Assisted Therapy: Barriers, Challenges, and Recommendations
2024 — A Cohort Based Case Series: Learnings from an Iterative Group Therapy Model to Support Psilocybin-Assisted Therapy for Patients with a Terminal Diagnosis
2024 — Mushroom poisoning of Panaeolus subbalteatus from Ningxia, northwest China, with species identification and tryptamine detection.
2024 — Psychedelics, Psychedelic-Assisted Therapy and Employees’ Wellbeing
2024 — The Birth of the Psychedelic Industry: Capitalizing on the Psychedelic Renaissance
2024 — Mystical Experience with Cancer Patients: Insights from Psychedelic-Assisted Psychotherapy and Guided Imagery
2024 — Psilocybin for Treatment of Obsessive Compulsive Disorder
2024 — G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?
2024 — Refractory CRPS pain treated with psilocybin: A case report.
2024 — Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.
2024 — Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders.
2024 — Rapidly Trading Down Depression's 3 Pillars to 5HT3-Receptors Through ECT or Psilocybin?
2024 — Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report.
2024 — [Psychedelic and dissociative agents in psychiatry: challenges in the treatment].
2024 — Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
2024 — Psilocybin desynchronization persists in the human brain.
2024 — Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.
2024 — Psilocybin: Medicine for My Soul. Relief from Emotional and Spiritual Pain as a Hospice Nurse Diagnosed with Cancer.
2024 — Effects of psilocybin on uncertain punishment learning.
2024 — Commentary on Darke et al.: Expanded psychedelic access requires new safety monitoring systems.
2024 — Stutterers' experiences on classic psychedelics: A preliminary self-report study.
2024 — A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia.
2024 — Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.
2024 — Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review.
2024 — Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Psychedelic Medicine
2024 — Einmalig Psilocybin: antidepressive Effekte
2024 — Psilocybin-induzierte mystische Erfahrungen in subjektiven Berichten: Ein Scoping Review mit qualitativer Inhaltsanalyse.
2024 — Psychedelic-assisted therapy: Magical thinking or a meaningful treatment for mental illness
2024 — Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol
2024 — Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms
2024 — Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner
2024 — The Epidemiology of Psychedelic Use Among United States Military Veterans
2024 — Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine.
2024 — Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience.
2024 — Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
2024 — B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult Populations
2024 — An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States
2024 — The Psychedelic Renaissance: A Catholic Perspective
2024 — Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials
2024 — Psychedelics as a potential treatment for tobacco use disorder: a systematic review.
2024 — Exploring U.K. cancer doctors’ attitudes toward psilocybin-assisted psychotherapy for cancer-related distress
2024 — Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus
2024 — Psychedelic research at a crossroads.
2024 — Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates the gabapentin-mediated analgesia
2024 — Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans
2024 — Premorbid Characteristics of the SAPAP3-Mouse Model of Obsessive-Compulsive Disorder: Behavior, Neuroplasticity, and Psilocybin Treatment
2024 — Psilocybin legalization in the United States and psychological reactance: A test of evidence uncertainty, controlling language, and an ambiguous call to action.
2024 — Distinct classes of antidepressants commonly act to shape pallidal structure and function in mice
2024 — Psychedelics as novel therapeutic agents for chronic pain: mechanisms and future perspectives
2024 — An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder
2024 — Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity
2024 — Salience, sensemaking, and setting in psilocybin microdosing: Methodological lessons and preliminary findings of a mixed method qualitative study
2024 — The Effects of Psilocybin on Shared Experience in Film Processing
2024 — The Action on Psilocybin in Neural Plasticity, Brain Reorganization and Cognitive Enhancement
2024 — Beyond the numbers: reimagining healing with psychedelics for eating disorders.
2024 — Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats.
2024 — Psilocybin prevents habituation to familiar stimuli and preserves sensitivity to sound following repeated stimulation in mouse primary auditory cortex
2024 — What should constitute a control condition in psychedelic drug trials?
2024 — Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.
2024 — What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study.
2024 — Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat.
2024 — Artificial intelligence and psychedelic medicine.
2024 — Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
2024 — Less is more? A review of psilocybin microdosing.
2024 — The role of psilocybin in depressive disorders.
2024 — Letter to editor regarding "Psilocybin-assisted therapy for depression: A systematic review and meta-analysis".
2024 — Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire.
2024 — Psilocybin for clinical indications: A scoping review.
2024 — Psilocybin in pharmacotherapy of obsessive-compulsive disorder.
2024 — Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
2024 — Effects of psilocybin on body weight, body composition, and metabolites in male and female mice.
2024 — Psilocybin and 2C-B at Encoding Distort Episodic Familiarity.
2024 — Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.
2024 — Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms.
2024 — Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms.
2024 — From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice.
2024 — From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice.
2024 — PR012/#955 Psilocybin assisted psychotherapy for patients with ovarian caner: a subset analysis of a randomized, double-blind, placebo-controlled, phase II clinical trial
2024 — Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine-A Systematic Review and Meta-Analysis
2024 — Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.
2024 — Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol
2024 — Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol
2024 — Neuroprotective effects of psilocybin in a rat model of stroke.
2024 — A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants
2024 — Memory, trauma, and self: Remembering and recovering from sexual abuse in psychedelic-assisted therapy
2024 — A psilocybin haven: the use of comparison to legitimate transgression at a psychedelic retreat
2024 — Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study
2024 — Does psilocybin reduce symptoms of depression in adults with major depressive disorder or life-threatening cancer?
2024 — The therapeutic potential and mechanisms of action of psilocybin-assisted therapy in anorexia nervosa treatment
2024 — Snapshot of 5-HT receptor activation in the mouse brain via IP detection.
2024 — A survey investigating United States federal grant submissions proposing to investigate therapeutic applications of psychedelics
2024 — Impact of Protonation Sites on Collision-Induced Dissociation-MS/MS Using CIDMD Quantum Chemistry Modeling.
2024 — Human brain changes after first psilocybin use
2024 — Psilocybin-assisted psychotherapy as an ‘anti-distressant’ with multidimensional properties
2024 — An Early Exploration into Individuals in Treatment Who Co-Use Alcohol and Hallucinogens
2024 — Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders
2024 — Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task.
2024 — Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
2024 — Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
2024 — Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
2024 — The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
2024 — The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics
2024 — The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin
2024 — The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics
2024 — Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration
2024 — Expert recommendations for Germany's integration of psychedelic-assisted therapy.
2024 — Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour
2024 — Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
2024 — Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner
2024 — “The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin
2024 — A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study
2024 — Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts
2024 — Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: Case report and thematic analysis of one participant's experience
2024 — Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts
2024 — The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin
2024 — Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.
2024 — [Depression and effectiveness of psychedelics: high-dose psilocybin has shown benefits in improving symptoms.].
2024 — Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.
2024 — Optimized psilocybin production in tryptophan catabolism-repressed fungi.
2024 — The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists.
2024 — Psilocybin reduces functional correlation and the encoding of spatial information by neurons in mouse retrosplenial cortex.
2024 — Psychedelic mushroom-containing chocolate exposures: Case series.
2024 — Psychoactive substances for the treatment of neuropsychiatric disorders.
2024 — Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.
2024 — Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice.
2024 — Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.
2024 — Novel treatments for anorexia nervosa: Insights from neuroplasticity research.
2024 — Phytochemical screening, phenolic and flavonoid contents, psilocybin, antioxidant, and acetylcholinesterase inhibition activities of the aqueous extract from the fungi Cyathus striatus, Laternea dringii, and Marasmius haematocephalus
2024 — Will Psychedelics Propel Your Career? Exploring the Potential Impact of Psychedelics on Work, Productivity and Well-Being
2024 — Psilocybin-unterstützte Psychotherapie reduziert Ängste und Depressionen
2024 — Psilocybin alters the circulating metabolomic profile in both non-clinical and clinical models
2024 — Pyramidal cell types and 5-HT receptors are essential for psilocybin's lasting drug action.
2024 — Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial
2024 — Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial.
2024 — Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats.
2024 — Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial
2024 — Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
2024 — PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)
2024 — Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics
2024 — Amid magic and menace: psychiatrists' attitudes to psilocybin therapy.
2024 — Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits
2024 — Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
2024 — Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
2024 — Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help
2024 — PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout
2024 — Psychedelic 5-HT2A receptor agonism: neuronal signatures and altered neurovascular coupling.
2024 — Expanding the Therapeutic Horizons of Psilocybin in Mental Health.
2024 — Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.
2024 — Psilocybin Fungi Unveiled: Morphological Characteristics and Pharmacological Potentials
2024 — A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder
2024 — Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study.
2024 — Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)
2024 — Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression.
2024 — Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science.
2024 — Neuroimaging of Serotonergic and Psychedelic Agonist Drug Challenges in Non-Human Primates
2024 — Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration
2024 — A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient.
2024 — Narrative review of psilocybin, an important psychoactive substance with potential peri-anesthetic implications
2024 — Exploring Psychotherapeutic Benefits of Psilocybin and Psychedelics In Controlled Medical Settings
2024 — Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials.
2024 — Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.
2024 — Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy.
2024 — Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.
2024 — Psilocybin and hallucinogenic mushrooms.
2024 — The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.
2024 — Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.
2024 — Psychedelics for the Treatment of Obsessive-Compulsive Disorder: Efficacy and Proposed Mechanisms.
2024 — The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.
2024 — Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
2024 — Impact of psilocybin on cognitive function: A systematic review.
2024 — Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents.
2024 — Exploring the regulatory framework of psychedelics in the US & Europe.
2024 — New frontiers in the biosynthesis of psychoactive specialized metabolites.
2024 — Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.
2024 — Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.
2024 — God hasn’t died, it has merely been encapsulated - Psilocybin and ayahuasca in the psychedelic renaissance: Intersections between religion, indigenous cosmologies, spirituality, and science
2024 — Exploring Therapeutic Potentials and Pathways of Psychedelics in Alzheimer’s Disease-Related Dementia
2024 — Differential in Vitro Activation Profiles for Psychedelic versus Non-psychedelic Ergolines at the 5-HT2A Receptor
2024 — Psilocybin Microdosing for Anxiety Relief in Young Adults: A Comparative Review of Emerging Evidence
2024 — Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.
2024 — Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study.
2024 — The Second Methylation in Psilocybin Biosynthesis Is Enabled by a Hydrogen Bonding Network Extending into the Secondary Sphere Surrounding the Methyltransferase Active Site.
2024 — Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.
2024 — Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
2024 — The many faces of psilocybin-related psychosis: A case series
2024 — Chronic pain education: past, present, and future of psychedelics for the management of chronic pain
2024 — Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience.
2024 — Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications
2024 — Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.
2024 — Legal and Ethics Concerns of Psilocybin as Medicine.
2024 — Short- and long-term reconfiguration of rat prefrontal cortical networks following single doses of psilocybin
2024 — Disentangling debate about therapeutic and recreational use of psychedelics
2024 — The Neurobiological Effect of 5-HT2AR Modulation
2024 — Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways
2024 — Classic psychedelics and the treatment for alcoholism.
2024 — Characterizing psilocybin as an antidepressant for adolescence in male and female rats
2024 — Brain dynamics of classical psychedelics show paradoxical hierarchical flattening with increased complexity
2024 — Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.
2024 — Psilocybin as a Disease-Modifying Drug-A Salutogenic Approach in Psychiatry.
2024 — Theoretical Description for Psilocin and Coprine Electrochemical Determination in Mushroom Pulp and Biological Liquids over Cobalt (II) Oxyhydroxide-Modified Electrode
2024 — Neuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD): A comparative analysis with psychedelic-using and non-using controls.
2024 — Political Attitudes towards the Legalization of Cannabis and Psilocybin
2024 — Use Cases for Art Therapy Intervention in Clinical Psychedelic Praxis
2024 — Comparative Efficacy of Hallucinogens in Treating Mood Disorders Through a Meta-Analysis of Symptom Reduction, Dosage, and Duration
2024 — Psilocybin-containing mushrooms as a prospective therapeutic for Parkinson’s disease. Pre-clinical study
2024 — Treatment-Resistant Depression: A Comprehensive Insight of Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Psychedelic-Assisted Psychotherapy
2024 — Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse
2025 — High hopes? Precision psychedelic addiction medicine.
2025 — Self-administered complementary and alternative methods of treating mental disorders among students in Wrocław: a cross-sectional study.
2025 — Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey.
2025 — Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.
2025 — Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.
2025 — Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.
2025 — The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.
2025 — Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression.
2025 — : A new species from central Florida, with notes on and.
2025 — Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.
2025 — Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use.
2025 — High Risk, Low Key: The New Face of Drug Use.
2025 — Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.
2025 — Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.
2025 — Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis.
2025 — Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions.
2025 — Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire.
2025 — Correction: Therapeutic and legal aspects of psilocybin in cancer-related depression.
2025 — Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.
2025 — Psychedelics and mental health: reimagining care through science, insight, and compassion.
2025 — Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review.
2025 — Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial.
2025 — A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy.
2025 — Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.
2025 — Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (): A Systematic Review.
2025 — Magic of the Mushrooms: Effects of Psilocybin Decriminalization.
2025 — Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.
2025 — Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.
2025 — Therapeutic and legal aspects of psilocybin in cancer-related depression.
2025 — Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.
2025 — What fMRI studies say about the nature of the psychedelic effect: a scoping review.
2025 — Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine.
2025 — Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study.
2025 — PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction.
2025 — Serotonin 5-HT2A receptor expression is chronically decreased in the anterior cerebral cortex of male rats following repetitive low-level blast exposure.
2025 — Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.
2025 — Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.
2025 — Leveraging psychedelic neuroscience to boost human creativity using artificial intelligence.
2025 — Additions to the sect. (Agaricales) in China: new species from tropical rainforests, new geographical distributions, and toxin detection.
2025 — Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes.
2025 — Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.
2025 — A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.
2025 — A landscape analysis of psychedelic retreat organizations advertising online.
2025 — Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome.
2025 — Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy.
2025 — The phenomenology of psilocybin: transformative insights for research and clinical practice.
2025 — Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
2025 — Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care.
2025 — Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample.
2025 — Psychedelic Microdosing among Young Adults from Southern California.
2025 — Is there room for ethics of authenticity in psilocybin research?
2025 — Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.
2025 — Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications.
2025 — A review of psychedelics trials completed in depression, informed by European regulatory perspectives.
2025 — Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy.
2025 — Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.
2025 — Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.
2025 — Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.
2025 — Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial.
2025 — Social pain: A systematic review on interventions.
2025 — Mushroom poisoning: An updated review.
2025 — Psilocybin alleviates high-glucose and high-lipid-induced skin aging in BJ5Ta fibroblasts.
2025 — "" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms.
2025 — Psychedelic-assisted therapies for existential and spiritual suffering in palliative care.
2025 — Brain changes associated with depression treatment: a meta-analysis.
2025 — An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers.
2025 — Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.
2025 — Emerging Risks of Amanita Muscaria: Case Reports on Increasing Consumption and Health Risks.
2025 — Clinical pharmacology.
2025 — Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease.
2025 — Post-traumatic stress disorder in psychedelic research.
2025 — Psychedelics and substance use disorder treatment.
2025 — Serotonergic psychedelics for depression: A comprehensive overview.
2025 — Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?
2025 — Molecular brain imaging of psychedelic action.
2025 — Effects of psychedelics on human oscillatory brain activity.
2025 — Human neuroimaging: fMRI.
2025 — Geographical Differences in Self-Reported Past 12-Month Drug Use: Results from the NDEWS Rapid Street Reporting, 2021-2023.
2025 — Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder.
2025 — Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.
2025 — Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions.
2025 — Insights into therapeutic potential and practical applications of natural toxins from poisonous mushrooms.
2025 — Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder.
2025 — Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
2025 — Psychedelic Medicine Exceptionalism.
2025 — Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial.
2025 — Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics.
2025 — Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.
2025 — Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
2025 — Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
2025 — Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression.
2025 — Psilocybin: From Psychiatric Pariah to Perceived Panacea.
2025 — Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
2025 — Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.
2025 — Quantitative LC-QToF-MS Analysis of Mycochemicals in Amanita muscaria, Psilocybe spp. (Agaricomycetes), and Consumer Products.
2025 — Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.
2025 — Practical considerations in the establishment of psychedelic research programs.
2025 — Associations between psychedelic use and cannabis use disorder in a nationally representative sample.
2025 — Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression.
2025 — Australian psychologists' attitudes towards psychedelic-assisted therapy and training following a world-first drug down-scheduling.
2025 — Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.
2025 — Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.
2025 — Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention.
2025 — Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.
2025 — Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms.
2025 — Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.
2025 — Subjective Effects of Psychedelics Are the Plausible Mechanism of Psychedelic Moral Enhancement Rather than a Risk. Comment on Tang, B.L. Psychedelics for Moral Bioenhancement in Healthy Individuals-A Violation of the Non-Maleficence Principle? Psychoactives 2025, 4, 5
2025 — From Safe Touch to Sexual Abuse: Walking the Tightrope of Patient Safety in Psychedelic Therapy
2025 — Moral Considerations and the Experience of Ego Dissolution: Insights from Psilocybin
2025 — Mushroom bioactives-polysaccharides to psilocybin: a viewpoint on the therapeutic use of mushrooms for consumers and patients for health and neuroplasticity
2025 — The effects of psychedelics on neuroplasticity: A review of current research and the possibility of therapeutic application in psychiatry
2025 — Psilocybin: revealing the enigmas of a revolutionary fungi
2025 — Therapieresistente Depression: Studie zur Psilocybin-augmentierten Psychotherapie nicht erfolgreich
2025 — Uncovering the dynamics of psilocybin in human neural pain circuits with intracranial neural recordings
2025 — Long-term effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 model of OCD-like behavior
2025 — Effects of escitalopram and psilocybin therapy on mesolimbic resting-state functional connectivity in depression
2025 — Neurotoxic and Neuroprotective Effects of Psychedelics in a Human Neuroblastoma Cell Model
2025 — Attitudes Towards Psilocybin: A General Population’s Opinions on Psilocybin and Psilocybin-Assisted Therapies
2025 — In Silico Evaluation of Tryptamine-Derived Schiff Bases as Modulators of the Serotonin 5-HT₂A Receptor
2025 — Alternative therapy for neurological and psychiatric disorders using psilocybin
2025 — Psychedelics induced modulation of motor recovery after stroke
2025 — Psilocybin rewires specific mouse cortical networks in lasting ways
2025 — Hallucinogen Usage, Experiencing Mystical Phenomena, and Transformational Identity Change
2025 — Additional file 1 of “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke
2025 — Clinical use of psilocybin in mental disorders:: a bibliometric analysis in Scopus and Web of Science
2025 — The Right to 'Trip:' Navigating Psilocybin-Assisted Psychotherapy Under the Right to Try Pathway
2025 — [Psychedelics and pyschodelic-associated psychotherapies - Who is PAP for after all?].
2025 — Beyond the veil of perception: investigating the relationship between predictors of psychedelic experiences
2025 — Exploring the relationship between personality traits, attitudes toward psilocybin use, and motivations for using psilocybin
2025 — Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation.
2025 — Perturbing whole-brain models of brain hierarchy: an application for depression following pharmacological treatment
2025 — Single-nucleus transcriptomics reveals time-dependent and cell-type-specific effects of psilocybin on gene expression.
2025 — Structural insights into tryptamine psychedelics: The role of hydroxyl indole ring site in 5-HT receptor activation and psychedelic-like activity.
2025 — Psilocybin induces sex- and context-specific recruitment of the stress axis
2025 — Molecular Phylogeny and Morphology Reveal Four New Species of (Bolbitiaceae, Agaricales) from the Qinghai-Xizang Plateau, China.
2025 — Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.
2025 — Cell-type specific transcriptional modulation by psilocybin induces sustained plasticity in mouse medial prefrontal cortex
2025 — PSYCHEDELICS IN THE TREATMENT OF MENTAL DISORDERS
2025 — Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.
2025 — Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.
2025 — Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review.
2025 — Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats.
2025 — Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).
2025 — Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.
2025 — The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.
2025 — Study finds encouraging results in psilocybin treatment for TRD patients
2025 — What are the benefits and harms of classical psychedelics (psilocybin and LSD) for treating anxiety, depression, and existential distress in people with life-threatening diseases?
2025 — Age- and estrous-dependent effects of psilocybin in rats
2025 — The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
2025 — Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
2025 — Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.
2025 — Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.
2025 — Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.
2025 — A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression
2025 — When death is desired: A case of MAiD & the CL psychiatrist.
2025 — Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?
2025 — Exploring Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps.
2025 — From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).
2025 — Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.
2025 — DETERMINATION OF TRYPTAMINE ALKALOIDS AND THEIR STABILITY IN PSYCHOTROPIC MUSHROOMS
2025 — Among Psychedelics, Only Psilocybin Has Demonstrated Benefit to Treat Depression.
2025 — The Acceptability of Psychedelic-Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour.
2025 — Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.
2025 — Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review.
2025 — Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.
2025 — Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.
2025 — The safety of psilocybin-assisted psychotherapy: A systematic review.
2025 — Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis.
2025 — Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis.
2025 — Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.
2025 — How psychedelics legalization debates could differ from cannabis.
2025 — A clinical research perspective on the regulation of medical and non-medical use of psychedelic drugs.
2025 — Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
2025 — A Systematic Review of Interventions for Demoralization in Patients with Chronic Diseases.
2025 — EFFECT OF ACUTE PSILOCYBIN ON THERMAL AND NEUROPATHIC PAIN IN RODENTS
2025 — ASSOCIATIONS BETWEEN ESCITALOPRAM AND PSILOCYBIN THERAPY AND BRAIN RESTING-STATE FUNCTIONAL CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER
2025 — BEHAVIORAL PHENOTYPING AND METABOLOMIC COMPARISON OF CHEMICALLY SYNTHESIZED PSILOCYBIN AND PSYCHEDELIC MUSHROOM EXTRACT IN A ZEBRAFISH DEPRESSION MODEL
2025 — ANXIOLYTIC- AND PROCOGNITIVE-LIKE EFFECTS OF A30-DAY CHRONIC TREATMENT WITH A LOW NON-PSYCHEDELIC DOSE OF PSILOCYBIN IN C57BL/6J MICE
2025 — PSILOCYBIN MITIGATES BEHAVIORAL DESPAIR AND COGNITIVE RECOGNITION IMPAIRMENTS BY REGULATING THE HYPOTHALAMIC- PITUITARY-ADRENAL (HPA) AXIS VIA THE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) SIGNALING PATHWAY MEDIATED BY THE ENDOCANNABINOID SYSTEM (ECS)
2025 — Lifetime Psilocybin Use and Opioid Use Disorder in Pregnant and Non-Pregnant Women of Reproductive Age
2025 — Oregon’s Emerging Psilocybin Services Workforce: An Environmental Scan
2025 — Prevalence of Use of Psilocybin and MDMA in Multiple US Cities
2025 — Source Localized Auditory Erp Sensory and Preattentive Correlates of Psilocybin-Induced Ego-Dissolution Related Effects
2025 — Latent Class Analysis of Changes in Substance Use and Depressive Symptoms following Naturalistic Psilocybin Use: Results from a Prospective Longitudinal Survey
2025 — International Drug Policy Study Trends With Psychedelic Drugs: A Spotlight on Psilocybin, LSD, and MDMA
2025 — Clinical Trial Comparing Psilocybin to Nicotine Patch for Tobacco Addiction
2025 — BEHAVIORAL ANALYSES OF ANTIDEPRESSANT-LIKE EFFECT OF SEROTONERGIC PSYCHEDELICS IN MICE
2025 — Direct effects of psilocybin on serotonin receptors regulate lipid accumulation in hepatic cells and adipocytes
2025 — Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver Disease
2025 — Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent.
2025 — Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches.
2025 — Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.
2025 — Funding Success of United States Federal Grant Applications Proposing to Study Therapeutic Applications of Psychedelics: A Survey Study
2025 — Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners
2025 — The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.
2025 — Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.
2025 — Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats
2025 — Psychedelic Information Theory
2025 — Psychedelics for Moral Bioenhancement in Healthy Individuals-A Violation of the Non-Maleficence Principle?
2025 — A qualitative analysis of the psychedelic mushroom come-up and come-down.
2025 — Psilocybin alters visual contextual computations
2025 — High-quality draft genomes of ecologically and geographically diverse species.
2025 — Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländern
2025 — Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.
2025 — Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution.
2025 — Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases
2025 — Esse quam Videre: Critical Reflections on the Use of Psilocybin as an Adjuvant in Psychedelic-Assisted Psychotherapy
2025 — Psychedelics and Suicide-Related Outcomes: A Systematic Review.
2025 — BROAD SPECTRUM OF THERAPEUTIC PROPERTIES OF PSILOCYBIN: A LITERATURE REVIEW
2025 — The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.
2025 — The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.
2025 — The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.
2025 — Psychedelics are Bringing a new wind to the Pharmacopoeia
2025 — Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report.
2025 — Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
2025 — Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
2025 — Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample
2025 — Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
2025 — Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample
2025 — Anhedonia: Current and future treatments.
2025 — A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress.
2025 — A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.
2025 — Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder.
2025 — Participants' Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis.
2025 — Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder.
2025 — Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.
2025 — Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment.
2025 — Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts.
2025 — Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons.
2025 — Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
2025 — Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.
2025 — The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.
2025 — Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: A case report.
2025 — Molecular insights into the modulation of the 5 HT2 A receptor by serotonin, psilocin, and the G protein subunit Gqα
2025 — A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.
2025 — Elucidating the Phase I metabolism of psilocin in vitro
2025 — The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
2025 — Treatment Expectancies and Psilocybin vs Escitalopram for Depression.
2025 — Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression.
2025 — Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
2025 — Evaluating the Influence of CYP450 Enzyme Inducers on the Efficacy of Psilocybin as a Treatment for Neuropsychiatric Disorders (Abstract ID: 167358)
2025 — Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.
2025 — Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015-2020.
2025 — Psychedelic-assisted therapy: An overview for the internist.
2025 — Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?
2025 — Vermont Primary Care Provider Perspectives on Psychedelics - A Cross-Sectional Study.
2025 — Further education in psychedelic-assisted therapy - experiences from Switzerland.
2025 — Improved LC-MS Detection of Opioids, Amphetamines, and Psychedelics Using TrEnDi.
2025 — Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
2025 — Risks of using psilocybin in treatment of treatment-resistant depression
2025 — Psychedelics for Substance Use Disorders: Updates for the Psychiatric Trainee
2025 — Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study
2025 — Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications
2025 — Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study
2025 — Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition.
2025 — Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression
2025 — Psychedelics and autobiographical memory - Six open questions
2025 — Psychedelics and autobiographical memory - Six open questions
2025 — PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS
2025 — Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
2025 — Interview with Allen Kalpin and Reiko Ikemoto-Joseph: psychedelics and ISTDP
2025 — BIOLOGICAL ACTIVITY OF PSILOCYBIN EXTRACTS FROM THE FRUITING BODIES OF PSILOCYBE CUBENSIS ANTIOXIDANT AND ANTIMICROBIAL POTENTIAL
2025 — Psychedelics and Pro-Social Behaviors: A Perspective on Autism Spectrum Disorders.
2025 — Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation.
2025 — The renaissance of psychedelics in modern psychiatry: a new breakthrough or the myth of a “magic bullet”?
2025 — Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.
2025 — Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner.
2025 — Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
2025 — The psychedelic psilocybin and light exposure have similar and synergistic effects on gene expression patterns in the visual cortex.
2025 — A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout
2025 — Psilocybin in Alcohol Use Disorder With Comorbid Depression
2025 — Molecular Imaging Study of Harmine/DMT: a Basic Research Approach
2025 — Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey.
2025 — Psychedelics in neuroinflammation: Mechanisms and therapeutic potential.
2025 — Is there a place for psychedelics in sports practice?
2025 — The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial
2025 — Current U.S. Approaches to Studying Psychedelic Medicines Compared to Psychedelics Use Among Indigenous Groups: What Are We Missing?
2025 — Structural basis for psilocybin biosynthesis.
2025 — LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice.
2025 — Pharmacokinetics of Psilocybin: A Systematic Review.
2025 — Intravenous psilocybin induces dose-dependent changes in functional network organization in rat cortex.
2025 — Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community
2025 — Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)
2025 — Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community
2025 — Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases
2025 — Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN
2025 — Utilizing Psychedelics to Enhance Well-Being: A Systematic Review.
2025 — Effects of a single dose of psilocybin on diet-induced weight loss in obese mice
2025 — Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.
2025 — From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.
2025 — De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli.
2025 — Psilocybin Dispensaries and Advertising-Buyer Beware.
2025 — Psilocybin Dispensaries and Online Health Claims in Canada.
2025 — Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.
2025 — A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.
2025 — Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways
2025 — Quantitative analysis of recreational psychoactive mushroom gummies in Portland, Oregon.
2025 — Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.
2025 — Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor.
2025 — Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report.
2025 — The remarkable reimagining of psilocybin.
2025 — A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.
2025 — Minorities’ diminished psychedelic returns: Depression, suicide, distress, and serious mental illness
2025 — Clarifying the legal landscape of psilocybin regulation: A medico-legal perspective
2025 — Reporting of psychotherapeutic methods in psychedelic treatments: on the road to ethical, professional and regulatory oversight
2025 — Psilocybin Has No Analgesic Properties in Multiple Mouse Models of Acute and Chronic Pain
2025 — Psilocybe cubensis y Panaeolus cyanescens (Basidiomycota, Agaricales), dos especies de hongos alucinógenos en el NE de Argentina
2025 — Pictorial Representation of Illness and Self Measure: A Putative Transdiagnostic Tool for Evaluating Therapeutic Effects of Psilocybin-Assisted Therapy in Fibromyalgia
2025 — Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disorders
2025 — Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
2025 — Psilocybin has a narrow therapeutic window as an antidepressant treatment.
2025 — Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis.
2025 — The effect of low-dose psilocybin on brain neurotransmission and rat behavior.
2025 — Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.
2025 — Therapeutic Potential of Psilocybin-Assisted Therapy in Hospice and Palliative Care
2025 — The compulsive eating paradigm: can psychedelics help in treating obesity?
2025 — Psilocybin’s Effects on Headache Frequency are Not Related to Acute Psychedelic Effects or Measures of Mental Health: Secondary Analysis of Clinical Trials in Migraine and Cluster Headache (P7-12.001)
2025 — Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization
2025 — The Emergence of Psilocybin in Psychiatry and Neuroscience.
2025 — Psilocybin-assisted Interpersonal Therapy for Depression
2025 — 323. Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation
2025 — 595. Psilocybin-Assisted Therapy for Relapse Prevention in Alcohol Use Disorder: A RCT
2025 — 13. Safety, Feasibility, and Tolerability of Psilocybin in Older Adults With Amnestic MCI: Preliminary Data From a SV2a PET Imaging Study
2025 — 166. Dynamic Mediodorsal Thalamus Activity Predicts and Reflects Longitudinal Treatment Outcomes in Psilocybin Therapy for Treatment-Resistant Depression
2025 — 58. Acute Behavioral Effects of Psilocybin and Its Pharmacokinetics in Nonhuman Primates
2025 — 186. Assessing Cognitive Outcomes in Treatment-Resistant Depression Following Psilocybin-Assisted Psychotherapy
2025 — 187. Changes in Symptoms of Anhedonia With Psilocybin-Assisted Psychotherapy: A Secondary Analysis of a Randomized Clinical Trial for Treatment-Resistant Depression
2025 — 194. Improving Workplace and Psychosocial Function in Treatment-Resistant Depression: Exploratory Outcomes From an Open-Label Feasibility Trial of Psilocybin-Assisted Psychotherapy
2025 — 630. Synthetic Psilocybin (COMP360) for Chronic Active Suicidal Ideation: An Open-Label Study
2025 — 458. Microdoses of Psilocybin Combined With Eugenol are Absorbed and Induce Unique Cerebellar Gene Expression
2025 — Precision Functional Mapping of Psilocybin’s Acute and Persistent Brain Effects
2025 — 188. Mapping Psilocybin Therapy: A Systematic Review of Therapeutic Frameworks, Adaptations, and Standardization Across Contemporary Clinical Trials
2025 — Functional and structural characterization of the human indolethylamine N-methyltransferase through fluorometric, thermal and computational docking analyses.
2025 — Synthesis and In Vitro Profiling of Psilocin Derivatives: Improved Stability and Synthetic Properties
2025 — Psilocybin as a Tool in the Management of Palliative Care: An Historical, Pharmacological, and Clinical Approach
2025 — Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond.
2025 — Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).
2025 — PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour
2025 — Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice
2025 — The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training
2025 — Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement.
2025 — A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia
2025 — Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans
2025 — Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters.
2025 — Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.
2025 — Regulatory Challenges of Integrating Psychedelics into Mental Health Sector
2025 — Exploring the perceived usefulness of integration support after naturalistic psychedelic experiences in people concerned about their substance use: A survey
2025 — [Treatment with psychedelics: potential benefits in Parkinson's disease].
2025 — Undergraduate Students' Perceptions and Understanding of Psychedelic-Assisted Therapy
2025 — Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis
2025 — Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences.
2025 — University Students’ Motives for Psilocybin Use: A Mixed-Methods Analysis
2025 — Calcium Activation Mechanism of a Noncanonical Aromatic L-Amino Acid Decarboxylase from Psilocybin Mushroom
2025 — Psilocybin Mushrooms: Identifying the Profile of the Most Likely Users
2025 — Psychedelics in the treatment of cluster headaches
2025 — FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD
2025 — 0391 Racial/Ethnic Differences in Psychedelic Use and Sleep Satisfaction: Preliminary Findings from the Herbal Heart Study
2025 — Improving Best Practice Indicators for Psilocybin Assisted Therapy Using a Mul-tiphase Mixed Methods Delphi Study
2025 — The benefits and harm of psychedelics in the treatment of patients with mental health and substance abuse disorders: an integrative literature review
2025 — Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?
2025 — From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs.
2025 — Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.
2025 — Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.
2025 — Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus.
2025 — Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.
2025 — Psilocybin for disorders of consciousness: A case-report study.
2025 — Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.
2025 — Polysubstance Use Profiles Among the General Adult Population, United States, 2022.
2025 — IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT receptors in mouse models of chronic pain.
2025 — Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.
2025 — The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.
2025 — Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.
2025 — Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.
2025 — Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.
2025 — ALSUntangled #77: Psilocybin.
2025 — Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis.
2025 — Neurochemical characterization of 5-HTR partial agonists with simultaneous PET-MRI.
2025 — Identifying Three Psilocybin Use Patterns by Frequency and Quantity.
2025 — Pharmacokinetics (PK) of psilocybin and psilocin in plasma following intravenous administration of psilocin and oral administration of psilocybin to male beagle dogs
2025 — Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: A case series
2025 — Psilocybin-gestützte Therapie von Depression, Angst und Suchtstörungen: Neurobiologische Grundlagen und klinische Anwendung
2025 — Evaluating the Effectiveness of Psychedelic-Assisted Therapy in Treating Alcohol Use Disorders: A Review
2025 — Psychedelic therapy as relational medicine: psychosocial mechanisms in clinical and naturalistic contexts
2025 — Psilocybin Mitigates Behavioral Despair and Cognitive Impairment in Treatment-resistant Depression Model using Wistar Kyoto Rats
2025 — Michael A. Wheeler: Psychedelics and neuroimmune circuits-what a strange trip, indeed
2025 — Exploring the Role of Psychedelics in Modulating Ego and Treating Neuropsychiatric Disorders.
2025 — Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
2025 — Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies.
2025 — Psilocybin-induced modulation of visual salience processing
2025 — Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder
2025 — Music and non-music approaches in psilocybin-assisted psychotherapy: The sound of silence
2025 — The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress.
2025 — Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments
2025 — Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase
2025 — Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments
2025 — We need to talk about shrooms.
2025 — In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes.
2025 — Age and cannabis co-use moderate experience and perceived benefits of psilocybin
2025 — Age and cannabis co-use moderate experience and perceived benefits of psilocybin
2025 — Ergotamine enhances circadian amplitude and diurnally mitigates nitroglycerin-induced mechanical hypersensitivity.
2025 — Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
2025 — The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review.
2025 — Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa.
2025 — Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)
2025 — Patients' Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment.
2025 — Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical Population
2025 — Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin
2025 — Mystical States & Psilocybin. From Dissociation Towards Association: A Conversational Model Discussion
2025 — Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling
2025 — The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review.
2025 — Characterization and Identification of an Antimicrobial Compound Psilocybin from Psychedelic Mushroom.
2025 — Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress.
2025 — There's More Than One Way to Bring Health Back: Divergent Effects of Psilocybin and Escitalopram Treatment on Emotional Brain Function in Depression.
2025 — Pharmacologic interventions for alcohol use disorder.
2025 — The pharmacological treatment of anxiety in people with eating disorders: A systematic review.
2025 — Innovation and inequity in psychedelic research at the Mayo Clinic.
2025 — Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.
2025 — Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.
2025 — Psilocybin's lasting action requires pyramidal cell types and 5-HT receptors.
2025 — The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.
2025 — Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.
2025 — Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use.
2025 — Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis.
2025 — Psilocybin increases emotional empathy in patients with major depression.
2025 — Correction to: Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.
2025 — Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
2025 — In vitro assessment of psilocin for CYP-dependent drug-drug interaction potential using rapid luminescent assays
2025 — Effects of Psilocybin on Mouse Brain Microstructure.
2025 — Erin Mauney: Psychedelics as modulators of the gut-brain interaction
2025 — Psilocybin's acute and persistent brain effects: a precision imaging drug trial.
2025 — Optimizing Microdosing and Meditation
2025 — Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study
2025 — Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: A qualitative-quantitative approach
2025 — Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice.
2025 — Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: A qualitative-quantitative approach
2025 — Psilocybin With Intracranial Neural Sensing
2025 — Psychedelic fungi.
2025 — Psilocybin and hallucinogenic mushrooms - ERRATUM.
2025 — Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder
2025 — Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults
2025 — Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder
2025 — Is there mush-room to improve the environmental sustainability of psilocybin production?
2025 — Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders
2025 — A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants
2025 — Advancing the Anthropology of Psychedelics: Integrating Clinical Evidence, Sociocultural Insights, and Ethical Frameworks
2025 — Mycelium Growth and Development of spp. Mother Cultures on Agar-Based Media.
2025 — The Intersection of Psychedelics and Sleep: Exploring the Impacts on Sleep Architecture, Dream States, and Therapeutic Implications.
2025 — The Selective Serotonin 5-HT Receptor Agonist ()-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents.
2025 — The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
2025 — Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress.
2025 — Long-term benefits of single-dose psilocybin in depressed patients with cancer.
2025 — Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes.
2025 — The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses.
2025 — Correction: Psilocybin's acute and persistent brain effects: a precision imaging drug trials.
2025 — Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.
2025 — Molecular, haemodynamic and functional effects of LSD in the human brain
2025 — The Emerging Use of Psilocybin in Adult Populations with Alcohol Use Disorder: A Scoping Review
2025 — Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study.
2025 — Psilocybin Modulates TPJ Effective Connectivity during Out-of-Body Experiences
2025 — Visual Surround Suppression and Perceptual Expectation Under Psilocybin
2025 — A Scoping Review of Research in Naturalistic Studies with Psychedelics.
2025 — Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism
2025 — Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease
2025 — Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics
2025 — Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis.
2025 — Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience
2025 — Prolonged hallucinogenic effects following Psilocybe cubensis ingestion: Case report
2025 — Untargeted analysis of psilocybin and non-psilocybin mushrooms using liquid chromatography quadrupole time of flight mass spectrometry
2025 — Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances.
2025 — Synthesis of Psilocin, Psilocybin and 5-MeO-DMT Succinate, All Labelled With Carbon-14 at the Indole 2-Position
2025 — Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.
2025 — Chemical Composition and Biological Activities of Mushrooms: Gaps and Perspectives.
2025 — Psychedelic drugs for the treatment of substance use disorders.
2025 — Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic-Assisted Therapy
2025 — Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.
2025 — 4-HIAA Blocks Methamphetamine-Induced Conditioned Place Preference in Mice Through Modulation of the 5-HT Pathway in the Nucleus Accumbens.
2025 — Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.
2025 — 5-HT receptors: Pharmacology and functional selectivity.
2025 — Development and validation of an analytical method for the determination of select 4-position ring-substituted tryptamines in plasma by liquid chromatography-tandem mass spectrometry.
2025 — Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons.
2025 — Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.
2025 — The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.
2025 — Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.
2025 — The Rise of Psilocybin Use in the United States: A Multisource Observational Study.
2025 — Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis.
2025 — Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
2025 — Exploring serotonergic psychedelics as a treatment for personality disorders.
2025 — Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.
2025 — Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.
2025 — Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
2025 — Effects of psilocybin, the 5-HT receptor agonist TCB-2, and the 5-HT receptor antagonist M100907 on visual attention in male mice in the continuous performance test.
2025 — Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report
2025 — Psychedelic and Medicinal Mushrooms: Potent Source of Active Metabolites and Medicines
2025 — Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging
2025 — Beyond prohibition: A public health analysis of naturalistic psychedelic use
2025 — Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice
2025 — Exploring Jordanian Physicians' and Medical Students' Perspectives on Ketamine and Psychedelic-Assisted Therapies: An Insight from the Middle East.
2025 — An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression
2025 — Explore the effect of psilocybin on depression and anxiety
2025 — Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models.
2025 — An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression
2025 — Psilocybin treatment extends cellular lifespan and improves survival of aged mice.
2025 — Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies
2025 — The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin
2025 — Females in Psychedelic Research: A Perspective for Advancing Research and Practice.
2025 — Equitable access to psilocybin-assisted psychotherapy in New Zealand.
2025 — Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome.
2025 — Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats.
2025 — Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases
2025 — Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review.
2025 — Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases
2025 — Stronger visual surround suppression under psilocybin: A psychophysical and EEG pilot study
2025 — Rise of the Mushrooms: Effects of Psilocybin Reforms on Psychedelic Usage Patterns
2025 — Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder
2025 — "I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke.
2025 — Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms
2025 — The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)
2025 — Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
2025 — Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial.
2025 — Molecular Pathways Potentially Involved in Hallucinatory Experiences During Sleep Paralysis: The Emerging Role of β-Arrestin-2.
2025 — Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study
2025 — Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)
2025 — Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.
2025 — Electrophysiological effects of psilocybin co-administered with midazolam
2025 — Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms.
2025 — Meditation, Psychedelics, and Brain Connectivity: A Randomised Controlled Resting-State fMRI Study of N,N-Dimethyltryptamine and Harmine in a Meditation Retreat
2025 — Psilocybin-assisted treatment of depression
2025 — Preparing Social Work for Psychedelic-Assisted Therapy
2025 — Natural hallucinogens of fungal and animal origin: action and potentialapplications - a narrative review.
2025 — Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns.
2025 — 551. PSYCHEDELICS AND OCD: TRANSLATIONAL APPROACHES
2025 — 577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES
2025 — 204. A NOVEL, NON-HALLUCINOGENIC PSYCHEDELIC FOR THE TREATMENT OF OCD AND TIC DISORDER
2025 — Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders:.
2025 — Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review.
2025 — Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.
2025 — Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.
2025 — Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher.
2025 — Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.
2025 — Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.
2025 — Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.
2025 — Navigating Intentional and Attentional Practices for Healing Across Psychedelic and Biofield Settings: A Comparative Ethnographic Study.
2025 — Pathway engineering for the biosynthesis of psychedelics.
2025 — Letter to the editor: Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024).
2025 — Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.
2025 — Development and validation of a HPLC-DAD method for determining the content of tryptamines in methanolic extracts of fruiting bodies of mushrooms belonging to species of the Psilocybe genus.
2025 — Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?
2025 — 597. ARE SIDE EFFECTS NECESSARY FOR ANTIDEPRESSIVE TREATMENT: THE PSILOCYBIN EXPERIENCE
2025 — 476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS
2025 — 564. TOWARD AN UNDERSTANDING OF THE THERAPEUTICALLY RELEVANT MECHANISMS OF PSILOCYBIN FOR ANOREXIA NERVOSA
2025 — 205. SYNERGISTIC BEHAVIORAL AND NEUROPLASTIC EFFECTS OF PSILOCYBIN-NMDAR MODULATOR ADMINISTRATION
2025 — 229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL
2025 — 363. DIFFERENTIAL EFFECTS OF PSILOCYBIN AND LISURIDE ON SEROTONIN AND DOPAMINE NEURONAL ACTIVITY AND BEHAVIOR
2025 — 694. INVESTIGATING THE POTENTIAL OF PSILOCYBIN FOR COMPULSIVE EATING IN A RAT MODEL OF BINGE EATING
2025 — 426. THE MGLUR2/3 ANTAGONIST ENHANCES THE BEHAVIORAL AND CELLULAR ANTIDEPRESSANT-LIKE EFFECTS OF PSILOCYBIN AND SCOPOLAMINE
2025 — 620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDER
2025 — 164. PSILOCYBIN DURING THE POSTPARTUM PERIOD INDUCES LONG-LASTING ADVERSE EFFECTS IN BOTH MOTHERS AND OFFSPRING
2025 — 317. PSILOCYBIN DOES NOT INDUCE CONDITIONED PLACE PREFERENCE, BUT MODIFIES BEHAVIORAL PATTERNS IN SPRAGUE-DAWLEY RATS
2025 — 631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS
2025 — 519. PSILOCYBIN ASSISTED PSYCHOTHERAPY FOR OBSESSIVE COMPULSIVE DISORDER, BODY DYSMORPHIC DISORDER, AND ANOREXIA NERVOSA: STUDY PROTOCOL
2025 — Psychedelics as treatment of alcohol use disorders: insights from preclinical models and comparison of the different psychedelics psilocybin, LSD and ketamine
2025 — 670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE?
2025 — 544. MOLECULAR AND CELLULAR MECHANISMS OF THE LONG-LASTING EFFECTS OF PSYCHEDELICS AND THEIR NON-HALLUCINOGENIC DERIVATIVES
2025 — Interventions to support spirituality among adults with cancer: a scoping review.
2025 — Latent Classes of Lifetime Use of Seven Hallucinogens in the United States.
2025 — Psychedelics, Spirituality, and Fundamentalism: A Brain Network Approach to Cognitive Flexibility and Rigidity.
2025 — Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
2025 — Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
2025 — Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker.
2025 — The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?
2025 — The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal.
2025 — The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin
2025 — Intersecting Psychedelic Pharmacology and Gut-Brain Axis Signaling in Neurodegenerative Disorders
2025 — Psychedelics and Headache Disorders: an Update.
2025 — Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.
2025 — Psychedelic researchers’ own experiences of psychedelic substances, their link to opinions of psychedelics, and reflections on positionality
2025 — Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.
2025 — Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource
2025 — Selective Phosphorylation of Phenols and Benzenediols by the Kinase PsiK and Variants Thereof.
2025 — Serotonin and psilocybin activate 5-HT receptors to suppress cortical signaling through the claustrum.
2025 — Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis
2025 — A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
2025 — Effects of Psilocybin in Post-Treatment Lyme Disease
2025 — Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study
2025 — Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?
2025 — Psychedelics and the Serotonin Hypothesis of Eating Disorders.
2025 — Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures
2025 — Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion.
2025 — Context-dependent structurally informed effective connectivity under psilocybin
2025 — “To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy
2025 — Psilocybin: Systematic review of its use in the treatment of depression
2025 — Psychedelic minimalism: the case against music in psychedelic therapy settings
2025 — Unsupervised Extractive Summarization of Psychedelic User Experience Reports
2025 — Freedom of Recreation: A Critique of the Prohibition, Decriminalization, and Legal Regulation of Psychedelics for Recreational Use
2025 — Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.
2025 — An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.
2025 — Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.
2025 — „Wir haben gezeigt, dass die Psilocybin-unterstützte Psychotherapie wirksam ist“
2025 — A lexicon for psychedelic research and treatment
2025 — Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial.
2025 — Severe Rhabdomyolysis With Stage 3 Acute Kidney Injury After Ayahuasca Use Managed Without Renal Replacement Therapy: A Case Report.
2025 — Psychedelic use in Poland: prevalence, correlates and social attitudes.
2025 — Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation.
2025 — Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers.
2025 — A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction.
2025 — Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.
2025 — Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.
2025 — Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats
2025 — Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression.
2025 — Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms.
2025 — “Wood-lover paralysis”: Describing a toxidrome with symptoms of weakness caused by some lignicolous “wood-loving” Psilocybe mushrooms
2025 — Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire.
2025 — Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.
2025 — Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa
2025 — Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review.
2025 — Psilocybin biosynthesis enhancement through gene source optimization.
2025 — Lifetime classic psychedelic use and headaches: A cross-sectional study.
2025 — Quantitative natural language processing markers of psychoactive drug effects: A pre-registered systematic review.
2025 — A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.
2025 — Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review
2025 — Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa.
2025 — "Wood-lover paralysis": Describing a toxidrome with symptoms of weakness caused by some lignicolous "wood-loving" Psilocybe mushrooms.
2025 — PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH
2025 — Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report
2025 — We may know why psilocybin helps treat mental health conditions
2025 — Active Constituents of Psilocybin Mushroom Edibles.
2025 — Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial
2025 — Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
2025 — Gregor Hasler: Three Guiding Questions - How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use?
2025 — The Psychedelic Reset: How Psychedelics May Reshape the Corticostriatal Circuit in Anorexia Nervosa
2025 — Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour
2025 — Integrating Holistic Communication into Psychedelic-Assisted Therapies in Hospice and Palliative Care: An Approach Based on Peplau's Theory.
2025 — Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.
2025 — Sample composition and HIV prevention indicator differences using physical vs virtual venue recruitment of men who have sex with men in San Francisco.
2025 — Blunted psychedelic drug effects in older adults
2025 — Blunted psychedelic drug effects in older adults
2025 — Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
2025 — Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.
2025 — Therapeutic Divergence in 5-HTA Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome.
2025 — The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting
2025 — Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy.
2025 — Mindset Over Molecule: Comparing Self-Transcendent and Mystical Experiences Across Recreational Psilocybin, MDMA, and Cannabis Use
2025 — Effective connectivity of the human claustrum: Triple networks, subcortical circuits, and psychedelic modulation
2025 — Serotonin 5-HT2C Receptor SignalingAnalysis Reveals Psychedelic Biased Agonism
2025 — Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
2025 — The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.
2025 — Trauma under psychedelics: how psychoactive substances impact trauma processing
2025 — Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia
2025 — Efficacy of Psychedelics Therapy Across Psychiatric Disorders: An Umbrella Review of Meta-Analyses
2025 — Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US.
2025 — Reappraisal of the hype and hope offered by psilocybin treatment of depression.
2025 — Psychedelics Relax Priors and Reshape Orbitofrontal Dynamics
2025 — S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial
2025 — Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study.
2025 — Unterschiedliche Reaktionen und Enzyme in der Psilocybin- Biosynthese bei Inocybe- und Psilocybe -Pilzen
2025 — Electrodynamics of the Psychedelic Experience
2025 — With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
2025 — Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism
2025 — Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative review
2025 — Regional Specificity of the Cingulate Cortex Thickness Association with the Intensity of Psilocybin Experience: A Replication Study
2025 — Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.
2025 — Psychedelics Offer Healing and Ecological Remembrance for Marginalized Individuals Failed by U.S. Health Care
2025 — Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat
2025 — Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review
2025 — Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds
2025 — Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring.
2025 — B-302 Psychedelics and Dissociative Anesthetics: Concentrations in Suspected Impaired Driving Investigations, 2024
2025 — 3642 Down the rabbit hole: case reports of a hallucinogen-induced disorder of neuroperception
2025 — [Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?].
2025 — Publisher Correction: Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors.
2025 — Dynamic myocardial injury and variable hallucination latency in poisoning: a molecularly confirmed case series from China.
2025 — Serotonin 5-HT Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.
2025 — Concomitant use of antidepressants and classic psychedelics: A scoping review.
2025 — US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022.
2025 — Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations.
2025 — Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.
2025 — The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
2025 — Treatment with LSD and psilocybin at the department of psychiatry at Frederiksberg Hospital in Denmark from 1960 to 1973: an analysis of 324 cases.
2025 — The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.
2025 — Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.
2025 — Correction to: Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs.
2025 — Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice.
2025 — Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs.
2025 — Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway
2025 — Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude.
2025 — Gestational LSD exposure in mouse rapidly reaches embryonic CSF and is associated with altered choroid plexus signaling, cerebral cortical development, and offspring behavior
2025 — Psychedelics and autobiographical memory - six open questions.
2025 — Understanding psilocybin mushrooms and aiding in setting standards for a burgeoning industry in Jamaica
2025 — Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.
2025 — Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior.
2025 — Psilocybin-assisted psychotherapy in adults with depression - A literature review.
2025 — Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
2025 — Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview
2025 — An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109
2025 — Psilocybin as a Treatment for Depression
2025 — Harm reduction practises for users of psychedelic drugs: a scoping review.
2025 — Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders
2025 — Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.
2025 — Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD
2025 — Towards Novel Antidepressant Strategies: A Comparative Study of Ketamine, Psilocybin, and Fluoxetine in a Chronic Stress Model
2025 — A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine
2025 — Neurocomputational evidence of sustained Self-Other mergence after psychedelics
2025 — Psychedelics in Practice: Science, Safety, and the Future of Healing
2025 — Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study.
2025 — Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice.
2025 — The Research Deficit and Expert Disagreement Regarding Music Selection for Psychedelic Assisted Therapy.
2025 — Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats.
2025 — A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer
2025 — Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
2025 — Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA)
2025 — Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers
2025 — Structure-GuidedDesign of Novel 5-HT2A Partial Agonists as PsychedelicAnalogues with Antidepressant Effects
2025 — Psychedelic compounds directly excite 5-HT2A layer V medial prefrontal cortex neurons through 5-HT2A Gq activation
2025 — Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review
2025 — The THRIVE Model of Psychedelic Integration: A Holistic Framework Bridging Indigenous Knowledge and Evidence-Based Practice
2025 — Is there more to magic mushrooms than psilocybin?
2025 — Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
2025 — Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy
2025 — A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.
2025 — Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report.
2025 — Structure-Guided Design of Novel 5-HT Partial Agonists as Psychedelic Analogues with Antidepressant Effects.
2025 — Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence
2025 — Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.
2025 — A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?
2025 — Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
2025 — Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin
2025 — “It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics
2025 — Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
2025 — Paper spray and direct mushroom spray mass spectrometry methods for the analysis of psycho-neurological disorder toxins
2025 — Acute Kidney Failure and Myocarditis Triggered by Magic Mushroom Toxicity in a Patient With Prior Cocaine Exposure.
2025 — Psychedelic 5-HT receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function.
2025 — Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.
2025 — Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain.
2025 — Emerging mechanisms of psilocybin-induced neuroplasticity.
2025 — N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences.
2025 — The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives.
2025 — Psilocybin-assisted psychotherapy, combined antipsychotic and antidepressant treatment for bipolar depression, duration of birth control pill use and risk of depression, handgrip strength and cognitive function, mood disorders in epilepsy, and mental health issues among physicians.
2025 — The emotional architecture of the psychedelic brain.
2025 — Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.
2025 — Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.
2025 — Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis.
2025 — [Acceptance of psilocybin-assisted therapy in German-speaking countries].
2025 — Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?
2025 — CNSC-36. PSILOCYBIN INDUCES SUSTAINED GLIOMA GROWTH THROUGH SEROTONERGIC AND TRKB PATHWAYS
2025 — 92. Mushrooms and Mania: Differentiating Psilocybin-Induced Mania From First-Break Bipolar Mania
2025 — Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy
2025 — Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review.
2025 — A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder.
2025 — Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study.
2025 — Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are required
2025 — Psilocybin and chronic neuropathic pain: a systematic review.
2025 — Psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice via epigenetic regulation of plasticity- and immune-related genes
2025 — A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer
2025 — Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
2025 — Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm
2025 — Correction: Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice.
2025 — Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity
2025 — The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample.
2025 — Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
2025 — Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms.
2025 — Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms
2025 — Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes
2025 — Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
2025 — Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.
2025 — Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders
2025 — Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy.
2025 — Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations.
2025 — A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens
2025 — Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder.
2025 — Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.
2025 — Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents
2025 — Spiritual dimension and psychedelic experiences: A phenomenological approach
2025 — Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial
2025 — Unmixing the Psychedelic Connectome: Brain Network Traits of Psilocybin
2025 — Standardization of Psilocybin Dosing in a Natural Product-Based Retreat Setting: A Practical Method for Dose Quantification and Adjustment Across Sessions
2025 — Psilocybin Experiential Therapist Training: Insights from a World-First Study
2025 — Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder
2025 — Psychedelic Rejuvenation Hypothesis: A Framework for Cellular and Psychological Restoration
2025 — Salience, sensemaking, and setting in psilocybin microdosing
2025 — Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.
2025 — Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics.
2025 — Synaptic priming: A framework for pharmacotherapy in depression.
2025 — Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.
2025 — A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression
2025 — Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans
2025 — Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?
2025 — Sex-specific role of the 5-HT receptor in psilocybin-induced extinction of opioid reward.
2025 — Exploring the first use of psychedelic macrodoses in Latin American adults: Sociodemographic profiles, consumption factors, and subjective experiences
2025 — Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports
2025 — Self-reported improvement in depression, anxiety, and substance use in Spanish-speakers after a memorable psychedelic experience
2025 — Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review
2025 — Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Disorders: A Scoping Review
2025 — Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms
2025 — Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.
2025 — Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life
2025 — A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model.
2025 — Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder
2025 — Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.
2025 — Psilocybin vs Ketamine for Alcohol Use Disorder
2025 — Persistent Altered States: Psychological Treatment of Psychedelic Adverse Effects
2025 — Efficacy of psilocybin on death anxiety in terminal patients: a narrative review
2025 — A causal pluralist theory of the interaction of substance, set and setting in psychedelic experience
2025 — Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.
2025 — Psilocybin, Spirituality, and the Potential for Personal Transformation: Commentary on Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions by Griffiths et al.
2025 — Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions, by Griffiths et al.
2025 — Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions.
2025 — Griffiths et al.'s Study of Psilocybin with Religious Professionals: A Theological Response from a Christian Perspective.
2025 — Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions: The Great Promise of Psychedelics: Evolving Human Consciousness.
2025 — Using Insights from a Study of Psilocybin with Clergy to Advance Research on Psychedelics, Spirituality, and the Sacred: Commentary on Griffiths et al. (2025).
2025 — Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.
2025 — Acute Blockade of the Serotonin Transporter With Low Doses of Escitalopram Does Not Alter the Behavioural Responses to Acute Psilocybin.
2025 — Sudden Loss of Consciousness Following Psilocybin Ingestion.
2025 — Psilocybin reduces comorbid chronic pain and depression in mice.
2025 — Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
2025 — Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity.
2025 — The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health.
2025 — Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats.
2025 — Corrigendum to "Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder" [Neuropharmacology 279 (2025) 110648].
2025 — Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.
2025 — Reply to Gattuso et al.: "Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024)".
2025 — Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.
2025 — Above the threshold, beyond the trip: the role of the 5-HT receptor in psychedelic-induced neuroplasticity and antidepressant effects.
2025 — Between enhancement and risk: A critical review of psychedelic microdosing.
2025 — Exploring the therapeutic potential of psychedelics in treating substance use disorders.
2025 — Avoiding Stigma and Sensationalism in Therapeutic Psilocybin Communications: Considerations for Reaching Older Patients.
2025 — [Psilocybin in the setting of treatment-resistant unipolar depression: A case report].
2025 — Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategy
2025 — Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland
2025 — Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement
2025 — Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis
2025 — Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study
2025 — Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic Psychedelics
2025 — Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
2025 — Psychedelics for the Treatment of Substance Use Disorders
2025 — Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
2025 — Taking a Trip into Nature’s Medicine Cabinet: A Country Comparison of Efforts to Reschedule Psilocybin and MDMA for Therapeutic Use
2025 — Psilocybin and Neuroplasticity: Mechanisms, Therapeutic Potential, and Future Directions
2025 — Psychedelic Assisted Psychotherapy (PAP): the Geneva University Hospital model
2025 — Unexpected Detection of Psilocybin in a 100 mg Tramadol Tablet: A Forensic Case Report
2025 — Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears
2025 — Questioning the recovery of dissociated traumatic memories under psilocybin: comment on "Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa".
2025 — Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study
2025 — Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges
2025 — Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study
2025 — Are Magic Mushrooms the Magic to Healing?
2025 — Unlocking the power of tryptamine alkaloids in Psilocybe fungi: chemistry, mental health potential and legal challenges
2025 — Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review
2025 — The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin-Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female Mice
2025 — Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study
2025 — Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.
2025 — Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency
2025 — The entropic brain today
2025 — The entropic brain today
2025 — Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.
2025 — Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.
2025 — The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.
2025 — Exploring Determinants of Psilocybin Acceptance as an Alternative Modality for Major Depressive Disorder: A Pilot Study
2025 — Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment
2025 — Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats
2025 — Which Psychotherapy Model Should be Used in Psilocybin Treatment for Depression?
2025 — Psilocybin reporting in media (PRiMe) for the treatment of depression.
2025 — Wherefore the magic? The evolutionary role of psilocybin in nature
2025 — Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development
2025 — Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study
2025 — From fungi to pharmacy: Applied technologies in psilocybin production and its therapeutic applications
2025 — Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.
2025 — Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.
2025 — The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.
2025 — A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder.
2025 — A Naturalistic Study on the Combined Neural and Psychological Effects of Psilocybin and Compassion Focused Imagery
2025 — Psilocybin modulates social behaviour in male and female mice in a time-dependent manner
2025 — Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
2025 — The genus Psilocybe in Italy
2025 — Allowing Similarities: Using Aldous Huxley’s Views on Mystical Experience to Assess the Import of Profound Unitive Experiences Occasioned by Psychedelic Substances
2025 — A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants
2025 — The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
2025 — A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder
2025 — Evolution and horizontal transfer of the psilocybin biosynthetic gene cluster drive the diversification of magic mushrooms
2025 — Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex
2025 — Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
2025 — Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks
2025 — Self-Transcendent Perceptual Dynamics and the Effects of Dispositional Mindfulness on Altered States of Consciousness: A Prospective Longitudinal Observational Study of a Naturalistic Psychedelic Retreat
2025 — Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
2025 — Psychedelics and neuroanesthesia: A narrative review of converging mechanisms
2026 — Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.
2026 — Marketing by online tobacco retailers: An observational cross-sectional study.
2026 — Phylogenomic systematics of (Boletaceae) reveals cryptic diversity, resolves global evolutionary relationships, and suggests a novel psychoactive lineage.
2026 — Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.
2026 — Metastability of resting-state bold fMRI as a reliable biomarker of individual brain dynamics: An interrogation of within-subject variability as a function of total acquisition time.
2026 — Correction: Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.
2026 — Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey.
2026 — The Effect of on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress.
2026 — Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology.
2026 — Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling.
2026 — Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.
2026 — Psychedelic therapy and postpartum depression: priorities and prospects.
2026 — 5 Years of bipolar disorder conversations on Reddit: Methods, key topics and future directions.
2026 — The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis.
2026 — The potential of event-related beta oscillations as biomarkers for neuromodulatory treatment efficacy.
2026 — Retraction: Acute psilocybin increased cortical activities in rats.
2026 — The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review.
2026 — A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry.
2026 — Systematic study of (, ) sensu lato and psilocybin-producing traits of species from China.
2026 — Rural-Urban Disparities in Access to Interventional Psychiatry Treatments among VA Patients.
2026 — Psychedelics: Future Therapeutics in Major Depression?
2026 — New Antidepressant Development in the Treatment of Depression.
2026 — Contextualizing Violence Risk Associated With Hallucinogens.
2026 — Classifying Psychedelic-Related Complications.
2026 — Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.
2026 — Magic mushrooms and mood: Exploring psilocybin as a depression treatment.
2026 — Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex.
2026 — Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.
2026 — Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin.
2026 — Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.
2026 — The Effect of Magic Mushroom (Psilocybe azurescens) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors.
2026 — An exploration of the relationships between the effects of psilocybin on behavior, 5-HT receptor occupancy, and neuroplastic effects in mice.
2026 — Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation.
2026 — Stepping back into life: How Psychedelic Assisted Psychotherapy transforms the way of life of the terminally ill.
2026 — Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy.
2026 — Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.
2026 — Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis.
2026 — 'Magic' mechanisms underlie psilocybin's effects in chronic pain.
2026 — Psilocybin Outside the Clinic: Public Health Challenges of Increasing Publicity, Accessibility, and Use.
2026 — A novel psychedelic 5-HT receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.
2026 — Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs.
2026 — Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.
2026 — Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.
2026 — Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics.
2026 — Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability.
2026 — Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi.
2026 — Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study.
2026 — Development of Psilocybe Mushroom Species Reference Material-Cultivation Parameters and Chemical Profiles.
2026 — Informed Consent in Psychedelic-Assisted Therapy.
2026 — Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis.
2026 — Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use.
2026 — Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies.
2026 — Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials.
2026 — Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.
2026 — Mechanisms of psilocybin on the treatment of posttraumatic stress disorder.
2026 — Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.
2026 — Toxicology and Pharmacological Interactions of Classic Psychedelics.
2026 — Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production
2026 — Characteristics of Ongoing Clinical Trials for Cocaine Use Disorder Registered on Global Clinical Trial Databases.
2026 — Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users' Patterns of Use and Perceived Effects.
2026 — A Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy.
2026 — Behavioral and neuronal effects of psilocybin in mice
2026 — Temporal effects of a single oral dose of psilocybin on plasma circulating miRNAs in humans
2026 — Preliminary results from an ongoing naturalistic survey study investigating dose-finding practices and effects of self-administered small amounts of psilocybin
2026 — Mismatch between psilocybin-induced head-twitch behaviour and psilocin brain levels in mice
2026 — Effects of low-dose psilocybin on EEG markers of sensory processing in autistic and non-autistic adults
2026 — Psilocybin increases connectivity between unimodal and transmodal networks in healthy volunteers listening to music
2026 — Preclinical evaluation of psilocybin as an anti-inflammatory agent
2026 — Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".
2026 — Oregon's Psilocybin Services: A Summary and Public Health Commentary.
2026 — The impact of drug control on wider research: Psychedelic mushroom exploration
2026 — Psilocybin Treatment for Refractory Depression: A Clinical Review
2026 — Relationship between cardiovascular effects and psychedelic experiences under psilocybin in patients with treatment-resistant depression
2026 — The role of 5-HT2A receptors in sleep architecture and memory consolidation in the animal model
2026 — An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes
2026 — Psilocybin and ibogaine as therapeutic candidates for cocaine addiction: Insights from a rat self-administration model
2026 — The impact of COMP360 psilocybin on anhedonia: post-hoc analyses from a phase IIb randomised controlled trial
2026 — Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial
2026 — Low dose psilocybin differentially alters resting-state network connectivity in autistic and non-autistic people
2026 — Electrical brain changes following psilocybin administration in sprague-dawley rats
2026 — ‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injury
2026 — Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men
2026 — Additional file 2 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
2026 — Additional file 1 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
2026 — Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"
2026 — Optimization of Psilocybin Extraction from Psilocybe cubensis Mushrooms and Characterization of the Fungal Extract
2026 — Cost-Effectiveness of Psilocybin-Assisted Therapy (PAT) for Patients with Treatment-Resistant Depression
2026 — Dynamic response of intrinsic connectivity networks to low-dose psilocybin during face matching in autistic adults
2026 — Self-reported benefits and harms of microdosing with natural psilocybin: preliminary results from a naturalistic study
2026 — Symptom-level antidepressant response to psilocybin: exploratory outcomes comparing psilocybin treatment to niacin
2026 — Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review
2026 — COMBINATION OF PSILOCYBIN AND COGNITIVE BEHAVIORAL THERAPY IMPROVES OXYTOCIN LEVELS AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
2026 — Motivation-based subtypes of psilocybin microdosers
2026 — COMPARATIVE EFFICACY AND ACCEPTABILITY OF PSILOCYBIN-KETAMINE AND TYPICAL ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER MANAGEMENT: A NETWORK META-ANALYSIS
2026 — Sex-dependent effects of psychedelics: review of evidence from rodent models.
2026 — Behavioral effects of psychedelic and non-psychedelic serotonin 2A receptor agonist drugs in pigs
2026 — Psychedelic Drugs
2026 — Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
2026 — Reported Safety Practices of Publicly Advertised Psychedelic Retreats.
2026 — The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis.
2026 — Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress
2026 — The one that abstained: Psilocybe fuscofulva genome suggests two recent origins of the psilocybin gene cluster in Psilocybe
2026 — An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.
2026 — Neuroscience: What doesn't kill you makes you stronger.
2026 — Associations of Couples' Psychedelic Use with Shared Reality and Relational Well-Being.
2026 — From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.
2026 — Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
2026 — Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations.
2026 — Sense-making around psilocybin in UK women experiencing cancer-related existential distress: An Interpretative Phenomenological Analysis
2026 — Intentions, Spirituality, Set, and Setting Are Associated with Mystical Experiences in Psilocybin-Assisted Therapy
2026 — XÂY DỰNG PHƯƠNG PHÁP ĐỊNH LƯỢNG PSILOCIN VÀ PSILOCYBIN TRONG HUYẾT TƯƠNG NGƯỜI BẰNG LC-MS/MS
2026 — Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
2026 — Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.
2026 — Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial
2026 — Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms
2026 — Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST
2026 — Psychedelics distinctly alter brain entropy and complexity compared to psychostimulants
2026 — Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study
2026 — Presence of 4-Hydroxy--methyl--ethyltryptamine in Commercially Available Products.
2026 — [Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].
2026 — Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
2026 — Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model.
2026 — Snapshot IP Detection Following 5-HTA Receptor Stimulation in the Mouse Brain.
2026 — Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
2026 — No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain.
2026 — THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
2026 — The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma
2026 — Does psilocybin help with mental health conditions?
2026 — Is psilocybin only effective as part of psychotherapy?
2026 — A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment
2026 — RAND: Microdosing surges as millions turned to psychedelics in 2025
2026 — The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression
2026 — The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence
2026 — Psychedelics in psychiatric treatment: a literature review
2026 — PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION
2026 — Psilocybin and the Evolutionary Significance of Altered Neural States: Interaction-Based Perspectives Beyond Deterrence Models
2026 — Psychedelic research and sexuality: opportunities and pitfalls
2026 — Protecting patient autonomy in psychedelic-assisted psychotherapy: a nursing ethics perspective
2026 — Regarding "The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses".
2026 — Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects
2026 — Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.
2026 — Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice.
2026 — [Pharmacological post-acute treatment of alcohol use disorder: Established strategies and innovative approaches].
2026 — We Licked the Toads so You Don't Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5-Methoxy-N,N-Dimethyltryptamine.
2026 — Psychedelic- and Substance-Assisted Therapies in Global Mental Health: Bridging Cultures, Evidence, and Access.
2026 — Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy.
2026 — Patient perspectives on research gaps in cluster headache.
2026 — The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior
2026 — Psilocybin and Bipolar Depression: Promise and Prudence.
2026 — Psychedelic experiences elicited by serotonergic psychedelics: Molecular mechanisms and functional connectivity changes in the brain.
2026 — Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia's clinical landscape.
2026 — Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.
2026 — Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research.
2026 — New treatments for OCD? Evidence for cannabinoids and psychedelics.
2026 — Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).
2026 — Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.
2026 — Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity.
2026 — Pharmacodynamic biomarker - or psychotherapeutic process? Comment on "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression".
2026 — Psilocybin use in bipolar disorder: A comprehensive review.
2026 — Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.
2026 — Love (Drugs), Happiness, and Morality.
2026 — Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials.
2026 — Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?
2026 — Compassionate use of psilocybin for treatment-resistant depression in Germany.
2026 — Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).
2026 — Psilocybin wirkt bei therapieresistenter Depression
2026 — Can LLMs Get High? A Dual-Metric Framework for Evaluating Psychedelic Simulation and Safety in Large Language Models
2026 — Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study
2026 — Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia
2026 — Acute psilocin increased cortical activity in rat
2026 — Distinguishing 4- vs 5-Hydroxy- N, N -Dimethyltryptamine (Psilocin vs Bufotenine) Using Hydrogen-Deuterium Back-Exchange
2026 — India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics.
2026 — A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design
2026 — Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers
2026 — Effects of cannabis and psychedelic use on cognitive, psychomotor, and driving performance: A review of recent literature
2026 — Activity-Dependent Neural Rewiring by Psilocybin: A Monosynaptic Rabies Virus Tracing Study
2026 — Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization
2026 — Exploring a Decade of Microdosing Research: A Qualitative Meta-synthesis of Microdosing Literature
2026 — Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers.
2026 — Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics.
2026 — Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure
2026 — Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
2026 — Psilocybin-Assisted Cognitive Behavioral Therapy for Depression
2026 — Development and assessment of a psychedelic-assisted therapy music playlist for clinical trials: Theory, intentionality, and metrics
2026 — Psilocybin and Animal Testing: Charting an End to the Use of Animals in Drug Development Research
2026 — Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
2026 — A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
2026 — Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies.
2026 — Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain.
2026 — Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials.
2026 — Management of obsessive-compulsive disorder in adults.
2026 — Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.
2026 — Rebuttal to "Questioning the recovery of dissociated traumatic memories under psilocybin".
2026 — Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study
2026 — Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis.
2026 — Effects of Psilocybin and Select Pharmaceutical Interactions
2026 — Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert Perspectives
2026 — Cogumelos do gênero Psilocybe nas Américas e no Brasil
2026 — Psychedelic medicine: mechanisms, evidence, and translation to practice.
2026 — Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial
2026 — Delayed psilocybin treatment after repeated mild traumatic brain injury recovers chronic behavioural deficits, reduces microglial density, and enhances hippocampal neurogenesis in rats
2026 — Investigation of Psychedelic Effects in Psychoactive Substances
2026 — Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
2026 — SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment
2026 — Pilot study of psilocybin in patients with post-treatment lyme disease
2026 — The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.
2026 — Psilocin as a Broad Inhibitor of CYP450 Enzymes: Integrated In Vitro and In Silico Evidence
2026 — Calcium activation mechanism of a noncanonical aromatic L-amino acid decarboxylase from psilocybin mushroom Psilocybe cubensis
2026 — Psychedelic therapy and cultural humility.
2026 — Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.
2026 — Psilocybin-assisted therapy for major depressive disorder: implications for clinical effectiveness, health economics, and regulatory decision-making
2026 — A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations
2026 — The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
2026 — Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications
2026 — Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy
2026 — Psychedelics, Eleusis, and the Invention of Religious Experience.
2026 — Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.
2026 — [Perspectives opened up by the physiopathological understanding of psychiatric disorders].
2026 — Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention
2026 — Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators.
2026 — Innovative Pharmacological Approaches to Eating Disorder Treatment.
2026 — Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence.
2026 — Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.
2026 — Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy
2026 — Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.
2026 — Psilocybin shapes neural plasticity in selective brain networks.
2026 — Psychoactive mushroom edibles: trends and toxicities reported to the United States National Poison Data System®, 2023-2024.
2026 — Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase).
2026 — Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocin
2026 — Meaning and Psychedelics in Palliative Care: A Narrative Review.
2026 — Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward
2026 — MedCheck: FDA Reviews NDA for Narcolepsy Drug, Green-Lights Psilocybin Trial for PTSD, and More
2026 — Psilocybin Reshapes Anterior Cingulate Network Neuropathic Topology to Reduce Chronic Pain
2026 — THE EFFECT OF PSILOCYBIN AND EUGENOL ON LIPOPOLYSACCHARIDE INDUCED INFLAMMATION IN SMALL AND LARGE INTESTINE OF MICE
2026 — Nicotinoyl-Tryptamine Derivatives as Potential Dual-Action Prodrugs for NAD⁺ Enhancement and Neuroprotection
2026 — Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons
2026 — Public attitudes diverge sharply on legal use of psychedelics
2026 — Mushroom-Derived Carbon Nanosheets for Efficient Photothermal De-Icing Applications.
2026 — Study of Psilocybin for Anorexia in Young Adults
2026 — Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin
2026 — Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.
2026 — The combination of exercise and psychedelics for the treatment of major depressive disorder.
2026 — Psilocybin microdosing in the United States: Insights from a nationally representative survey
2026 — Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report
2026 — “Diversity makes the richness of humanity”: The emergence and persistence of mental imagery after self-reported psilocybin truffles intake in an autistic woman with “blind imagination” (aphantasia): A33-month retrospective case report
2026 — Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review
2026 — Psilocybin or Nicotine Patch for Smoking Cessation
2026 — Age moderates the relationship between psychedelics use and mental health in naturalistic settings
2026 — Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
2026 — Discovery of the closest free-living relative of the domesticated 'magic mushroom' Psilocybe cubensis in Africa.
2026 — Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs
2026 — Psilocybin-facilitated Treatment for Chronic Pain
2026 — Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health
2026 — Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.
2026 — Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials.
2026 — The renaissance of research on psychedelics in child and adolescent psychopharmacology.
2026 — Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
2026 — Editorial: Psychedelic substances and neurological diseases: from basics to clinical application
2026 — Psychedelic Terminology Preference in the 2024 National Survey Investigating Hallucinogenic Trends (NSIHT).
2026 — Explainable AI framework for psilocybin depression treatment optimization
2026 — Hallucinogens for Mood and Anxiety Disorders: A Critical Review of Psychedelic-Assisted Therapies
2026 — A fungus among us: investigating queensland’s largest magic mushroom growing operation
2026 — Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
2026 — Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study
2026 — Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder
2026 — Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution
2026 — Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies
2026 — PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS
2026 — Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy.
2026 — Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.
2026 — Psychedelics in functional disorders: A scoping review.
2026 — Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
2026 — When I use a word... The psychedelic mind’s eye
2026 — Psilocybin, Lp(a), CAC, Niere und Darmkrebs - Evidenz-Quickies KW12
2026 — Psychedelic-Assisted Psychotherapy: Attitudes of Law Enforcement and Military Personnel
2026 — “You can only take your clients as far as you’ve been yourself”: examining the intersections between psychedelic-assisted therapy, lived-living experience, and clinical practice
2026 — Integrated 5-HT -TrkB and G protein signaling in serotonergic psychedelic responses.
2026 — Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial
2026 — The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.
2026 — Psilocybin Prolongs the Neurovascular Coupling Response in Mouse Visual Cortex.
2026 — Psychedelic-Induced Constraint Destabilization and Reconstruction as a Mechanism for Cognitive Reset
2026 — Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)
2026 — Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors
2026 — Psychedelic Experiences and Finitude in Serious Illness: A Qualitative Synthesis
2026 — Classic psychedelic medicines for adolescent refractory mental health disease
2026 — Psilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory Cortex.
2026 — Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
2026 — Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression
2026 — Associations Between Psilocybin Use Motives and Cognitive, Affective, and Behavioural Self-Stigma
2026 — Unlocking 'stuckness' and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic-assisted therapy for substance use and mental health problems.
2026 — Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin
2026 — Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”
2026 — Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression
2026 — Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders
2026 — Reshaping human neurons.
2026 — Classic psychedelics in obsessive-compulsive disorder: a circuit-based framework
2026 — Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness-a psychometric analysis using the PES100 in controlled psychedelic studies
2026 — The astrocytes in the prefrontal cortex contribute to the rapid antidepressant-like effects of psilocybin in the chronic restraint stress mouse model
2026 — Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.
2026 — An international mega-analysis of psychedelic drug effects on brain circuit function.
2026 — Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.
2026 — Psychedelic-Assisted Therapy: Breakthrough for Whom?
2026 — Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats
2026 — Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil
2026 — PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial.
2026 — Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis
2026 — Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin
2026 — Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis.
2026 — Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols
2026 — Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions.
2026 — Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.
2026 — The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence.
2026 — Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury.
2026 — Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications
2026 — Psilocybin: Wirksam, aber kein Wundermittel
2026 — MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More!
2026 — 26-CCC-15854-ACC TALK ABOUT A BAD TRIP!: PSILOCYBIN USE WITH PRE-EXISTING CARDIOVASCULAR DISEASE, A CASE REPORT
2026 — "I've Done My Research": Psychedelics, PTSD, and the Therapeutic Alliance.
2026 — Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants
2026 — Psilocybin and human longevity
2026 — Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants.
2026 — Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes.
2026 — A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression
2026 — Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks - Including Life Between Lives and Transpersonal Hypnotherapy
2026 — Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder
2026 — Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.
2026 — Brain-MGF: Multimodal Graph Fusion Network for EEG-FMRI Brain Connectivity Analysis Under Psilocybin
2026 — Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression
2026 — Additional file 1 of Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression
2026 — Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration
2026 — Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat.
2026 — Observing the mind under psychedelics: conceptual metaphors used following four once-weekly macrodoses of psilocybin
2026 — Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol
2026 — Psilocybin acutely reduces low-frequency BOLD power and frequency-specific connectivity
2026 — CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial
2026 — A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience
2026 — Effects of a single dose of psilocybin on diet-induced weight loss in obese mice
2026 — Psilocybin Trends in States That Decriminalized Use
2026 — Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey
2026 — Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration
2026 — Psilocybin’s Kinematic Effect on Manual Dexterity
2026 — Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs.
2026 — Psilocybin reshapes cortical inhibition through selective interneuron recruitment.
2026 — Neural Entropy and Cognitive Flexibility: A Research Agenda for Psilocybin-Assisted Therapy [FUTURE DIRECTIONS v1.0]
2026 — Investigating Psychedelic Tryptamines: Extraction and Quantification from Psilocybe Mushrooms
2026 — Psilocybin and Psilocybe cubensis extract exhibit divergent behavioural and toxicological effects in rats
2026 — Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han rats
2026 — Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.
2026 — Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers
2026 — Comparative Medico-Legal Frameworks for Psilocybin Regulation: A March 2026 Update
2026 — Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity
2026 — Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins
2026 — Serotonergic Polypharmacology of 2-Halogenated Tryptamines.
2026 — Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials
2026 — The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes
2026 — Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.
2026 — Psilocybin as an alternative to conventional treatments: A systematic review
2026 — Distinct Modulatory Effects on Affective Biases by Different Serotonergic Psychedelics and MDMA in Male Rats: Possible Implications for Antidepressant Effects
2026 — Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy
2026 — A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
2026 — Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
2026 — Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations.
2026 — Psilocybin use among Basotho healers and non-healers in southern Africa
2026 — Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia
2026 — Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders.
2026 — 157. Opposing 5-HT Receptors Modulate Psilocybin's Action on Dendritic Calcium Dynamics
2026 — Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study.
2026 — The Harmonious Dance: A Narrative Review on Psychedelics and Music in Therapeutic Settings.
2026 — Specific and Multi-Product Clade I and Clade IV Sesquiterpene Synthases Contribute to the Psilocybe cubensis Volatilome.
2026 — Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review.
2026 — A128-Channel Wireless Wearable Myolink (W2 Myolink): Functional Characteristics and Multidisciplinary Experiments
2026 — Evaluating the evidence for repressed memory recovery in psychedelic contexts
2026 — The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder
2026 — A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain
2026 — Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)
2026 — Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption
2026 — Characterizing psilocybin’s effects on nociception and thermoregulation in preclinical pain models
2026 — Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings
2026 — Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations
2026 — Therapeutic Potential of Psilocybin in Alcohol and Opioid Use Disorders: A Promising Role for Psychedelics
2026 — Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM
2026 — Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.
2026 — New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants.
2026 — Associations between psychedelic use and migraine history in Swedish twins.
2026 — Effects of psychedelic use on authoritarian attitudes revisited.
2026 — Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review.
2026 — Trip killers: Addressing a critical knowledge gap in psychedelic research.
2026 — Psychological support in psychedelic-assisted therapy clinical trials: A systematic review.
2026 — Enlightenment in a Pill-Testing the Efficacy of Psilocybin
2026 — Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
2026 — A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder
2026 — Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health.
2026 — Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine
2026 — Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.
2026 — Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
2026 — Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience.
2026 — Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms
2026 — Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts
2026 — Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms.
2026 — The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures.
2026 — The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences.
2026 — The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.
2026 — Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review.
2026 — Landscape analysis of pre-registered clinical trials involving classical psychedelics.
2026 — High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats.
2026 — The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.
2026 — Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical
2026 — Cytochrome P450 Inhibition by Psilocybin and Psilocin: A Combined Molecular Dynamics and Enzymatic Screening Study
2026 — 6. Open-Label Extension of Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Continued Safety and Short-Term Efficacy Signal for Drinking, Craving, and Self-Efficacy
2026 — SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models
2026 — Preclinical evaluation of psilocybin and related compounds: Inhibition of cytochrome P450 isoforms
2026 — Effects of Psilocybin on Attentional Set-Shifting Following Chronic Unpredictable Stress in Rats (Abstract ID: 231339)
2026 — Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA
2026 — C29-12 Psilocybin Treatment Could Improve Outcomes for Age-associated Lung Diseases
2026 — Pure psilocybin reduces reward-associated preference while mushroom extract shows transient exploratory effects in rats
2026 — 483. Acute Functional Brain Changes Associated With Psilocybin in Depression and Healthy Adults: A Systematic Review and Coordinate-Based Meta-Analysis
2026 — 356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease
2026 — Profiling the Cell-Type Specific Effects of Psilocybin in Medial Prefrontal Cortexh
2026 — PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554)
2026 — Acute Effects of 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) Compared With Psilocybin and MDMA in Healthy Participants
2026 — Prohedonic Effects of Psilocybin (COMP360) in a Touchscreen-Based Rodent Probabilistic Reward Task (Abstract ID: 227883)
2026 — Sex-Specific Effects of Psilocin on Paraventricular Nucleus of the Thalamus (PVT) Circuitry and Threat Responding Behavior in Male and Female Rats
2026 — Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS
2026 — Effects of Psilocybin Treatment on Cognitive Effort Avoidance in Major Depressive Disorder and Co-Occurring Alcohol Use Disorder
2026 — Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder
2026 — A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression
2026 — A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control
2026 — Human brain changes after first psilocybin use
2026 — Magic mushroom compound shows promise against cocaine addiction.
2026 — A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder
2026 — Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study
2026 — A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer
2026 — Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’
2026 — The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus
2026 — Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder-A Critical Appraisal
2026 — Psilocybin in the Treatment of Cocaine Use Disorder
2026 — Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review
2026 — Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial
2026 — Exploring new avenues: Psychedelic-assisted therapy for young people.
2026 — Neural correlates of insight on psilocybin: a within-subjects, healthy volunteer study
2026 — 0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study
2026 — 1080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral Power
2026 — 1020 Long-term Impact of Psilocybin Administration on Sleep-Continuity via Wearable Sensor Time-series: Preliminary-results in Post-Treatment Lyme Disease
2026 — Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT
2026 — The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.
2026 — From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice
2026 — Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review
2026 — Psychedelic Use and Missed Needed Mental Health Treatment: Gender Differences in Unmet Perceived Need for Care
2026 — Treatment-Resistant Depression in the 21st Century: A Scoping Review of Psychedelics and Neuromodulation in Transforming Care
2026 — Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin
2026 — Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample
2026 — Psilocybin for Treatment of Obsessive Compulsive Disorder
2026 — Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization
2026 — Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation
2026 — Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care
2026 — Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae.
2026 — Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.
2026 — Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)
2026 — Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression
2026 — Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program.
2026 — Psilocybin-facilitated Treatment for Cocaine Use
2026 — Ancient Wisdom, Modern Questions: Western and Orthodox Christianity Engage Psychedelic Spirituality
2026 — Psilocybin-assisted Cognitive Behavioral Therapy for Depression
2026 — 361 Effect of intravenous psilocybin on mechanical hypersensitivity in a rat model of reserpine-induced chronic centralized pain
2026 — 265 Self-reported rates of psilocybin use in North Florida, 2012 to present
2026 — A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression
2026 — PsiConnect: Multimodal Neuroimaging of Context-Dependent Brain and Behaviour Dynamics under Psilocybin
2026 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
2026 — Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer Patients
2026 — The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach
2026 — Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential
2026 — Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake
2026 — Serotonergic Psychedelics as a Potential Therapeutic Strategy for Anxiety, A Systematic Review
2026 — Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder
2026 — Environmental and Internal Gating of Memory: ARCH Multiplicative Threshold Framework for Encoding and Retrieval
2026 — Catatonia Associated With First-Time Psilocybin Exposure: A Case Report
2026 — Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial
2026 — Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report
2026 — Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions.
2026 — Psilocybin-induced neurocardiogenic syncope: a case report
2026 — Rapid and Sensitive Detection of Psilocybin and Psilocin in Urine by Surface-Enhanced Raman Spectroscopy
2026 — Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.
2026 — A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT₂A-TrkB mechanistic paradox
2026 — Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache
2026 — Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis
2026 — U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.
2026 — Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats
2026 — Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial
2026 — Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
2026 — Psychedelic Therapy and the Role of Music: A Scoping Review of Quantitative Evidence on Subjective and Objective Outcomes.
2026 — Therapeutic advances in fibromyalgia: one year in review 2026.
2026 — Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL.
2026 — Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.
2026 — Hallucinogen-Assisted Psychotherapy for Trauma Disorders: A Bionian Lens.
2026 — Reorganization of Human Brain Waves Across Diverse States of Consciousness.
2026 — Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex
2026 — Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [F]FDG-PET study.
2026 — Suggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy.
2026 — Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics.
2026 — Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.
2026 — Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations
2026 — Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health.
2026 — Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence.
2026 — Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects.
2026 — Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.
2026 — Comparing Cannabis Use Motivations and Dependence Across Regular Cannabis Users Who Have or Have Not Recently Used Psilocybin.
2026 — Psilocybin: Chemical Foundations and Emerging Therapeutic Potential
2026 — EE341 COST-EFFECTIVENESS OF PSILOCYBIN-ASSISTED THERAPY (PAT) FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
2026 — Demoralization in Psilocybin-Assisted Therapy for Advanced Cancer: An Exploratory Network Analysis
2026 — EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CARE
2026 — Impact of formulation variables on the quality attributes of psilocybin-loaded oral thin films for early-phase development
2026 — Psilocybin shows rapid relief for depression symptoms
2026 — Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional survey
2026 — Acute Hallucinogen Intoxication Following Ingestion of a Commercially Available Mushroom Extract Product: A Case Report.
2026 — From Altered States to Altered Trajectories and From Molecules to Meaning: A Network Meta Analysis Mapping Comparative Efficacy of Psychedelic Assisted Therapies in Modern Psychiatry
2026 — A Molecule-Resolved Bibliometric Analysis of PubMed-Indexed Psychedelic Research (2015-2025): Volume, Temporal Trends, and Publication Types
2026 — Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapy
2026 — Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.
2026 — Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults
2026 — Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation
2026 — Studies on enzymatic hydrolysis of psilocin- O -glucuronide for screening of psilocin in human urine by liquid chromatography-triple quadrupole tandem mass spectrometry
2026 — 2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers
2026 — Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study
2026 — Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy
2026 — Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity
2026 — Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action
2026 — Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling
2026 — Alcohol consumption and substance use among French medical students: A nationwide cross-sectional study: Consommation d'alcool et de substances chez les étudiants en médecine de France: une étude transversale nationale.
2026 — Psilocybin-assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: A Randomized Dose-comparison Pilot Study (P7-17.001)
2026 — The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.
2026 — Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.
2026 — EEG microstate dynamics during psilocybin intoxication relate to acute experience and persisting psychological changes
2026 — Altered States, Enhanced Potential: Psychedelics and Physical Performance
2026 — Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments
2026 — Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential: A Systematic Review
2026 — THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
2026 — Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits.
2026 — Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis
2026 — Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA
2026 — The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function
2026 — Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice.
2026 — Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem
2026 — Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.
2026 — Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico
2026 — Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use
2026 — “I even saw four deer grazing”: online-offline entanglements in the psilocybin pluriverse
2026 — DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish
2026 — Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States.
2026 — Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes
2026 — Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects.
2026 — Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1
2026 — Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial
2026 — Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy
2026 — Blocking 5-HT2B receptors abolishes psilocybin's efficacy in the rat forced swim test.
2026 — Psilocybin-Assisted Therapy for Prolonged Grief
2026 — Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial
2026 — Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care
2026 — Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy.
2026 — PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW
2026 — Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
2026 — Anthracaurisin A─Discovery of a Cytotoxic -Sesquiterpene Dimer from Patagonian.
2026 — Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram
2026 — Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex
2026 — 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
2026 — Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development
2026 — Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.
2026 — Chemical ecology and convergent evolution of natural hallucinogens: From ecological defense to conserved neural targets.
2026 — Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”
2026 — The relevance of the 5HT2A-mGlu2 heterodimer in explaining the clinical ambivalence of psilocybin
2026 — Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.
2026 — Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants
2026 — Psychedelics as a potential treatment for borderline personality disorder: A narrative review.
2026 — Three cases of wood-lover paralysis: clinical insights from Victoria, Australia.
2026 — Recreational drug poisonings reported to six European poison centres from 2021 to 2024.
2026 — Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.
2026 — Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice.
2026 — Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.
2026 — Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
2026 — Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.
2026 — Psychedelics, entactogens and psychoplastogens for depression and related disorders.
2026 — Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists.
2026 — The Australia story: Current status and future challenges for the clinical applications of psychedelics.
2026 — Psilocybin as a novel treatment for chronic pain.
2026 — Chemistry/structural biology of psychedelic drugs and their receptor(s).
2026 — Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis.
2026 — The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.
2026 — The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.
2026 — Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats
2026 — MFCC-DFT mapping of ligand recognition at the 5-HT receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.
2026 — Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders
2026 — Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.
2026 — An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder
2026 — Provider perspectives on challenges in treatment during psychedelic therapy.
2026 — Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days.
2026 — Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review
2026 — Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence
2026 — Raman Activity Investigation and Utilization of Psilocybin
2026 — Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits
2026 — A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)
2026 — Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
2026 — Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.
2026 — Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
2026 — Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?
2026 — Psilocybin helps woman with Alzheimer's
2026 — Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study
2026 — Unmixing the psychedelic connectome: Brain network traits of psilocybin
2026 — Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015-2019
2026 — Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?
2026 — Surprising Variability in Tryptamine Profiles of Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions.
2026 — Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions
2026 — Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development
2026 — Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review
2026 — The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer
2026 — Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
2026 — Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation
2026 — Caution in interpreting value-related change after psilocybin: Comment on Kerr-Gaffney et al. (2026)
2026 — Synthesis and Biological Evaluation of 4-Bromo-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.
2026 — Psilocybin therapy for adult females with anorexia nervosa: pilot study
2026 — Entourage-Psilocybin-Ganzpilz
2026 — Entourage-Psilocybin-Ganzpilz
2026 — Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin.
2026 — Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder
2026 — Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects
2026 — Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)
2026 — First molecular record of Panaeolus subbalteatus (Psathyrellaceae, Agaricales) from Pakistan.
2026 — The Effects of Psilocybin on Social Connectedness
2026 — Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol.
2026 — Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling.
2026 — Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
2026 — PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial
2026 — PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial
2026 — Psychedelics produce enduring enhancement of reward responsiveness in male rats.
2026 — Epigenetic landscapes of classical psychedelics and ketamine: molecular mechanisms of long-lasting neuromodulation.
2026 — Psilocybin bei Depression: Systematisches Review und Meta-Analyse zur antidepressiven Wirksamkeit
2026 — National bill seeks to jump-start psychedelic treatment for veterans
2026 — Psilocybin-induced behavioral and cellular effects
2026 — MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments
2026 — Mechanistic Studies of Psilocybin in Headache Disorders
2026 — Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview
2026 — Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.
2026 — Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial
2026 — Shurooms: The First Ethnomycological Study from Within the African Initiatory Tradition - Ewe, Soma, and the Ceremonial Architecture of Psilocybin Healing (N = 300+)
2026 — Psilocybin's effect on human brain synaptic plasticity.
2026 — The ANCHOR Framework for Psychedelic Accompaniment
2026 — Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder
2026 — Uncovering the spatiotemporal structure of neural avalanches through optimal transport and dynamic time warping
2026 — Integrated 5-HT-TrkB and G protein signaling in serotonergic psychedelic responses.
2026 — Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder
2026 — Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
2026 — Publication bias in randomized trials of psilocybin for depression: a Robust Bayesian Meta-Analysis
2026 — A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin
2026 — Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression
2026 — A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults
2026 — Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis
2026 — Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors.
2026 — Longitudinal neural and psychological changes following psilocybin under compassion imagery priming
2026 — The "dark magic mushroom" co-produces amatoxins and psilocybin.
2026 — Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)
2026 — Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
2026 — A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
2026 — No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study
2026 — Estimating Cardiac 5-HT2B Safety Margins for Repeated Low-Dose Psilocybin Using an Exposure-Response Model
2026 — Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research.
2026 — Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review
2026 — [Illicit use of classic psychedelics and suicidality: A systematic literature review].
2026 — Network Pharmacology-Guided Discovery of Fungal Autophagy Modulators for Tauopathies: Structural and Proteomic Evidence
2026 — A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in Depression
2026 — Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.
2026 — Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortex
2026 — Identifying factors that contribute to the behavioral effects of psilocybin in preclinical mouse models
2026 — Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.
2026 — Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.
2026 — Is BOLD Measurement-Invariant Across Pharmacological State? A Pre-Registered Test of Haemodynamic Response Function Drug-Invariance Using Simultaneous EEG-fMRI (PsiConnect)
2026 — An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD
2026 — Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica
2026 — Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial
2026 — Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder
2026 — Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
2026 — Childhood trauma and psychological outcomes following psychedelic use: a scoping review
2026 — Shrooming Ahead: How the U.S. is Marching Toward Psilocybin Legalization and What Other Countries May Learn
2026 — Beyond psilocybin: Do magic mushroom preparations contain other compounds with pharmacological effects?
2026 — Retreat from racism: A psychedelic group experience for racial stress and trauma
2026 — The Experience-Trajectory Framework: Substance-Specific Risk Stratification for Psychedelic Preparation and Aftercare Beyond Set and Setting
2026 — A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.
2026 — Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.
2026 — A25-year analysis of Armillaria (honey mushroom) poisoning in Wisconsin.
2026 — The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis
2026 — Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis
2026 — Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research.
2026 — Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders.
2026 — Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression
2026 — Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.
2026 — Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.
2026 — Classic psychedelics and personality: An updated systematic review.
2026 — A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.
2026 — Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms
2026 — In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin
2026 — Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature.
2026 — Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study
2026 — From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression.
2026 — Cardiovascular safety of psilocybin in psychiatric practice: a narrative review
2026 — One Dose of Psilocybin May Alter Brain Structure
2026 — Psilocybin for Fear of Cancer Recurrence
2026 — Evaluating psilocybin for the management of depression: a literature review
2026 — Psilocybin as a Treatment for Chronic Pain in Smokers
2026 — Where is the sweet spot for psychedelic-enhanced fear extinction? An integrative quantitative synthesis of dose-effect patterns in rodent models.
2026 — Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks
2026 — Simulated 5-HT2A receptor activation accounts for the high complexity of brain activity during psychedelic states
2026 — Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.
2026 — Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review.
2026 — Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.
2026 — Mapping excitatory synaptic plasticity evoked by single-dose psilocybin in mice
2026 — An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy
2026 — Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder
2026 — Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.
2026 — Correspondence: "Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy".
2026 — Open Label Psilocybin Brain Stimulation and Imaging Pilot Study
2026 — The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
2026 — Feasibility and Tolerability of Psilocybin for Phantom Limb Pain.
2026 — Advanced research eyes potential of psychedelics for complex cases
2026 — 'So many relationships in the room': Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy.
2026 — Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study
2026 — A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression
2026 — Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury
2026 — A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
2026 — An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)
2026 — An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.
2026 — Psilocybin acutely dissociates cognitive and affective empathy, with empathic concern predicting persisting positive psychological effects
2026 — Temporal effects of a single oral dose of psilocybin on plasma circulating miRNAs in healthy young adults
2026 — Circulating MicroRNAs and Their Associations with Neurotrophic, Inflammatory and Glutamate Markers in Healthy Volunteers
2026 — Could Psilocybin Be the Key to Treating Anorexia? -Breaking the Mind's Most Stubborn Loop
2026 — Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
2026 — Psilocybin Recovery Intervention for Stopping Methamphetamine Use
2026 — Psychedelics and astrocytes: a hypothesis-driven perspective on neuro-glial integration, network plasticity, and neuroimmune reprogramming.
2026 — Effects of naturalistic psychedelic use on executive functioning: An online survey of lifetime history and recent use in university students.
2026 — Psychedelic Therapy for Depression
2026 — A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
2026 — Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids
2026 — Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
2026 — TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
2026 — Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)
2026 — Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe Anxiety
2026 — Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and Colorado
2026 — Investigating the Effects of Psilocybin on Cognitive Flexibility in Touchscreen and Naturalistic Variations of the Probabilistic Reversal Learning Task
2026 — Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework
2026 — PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)
2026 — The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
2026 — Processing Intergenerational Trauma With Psilocybin-Assisted Therapy
2026 — Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)
2026 — Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertainty
2026 — Ayahuasca and Salvia divinorum as contrasting modes of consciousness reorganization: Implications for psychedelic-assisted psychotherapy
2026 — Safety for Home Administration of Microdose Psilocybin Use
2026 — The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults
2026 — Defining 'psychedelic'.
2026 — Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks.
2026 — Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer Care
2026 — The Abuse Liability of Classic Psychedelics: A Methodological Critique and Assessment of the Quality of Evidence of Recent Studies
2026 — Psychedelics align brain activity with context.
2026 — An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers
2026 — Prospective real-world evidence of mental health outcomes following supervised psilocybin services within Oregons state-regulated model
2026 — Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female Participants
2026 — Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services
2026 — The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing
2026 — Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression.
2026 — The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A Narrative Review
2026 — Psilocybin lengthens hippocampal sharp wave ripples
2026 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial
2026 — Exploring Psychedelics as Novel Therapeutics for Smoking Cessation: Mechanistic Insights from Animal Studies
2026 — The trials of translating psilocybin treatment from research to practice.
2026 — Complex Fatal Self-Harm Under Psilocybin Intoxication: Suicidal Manner of Death or Not?
2026 — Adverse Effect-Related Language in Recreational Psychedelic and non-Psychedelic Substance Experience Reports.
2026 — Distinct response of resting-state brain networks to psilocybin in autism
2026 — Appetite for change: How nutritional state and ventral striatal dopamine shape psilocybin effects on cognitive flexibility
2026 — JAMA study examines Oregon's psilocybin services model
2026 — Toward an Optimal Framework for Psilocybin Regulation: A Comparison of State Regulatory Approaches Across Key Dimensions.
2026 — Beyond head-twitch response: Acute psilocybin affects spontaneous behaviors in rats in a dose-dependent manner.
2026 — Psilocybin collapses visual change detection and drives cortical dynamics toward a state of surprise
2026 — Mystical and affective features of naturalistic psychedelic experiences: A comparison of dictionary-based and LLM-based text analysis methods
2026 — Aquahenosis: a non-pharmacological altered state of consciousness induced by floatation-REST in individuals with anxiety and depression.
2026 — Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases
2026 — Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session.
2026 — A dominant frontoparietal beta oscillatory brain state in the days after psilocybin and 5-MeO-DMT
2026 — “Am I a candidate for magic mushrooms?” A mystery shopper study of Oregon psilocybin service centers
2026 — Psilocybin enhances sociability only in altered behavioural state and does not need an awake experience to be effective
2026 — A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study
2026 — Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
2026 — Oncology Providers' Perspectives on Psychedelic-Assisted Therapy.
2026 — Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study
2026 — Nursing education for emerging psychedelic-assisted therapy: A role-calibrated curriculum approach.
2026 — A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin.
2026 — Differential effects of psilocybin derivatives on fentanyl-induced conditioned place preference in male and female mice.
2026 — An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study
2026 — Can psilocybin help a patient with chronic depression?
2026 — PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALS
2026 — HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPAN
2026 — Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.
2026 — Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review.
2026 — Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases.
2026 — Balancing safety and access in Oregon's psilocybin services.
2026 — Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress.
2026 — A suite of engineered mice for interrogating psychedelic drug actions.
2026 — Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.
2026 — A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.
2026 — Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.
2026 — CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.
2026 — Psychedelics stores, their regulation and public health: knowledge, perceptions, attitudes and opinions of Canadians.
2026 — Active placebo control interventions in pharmacological trials: a scoping review of the development process and a terminological analysis.
2026 — Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when?
2026 — Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges.
2026 — Single-crystal structure determination of psilocybin after dehydration.
2026 — AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression.
2026 — Mycotoxins in Basidiomycete Mycelium and Fruiting Bodies: Implications for Eu Novel Food Assessment and Selected International Regulatory Frameworks.
2026 — Factors Associated with Intentions to Use Psilocybin for Mental Health in Relation to Psychotherapy, Psychiatric Medications, and Natural/Synthetic Options.
2026 — Beyond Efficacy Signals: Regulatory, Methodological, and Translational Challenges in Clinical Research on Ketamine and Psilocybin in Psychiatry
2026 — Patterns of Psychedelic Use in Italy: Insights from the Global Psychedelic Survey
2026 — Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives.
2026 — Age and Cannabis Co-Use Are Associated with Differences in Experience and Perceived Benefits of Psilocybin: A Retrospective Study.
2026 — Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]
2026 — The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults
2026 — Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder
2026 — High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial
2026 — Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use Disorders
2026 — A response to the letter to editor: Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy.
2026 — Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
2026 — Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation.
2026 — Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission
2026 — Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)
2026 — Psilocybin and Affective Function in Chronic Lower Back Pain Depression
2026 — Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease
2026 — Effects of Psilocybin in Obsessive Compulsive Disorder
2026 — One dose of Psilocybin modulates Brain Activity among Depressive patients: Preliminary Neuroimaging Results from the PSILODAC Study
2026 — Psilocybin-induced changes in electroencephalography link acute and long-term effects.
2026 — Daily briefing: Psilocybin blocks side-effect of chemotherapy in mice.
2026 — Psilocybin as an emerging anxiolytic: mechanisms, evidence, and open questions.
2026 — Brain-wide reconfiguration of burst firing by psilocybin reveals 5-HT2A-dependent circuit dynamics
2026 — Who Is Reached by Supervised Psilocybin Services? Oregon Services Versus National Psilocybin Use
2026 — Psilocybin as a treatment for repetitive mild head injury: evidence from neuroradiology and molecular biology
2026 — Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD
2026 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence
2026 — A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease
2026 — A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial
2026 — Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care.
2026 — A Two-Threshold Model of Psilocybin Response Explains Variability in Psychedelic-Assisted Therapy for Treatment-Resistant Depression
2026 — Psychedelic 4-AcO-DMT attenuated looming-induced freezing behaviors by activating PrL CaMKIIα neurons in mice.
2026 — Psilocybin selectively suppresses novelty-induced grooming via 5-HT2B receptors: A microstructure analysis in Wistar rats.
2026 — Psilocybin-associated microRNA changes in the pig brain: Establishing an nCounter pipeline for cross-species microRNA quantification.
2026 — Cardiac Arrhythmia Associated with Psychoactive Drugs: An analysis of the FDA Adverse Event Reporting System
2026 — Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review
2026 — TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
2026 — Characterizing Psychedelic-Evoked Familiarity: A Comparative Study with Autobiographical and Déjà Vu Experiences.
2026 — Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization
2026 — Lifetime classic psychedelics use is associated with positive environmental attitudes and adopting a vegetarian diet
2026 — Modulating the Thermodynamics and Kinetics of Psychedelics at Serotonin Receptors via Terahertz Waves
2026 — [The use of psychedelics in psychiatry].
2026 — Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.
2026 — Neural correlates and behavioral outcomes of aesthetic chills and their prosthetic augmentation
2026 — Psilocybin Administration With 5-HT1a Blockade
2026 — A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)
2026 — Correlation of Ketamine and Classic Psychedelics with Pain-Related Neural Connectivity: A Scoping Review of Clinical Experiments on a Potential Therapeutic Target Concerning Ketamine and Classical Psychedelics Administration for Pain Relief
2026 — Comparative Policy Analysis of Psychedelic Therapy Regulation in Australia, Brazil, and the USA
2026 — Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies.
2026 — MDMA and Psilocybin Regulate Oligodendrocyte-Lineage Cell Numbers and Anxiety-Like Behaviors in a Rat Model of Fear.
2026 — Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology.
2026 — Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial
2026 — Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
2026 — PRoMiSS: Psilocybin and the Role of Music in Set and Setting
2026 — 5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice.
2026 — A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
2026 — Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service
2026 — Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD
2026 — Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disorders
2026 — Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal-hippocampal circuitry.
2026 — Development and Psychometric Validation of the ‘Psychedelic Flourishing Scale’
2026 — High ventilation breathwork as a non-pharmacological model for inducing psychedelic-like states: expert evaluations of therapeutic potential and risk.
2026 — Perceptions and Attitudes on Psilocybin-Assisted Therapy among Underrepresented People with Cancer.
2026 — Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.
2026 — Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.
2026 — Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
2026 — Psilocybin in the Treatment of Methamphetamine Use Disorder
2026 — A Case of Acute Mania and Rhabdomyolysis Associated With Long-Term, Daily Psilocybin Use.
2026 — An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.
2026 — Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.
2026 — A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults
2026 — EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW
2026 — Curious about Psilocybin? Prevalence and correlates of interest among adults with chronic pain.
2026 — ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy
2026 — Reply to 'Methodological concerns and interpretative limitations of assessing subjective effects of ketamine'.
2026 — Apomorphine and psilocybin to improve recovery from coma in the intensive care unit: protocol for a prospective, open-label, dose-escalation study.
2026 — Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study
2026 — Preclinical Anxiolytic- and Antidepressant-like Effects of α,α-Trehalose, a Bioactive Compound Identified in Psilocybe cubensis
2026 — Psilocybin and Contrasting Musical Compositions: Effects on Music-Evoked Emotional Responses in Healthy Adults
2026 — Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial
2026 — Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study
2026 — Age moderates the relationship between psychedelic use and mental health in naturalistic settings
2026 — Psilocybin for Treatment-Resistant Major Depression: Efficacy, Safety and Therapeutic Mechanisms
2026 — The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
2026 — Targeting the serotonin 1B receptor for the treatment of depression and anxiety.
2026 — Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT
2026 — Psilocybin in psychiatry: Current clinical evidence, mechanisms of action and translational perspectives. A literature review based on PubMed-indexed studies
2026 — Reduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trial
2026 — U.S. Veterans and Psychedelics: Prevalence of Use and Policy Preferences.
2026 — Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review
2026 — Worsening of Depression and Anxiety With Psilocybin: A Case Report in Cyclothymia.
2026 — Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.
2026 — Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats.
2026 — Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults
2026 — Large-Scale and Local Functional Connectivity Changes following Psilocybin Administration in Methamphetamine Use Disorder.
2026 — Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.
2026 — Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats
2026 — The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD
2026 — Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.
2026 — Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.
2026 — Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations.
2026 — Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics.
2026 — Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis.
2026 — Oregon’s State-Regulated Psilocybin Services: Early Real-World Safety Signals
2026 — Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's disease
2026 — MedCheck: Drugmakers Advance Psilocybin, Oral Pregnanolone for MDD, Plus FDA Approves Pediatric Tourette's Drug, and More
2026 — F25. COMPARING PSILOCYBIN-ASSISTED THERAPY AND SSRIS IN THE TREATMENT OF LATE-LIFE DEPRESSION
2026 — The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policy
2026 — Embeddedness under psilocybin.
2026 — Open-label, Single-arm fMRI Study Evaluating the Effects of Psilocybin on Craving in Nicotine Dependence.
2026 — Placebo, Psilocybin und der vermaledeite p-Wert
2026 — From regulation to practice: A scoping review of prescribers’ roles in psilocybin-assisted therapy
2026 — Through the PRISM: Reinterpreting Psychedelic Cognition as Motivational Reallocation
2026 — Psychedelics and disorders of consciousness: a new frontier in neurotherapeutics.
2026 — Study participant perceptions of the relevance of therapist and study team personal psychedelic experience
2026 — NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
2026 — Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment
2026 — An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.
2026 — Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled Trial
2026 — Psychedelics Restructure the Global Workspace of Consciousness
2026 — Caution before canonisation: a clinical and implementation science perspective on psychedelics
2026 — Psilocybin-Assisted Therapy in Depressive Disorders: Clinical Governance, Safety, and Translational Challenges
2026 — Psilocybin
2026 — Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial
2026 — What Is Psilocybin?
2026 — Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.
2026 — Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male mice
2026 — Music for psilocybin therapy and the temporal arc of psychedelic experience
2026 — Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation
2026 — Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis
2026 — Protecting axonal mitochondria prevents chemotherapy-driven neuropathy.
2026 — Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial
2026 — Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain
2026 — Engineering microbial platforms for diversified biosynthesis of antidepressant tryptophan-derived neuroactive compounds.
2026 — Molecular Mechanism of Psilocybin-Induced Longevity: The c-Fos-SIRT6 Epigenetic Axis
2026 — Psychedelics in neurosurgery: Potential utility in prevention, perioperative care, pain management, and neurorehabilitation
2026 — Psychedelics and Sleep: Preclinical and Human Studies-A Systematic Review
2026 — Psilocybin-Assisted Therapy for Existential Distress in Serious and Life-Limiting Illness: Emerging Trial Evidence, Barriers to Access, and the Case for Individualized Eligibility
2026 — Mystical experiences mediate the effects of psilocybin-assisted psychotherapy + mindfulness-based stress reduction on trait mindfulness and depression symptoms: mechanistic results from a randomized controlled trial
2026 — Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response
2026 — Investigating molecular and hemodynamic effects of LSD in the human brain.
2026 — An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life
2026 — Quality of Life and the Case for Consent-Based Psilocybin Access - Questions on the Regulatory Framework and Cost
2026 — Psilocybin enhances conditioned place preference learning in planarians.
2026 — Cannabis and Psilocybin Co-use: Associations with Stress and Well-being
2026 — Acute anxiogenic effects of psilocybin and the related tryptamine, norbaeocystin, in male and female rats.
2026 — Psilocybin-based interventions for depressive symptoms: robustness and variation across meta-analytic specifications
2026 — A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer
2026 — Language-associated brain representations covary with disruption of selfhood under psilocybin
2026 — Group psilocybin in an integrative retreat setting enhances social connection: an observational case report
2026 — AI-assisted characterization of psychedelic clinical trials from ClinicalTrials.gov
2026 — Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network
2026 — The Hidden Therapeutic Bridge: Exploring Psilocybin's Role in Depression, Inflammation, and Pain - A Narrative Review.
2026 — Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways.
2026 — Connectedness as a mechanism of change in psilocybin-assisted cognitive behavioral therapy for major depressive disorder
2026 — Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial
2026 — 5-HT2A receptors in layer 5 pyramidal neurons mediate the neuroplastic but not the hallucinogenic effects of psilocybin.
2026 — Aspirational Autonomy and Psychedelic-Assisted Therapy in Advanced Cancer: Ethical Lessons from Clinical Cases.
2026 — Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study
2026 — Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.
2026 — Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial
2026 — Stroboscopic light stimulation as a controllable probe of the psilocybin state: a mechanistic framework and a falsifiable prediction
2026 — Coding and Classification Errors in Study of Psilocybin Services
2026 — Context Shapes Alpha-Band Electrophysiological Signatures Under Psilocybin
2026 — The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin
2026 — French psychiatric caregivers' perceptions of psychedelics: A national survey.
2026 — Adverse outcomes of psychedelics self-reported: Survey
2026 — Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice.
2026 — From Altered States to Fundamental Peace: Taxonomies of Consciousness, Psychedelics and Hypnosis Through the Lens of the Yoga Vāsiṣṭha
2026 — A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)
2026 — Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
2026 — Psychoplastogens to Reduce Persistent Cognitive Symptoms for Traumatic Brain Injury as a Chronic Condition.
2026 — Investigation of the pharmacological and circuit basis for psychedelic drug effects on interval timing in mice.
2026 — Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain Durability
2026 — Biosynthesis of gold nanoparticles using Psilocybe cubensis extracts and their biostimulatory evaluation in Neuro2a cells
2026 — Michael Pollan’s Psychedelic Renaissance: Settler Colonial Time and the De-Indigenization of Mazatec Mushroom Medicine
2026 — Psilocybin for anhedonia in unipolar and bipolar depression: A systematic review of clinical and preclinical evidence.
2026 — Microdosing Psychedelics to Improve Mood
2026 — Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin
2026 — A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
2026 — Direct Quantitation of Psilocybin and Psilocin by H and P qNMR in Wild from Greece.
2026 — Clinical Evidence on Psilocybin and Its Representation in Media Reporting
2026 — Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial
2026 — A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)
2026 — Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease: A Nonrandomized Clinical Trial.
2026 — Mikrodosiertes Psilocybin im palliativmedizinischen Kontext
2026 — A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans
2026 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
2026 — A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
2026 — Sustained antidepressant-like effects of psychedelics through 5-HT2AR-β-arrestin signaling.
2026 — Psilocybin and Clinical Depression
2026 — Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patients
2026 — Direct Quantitation of Psilocybin and Psilocin by 1H and 31P qNMR in Wild Psilocybe from Greece
2026 — Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes
2026 — Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism
2026 — Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial
2026 — Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis.
2026 — Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.
2026 — Substantial Treatment-Seeking Interest, Narrow Eligibility: Diagnostic Heterogeneity and External Validity in the PRIDE Psilocybin Trial-Relevance to Precision Psychiatry
2026 — Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among Veterans
2026 — Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer
2026 — Magic pathways: the genes and enzymes of psilocybin biosynthesis.
2026 — Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025).
2026 — Psychedelic assisted psychotherapy (2020-2025): a scoping review of clinical evidence, mechanisms, safety, and ethics
2026 — High-Quality Genome Assembly and Transcriptomic Analysis Reveal Potential Pathways for Psilocybin Biosynthesis in Gymnopilus dilepis
2026 — Connectedness as a candidate pathway linking psilocybin retreat experiences to sustained wellbeing: a prospective naturalistic study
2026 — Quantum Chemical Topology and Energetic Analysis of Psychedelic and Non-Psychedelic Ligands in Coordination-Sphere Models of the Human 5-HT2A Receptor
2026 — An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
2026 — A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression
2026 — A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.
2026 — Multi-scale effects of single-dose psilocybin in the macaque brain
2026 — Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial
2026 — Psychedelics and Psychedelic-Inspired Compounds for Substance Use Disorders: Are We Treating the Disease or Opening a Learning Window?
2026 — Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
2026 — Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.
2026 — Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
2026 — Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
2026 — The Fireside Database: Large-scale evidence from 25,419 psychedelic support interactions.
2026 — The role of music therapy in psychedelic treatment: The case for safe, supported sound
2026 — The 'Civilising' of Psychedelics: Pharmaceuticalisation from Below as a Part-Process of American and European Informalisation
2026 — Structural plasticity and enhanced fear extinction following psilocybin in chronically stressed mice
2026 — Psychedelics restructure information in the human brain
2026 — Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.
2026 — Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression
2026 — Prevalence and Correlates of Past-Year Psilocybin Use in the United States
2026 — Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression
2026 — Safety and efficacy of psilocybin-assisted therapy for alcohol use disorder: Open-label extension of a phase II randomized controlled trial
2026 — Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.
2026 — α-Adrenergic receptor modulates 5-HT-mediated behavioral effects of MDMA and psilocybin in mice.
2026 — Pupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious states.
2026 — Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis
2026 — Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.
2026 — Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence.
2026 — Prior trauma shapes the effects of psilocybin on stress sensitization in mice
2026 — Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH.
2026 — How Psilocybin Alters Consciousness: Psychedelics can create a "hidden order" in brain activity that could explain how these drugs affect our sense of self.
2026 — Psilocybin Use in Psychiatry: Clinical Practice and Public Health Implications.
2026 — Furthering the Understanding of Psilocybin Use and Molecules Relevant to Depression and Schizophrenia.
2026 — A multi-institutional investigation of psilocybin’s effects on mouse behavior
2026 — PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment
2026 — Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease
2026 — Psilocybin FCR Early-Stage Breast Cancer
2026 — Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model
2026 — Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement